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ABSTRACT 
 
 
 This dissertation sought to explore the relatively understudied area of racial 
disparities in adherence to cardiovascular medication regimens among the elderly. Black 
and Hispanic seniors are well documented to have lower rates of adherence to their 
prescribed cardiovascular medications, relative to their white counterparts. This 
disproportionately lower adherence places these minority groups at higher risk for worse 
cardiovascular prognosis and premature cardiovascular death. The Medicare Program, 
which covers healthcare predominantly for elderly Americans, offers an interesting 
laboratory to study these disparities and their response to policy changes. Using 
nationally representative data from the Medical Expenditure Panel Survey on white, 
black, and Hispanic Medicare seniors, this dissertation was an endeavor to: 1) evaluate 
the impact on these disparities of the introduction of Medicare Part D, the prescription 
drug benefit, in 2006, 2) explore the heterogeneity of these disparities at various locations 
in the adherence distribution, signifying population subgroups with potentially distinct 
behavioral patterns, and 3) systematically estimate the extent to which the inequality in 
the determinants of adherence, such as socioeconomic status, insurance coverage, access 
to care, and experience with providers, contributes to the particularly significant and 
consequential black-white adherence differential. To pursue these aims, this dissertation 
used some of the recent advances in econometric techniques for the study of inequality, 
including the rank-and-replace procedure to adjust for health status in non-linear models, 
unconditional quantile regression, and distribution-wide Oaxaca-Blinder decomposition, 
respectively. The Institute of Medicine’s framework on racial healthcare disparities 
constituted the primary basis for defining and empirically estimating adherence 
disparities. These investigations contribute threefold to the literature: substantively, 
conceptually, and empirically. The substantive findings can improve our understanding of 
what works and what does not work for disparity reduction, bring our attention to 
disparities among subpopulations potentially deserving priority intervention, and 
systematically quantify the roles of clinical, social, and health-system factors in 
perpetuating adherence disparities. The various conceptualizations of adherence 
disparities employed in this dissertation, along with the state-of-the-art empirical 
approaches to implement them offer much needed examples to guide future research on 
disparities in general and medication-related disparities in particular. 
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CHAPTER 1.    INTRODUCTION 
 
 
“Ill fares the land, to hastening ills a prey,  
Where wealth accumulates, and men decay” 
 
Oliver Goldsmith,  
Anglo-Irish writer (1730-1774) 
 
 
Racial Disparities in Cardiovascular Disease 
 
Cardiovascular diseases are the leading cause of death.1 They are also the most 
costly conditions.2 Black Americans have 2-3 times higher likelihood of death due to 
cardiovascular disease at any given age.3,4 This disparity in cardiovascular death accounts 
for the largest share (34%) of the racial all-cause mortality differential in the United 
States, with the disparity in death due to uncontrolled hypertension making up most of 
that share.5 In the CARDIA study, Bibbins-Domingo et al found adult blacks to be 20 
times more likely than their white counterparts to develop heart failure before the age of 
50, pursuant to a striking disparity in uncontrolled blood pressure that persisted over 
more than 10 years of follow-up.6 Based on an analysis of the National Health and 
Nutrition Examination Survey, Fiscella et al estimated that bringing the blood pressure 
level among blacks to that among whites could save more than 7,000 lives annually from 
death due to heart disease or stroke.7 Hispanics as well are more likely to fall short of 
treatment goals, including having persistently elevated blood pressure8,9 and cholesterol 
levels.10,11 Among the social and behavioral factors that might explain the racial 
disparities in cardiovascular disease,8,12-14 the lower levels of adherence to cardiovascular 
medications among minorities is a repeatedly identified suspect that is amenable to 
intervention.7,8,12,15 
 
 
Medication Adherence 
 
Medication adherence is “the extent to which a patient’s behavior, relevant to 
medication and lifestyle recommendations, coincides with medical or health advice.”16,17 
Adherence as a process encompasses three components: initiation, implementation, and 
persistence.18 Regimen initiation refers to patients filling their newly prescribed 
medications,19,20 thereby initiating the adherence process. If the patient starts taking 
his/her medications but to varying degrees (in terms of the amount or frequency), then 
this is a problem with the implementation phase of the process or the actual “execution” 
of the regimen relative to what has been prescribed.21 The third phase of the adherence 
process, persistence, describes the degree of conformity of the actual duration to the 
recommended duration of therapy.16,22 Patient adherence to prescribed medications, that 
are indicated, safe, and effective, plays a key role in the realization of therapeutic goals, 
such as healthier blood pressure, blood glucose, and cholesterol, and positive overall 
health outcomes, such as reduction in morbidity, and mortality.23 In 2005, the cost of 
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poor medication adherence in the United States was estimated to be $500 billion in 
medication-related hospitalizations.24 In cardiovascular diseases, 40% of patients are 
estimated to be poorly adherent (having less than 80% medication possession) to their 
cardiovascular medications.25 Poor adherence to cardiovascular medications is associated 
with 25% higher risk for cardiovascular events, including coronary heart disease (CHD), 
stroke, and sudden cardiac death, and 60% higher risk for all-cause mortality.25 Poor 
adherence to beta-blockers, angiotensin-converting enzyme (ACE) inhibitors and statins 
among CHD patients is associated with 10-40% higher odds of hospitalization and 15-
32% higher odds of coronary revascularization. Overall, 9% of the risk for major 
cardiovascular events is directly attributable to poor adherence.25 Elderly patients, given 
their multiple chronic conditions, polypharmacy, and functional decline, are at especially 
high risk for the adverse effects of poor adherence.26,27 
 
 
Racial Disparities in Adherence among the Elderly 
 
Among the elderly, blacks and Hispanics with uncomplicated hypertension were 
about 45% less likely to be adherent to their antihypertensive medications, including 
alpha- and beta-blockers, ACE inhibitors, angiotensin II receptor blockers (ARBs), 
Calcium channel blockers (CCBs), diuretics and vasodilators.28 Zhang et al examined 
adherence to ACE inhibitors/ARBs and diuretics among seniors with heart failure, and 
found blacks, Hispanics, and Native Americans to be about 40% less likely to achieve 
adherence than whites.29 Zhang et al also reported that black and Hispanic seniors 
surviving acute myocardial infarction (AMI) were 20-30% less likely to adhere to beta-
blocker, ACE inhibitor, or statin therapy for 6 months or a year post-infarction.30 In an 
analysis across race and gender of AMI survivors, Lauffenburger et al reported that black 
and Hispanic women were least likely (having about 30-36% lower odds), compared with 
white men, to be adherent to these post-AMI preventive therapies.31 In a meta-analysis of 
published studies, Lewey et al estimated that generally patients of non-white race were at 
about 50% higher odds of non-adherence to statins than whites.32 Racial disparities in 
adherence persist even in settings with equal access to prescription drugs.11,33 Despite 
their significant role in placing minorities at a higher risk for adverse cardiovascular 
outcomes, adherence disparities have received very little attention in the literature. 
 
 
Medicare: the Policy Context  
 
 The Medicare program offers an interesting laboratory to study adherence 
disparities among the elderly and how these disparities respond to policy changes. 
Medicare covers the cost of healthcare for more than 50 million elderly and disabled 
Americans, with the elderly population (65 years and older) accounting for about 85% of 
the Medicare population.34 Medicare is the largest single payer for healthcare in the 
United States and spending on Medicare makes up about 16% of the federal budget, 
making it a very rich policy arena.34 One major policy change in Medicare, perhaps the 
largest since inception in 1965, was the introduction of the Medicare prescription drug 
benefit, Part D by the Medicare Modernization Act of 2003.35 Prior to 2003, a 
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“conspicuous failure in the US health policy”36 was the lack of a prescription drug benefit 
for Medicare seniors, making the United States the only industrialized country to have 
such a deficiency.36 Before Part D, 90% of Medicare elderly beneficiaries were taking 
prescription medications for their conditions, and 27% of them had no source of 
prescription drug coverage.37 Prevalence of drug uninsurance reached 34% among poor 
seniors.37 Rates of foregoing prescription drugs because of cost, i.e. cost-related non-
adherence (CRN), was about 26% in the overall Medicare population, 37% among those 
with no coverage, 35% among the low-income, and 35% among those with complex 
chronic diseases.37 Seniors with multiple chronic conditions had a striking 52% 
likelihood of CRN, with similar rates among patients with congestive heart failure and 
diabetes.37 Except for individuals with Medicaid and other public coverage (e.g. Veteran 
Affairs and Indian Health Services), covered beneficiaries had patchy, discontinuous and 
variable levels of drug coverage (through previous employers, HMOs, Medigap and other 
private plans, and States’ Pharmaceutical Assistance Programs) with various caps and 
deductibles that made beneficiaries, especially those who were sicker, seek to change 
plans during the year after reaching their catastrophic limits.36,37 Studies that examined 
the effect of the lack or restriction of drug coverage on seniors have shown detrimental 
effects of these limits on their health, especially among the low-income and those in poor 
health and multiple comorbidity (to the extent that limits and caps placed in some drug 
plans may have resulted in irreversible health problems that led to nursing home 
admissions).36 
 
 The introduction of Part D aimed to expand access to prescription drugs by 
reducing the financial out-of-pocket burden associated with them and to improve the 
quality of medication use by requiring drug plans to offer medication therapy 
management (MTM) services to their eligible Medicare enrollees.38,39 Rates of CRN, 
which motivated the introduction of Part D,36,40 decreased among Medicare enrollees 
following Part D implementation in 2006.41-43 Part D also increased drug use and reduced 
out-of-pocket expenditure.44,45 Among patients with cardiovascular diseases, Part D 
improved medication adherence in hypertension, hyperlipidemias, and heart failure.46 
Some have suggested that this improvement has led to a significant (about 4%) reduction 
in hospitalizations for acute myocardial infarction (MI), angina, and congestive heart 
failure (CHF).47 The Part D coverage gap, the “donut hole”, however, was associated 
with some reduction in adherence to cardiovascular medications.48-51 While optimal 
design and delivery of MTM services and the eligibility threshold are still active areas of 
research,52 early evaluations of MTM among beneficiaries in 2010 show the versatility of 
MTM for improving the quality of medication use process and its outcomes, including 
medication adherence in clinically complex patients.53 
 
 In addition to its general goals and provisions, Medicare Part D also further 
supported the low-income population, among whom racial/ethnic minorities are 
overrepresented, by creating the low-income subsidy (LIS). The LIS effectively 
eliminated cost-sharing for beneficiaries with limited assets and income below 150% of 
the federal poverty line (assets < $25,010 and income <$21,855 for a couple in 2010).54 
Dually eligible beneficiaries and those receiving Supplemental Security Income were 
automatically signed up for the LIS.55 Recent evidence suggests that the LIS brought 
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medication-related metrics, including adherence, duration of therapy, and overall 
exposure to prescription drugs, among LIS-recipients closer to those among the more 
advantaged non-LIS beneficiaries.56-58 
 
Although the goals and effects of Part D introduction underscore a potential for 
reduction of medication-related disparities, studies of minority experience with Part D 
raise some alarming signs. In comparison with whites, minorities have had greater 
difficulty navigating the Part D program, due in part to health literacy and socioeconomic 
disadvantage,59 and were more unaware of and confused by their Part D benefits.60 Very 
scant literature has formally examined the impact of Part D on drug-related disparities. In 
one pre-post study of elderly beneficiaries,61 Part D was associated with a larger decrease 
in out-of-pocket expenditure and unmet drug needs among black non-dually eligible 
beneficiaries, and a larger decrease in unmet drug needs only among Hispanic dual-
eligibles, relative to their white counterparts. In a difference-in-differences evaluation,62 
Part D was associated with a reduction of white-Hispanic disparities in expenditure and 
use of prescription drugs, but an increase in the white-black disparity in total drug 
expenditure. Minorities were also less likely to meet Part D utilization-based eligibility 
criteria for MTM services,63,64 depriving scores of minority patients from a benefit that is 
well-equipped to help them with their complex medication-related issues, including 
adherence behavior. 
 
 
Research Aims 
 
 This dissertation sought to examine the racial disparities in adherence to 
cardiovascular medications in the Medicare elderly population. Using nationally 
representative data from the Medical Expenditure Panel Survey (MEPS), the following 
three aims were pursued: 
 
 
Aim 1: To estimate the impact of Part D introduction on the racial disparities in 
adherence to cardiovascular medications  
 
By investigating the impact of Part D, we sought to answer two interrelated 
questions: 1) whether adherence behavior among blacks and Hispanics was further 
increased or reduced as a result of Part D coverage, and 2) to what extent the potential of 
Part D to reduce adherence disparities has been realized. Such an impact evaluation can 
inform future policy endeavors, by reinforcing our knowledge of what works and what 
does not work for disparities reduction, including further recognition of the potential of a 
policy change to exert unintended effects on both the absolute outcomes, adherence 
among minorities in this dissertation, as well as, from a social justice perspective, the 
state of adherence disparities among seniors. 
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Aim 2: To identify population subgroups along the distribution of adherence where 
disparities were most amplified 
 
 Although the traditional approach to studying adherence disparities at the mean 
probability of achieving 80% medication possession is informative, it risks overlooking 
significant disparities that might exist at other locations in the distribution. These 
locations signify population subgroups with potentially distinct patterns of adherence 
behavior, and they get indiscriminately lumped together when adherence is measured as a 
binary classification of patients above and below 80% medication possession. 
Investigating the extent of disparities along the distribution of adherence can thus bring to 
our attention disparities that might be deserving of tailored, and potentially priority, 
interventions. 
 
 
Aim 3: To identify the potential drivers of the black-white disparity in adherence 
 
After quantifying the extent of disparities across the distribution of adherence, 
identifying where they were most significant, and after evaluating how Part D changed 
the policy and coverage landscape for Medicare seniors, this dissertation turned to the 
question of what might be driving those persistent disparities. As it unfolded in studies 
for the first two aims, the black-white disparity in cardiovascular medication adherence 
was the largest and potentially the most consequential, given the higher burden of 
cardiovascular disease among blacks and their persistent social disadvantage.65 Despite a 
large literature on adherence behavior among blacks, conducting a systematic, 
comparative analysis of how the determinants of adherence disparately work to produce 
the observed patterns of adherence among blacks and whites remains a critical gap in the 
literature. For Aim 3, this dissertation built on the methods and findings under Aim 2 to 
investigate the potential sources of black-white differences in adherence across the 
distribution, in an attempt to reveal the determinants of adherence most responsible for 
the observed black-white differential, as well as the population subgroups among whom 
these determinants were significant. 
  
In the course of investigating these research questions, which were previously 
unstudied, disparities were conceptually defined according to the Institute of Medicine’s 
framework on studying racial healthcare disparities.66,67 Extending this framework to the 
study of disparities in adherence behavior is a much needed theoretical contribution. This 
dissertation also makes use of recent advances in state-of-the-art econometric methods to 
study inequality, including the rank-and-replace procedure to adjust for health status in 
non-linear models,68,69 unconditional quantiles regression,70 and Oaxaca-Blinder 
decomposition across outcome quantiles.71 Further, this dissertation introduces specific 
methodology with validation to measure adherence in MEPS, filling an important gap in 
the literature on prescription drug research. Finally, the substantive findings from this 
dissertation regarding adherence disparities carry implications for disparity reduction 
efforts under Medicare Part D. 
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CHAPTER 2.    IMPACT OF MEDICARE PART D ON RACIAL DISPARITIES 
IN ADHERENCE TO CARDIOVASCULAR MEDICATIONS AMONG THE 
ELDERLY 
 
 
Background 
  
 Patient adherence to evidence-based cardiovascular medications is imperative for 
attaining intermediate therapeutic goals, such as blood pressure and low-density 
lipoprotein levels, and for the subsequent realization of favorable health outcomes.23,72-74 
Poor adherence can have especially detrimental consequences among older adults, given 
their multiple comorbidities, polypharmacy, and declining cognitive function.75-77 
Further, across racial/ethnic groups, differentially worse adherence to cardiovascular 
medications, such as angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, and 
statins, have been repeatedly observed, even after adjustment for socioeconomic status 
and insurance coverage.28-32,78-85 Worse adherence among blacks and Hispanics, is a key 
predisposing factor for falling short of treatment goals, including having persistently 
elevated blood pressure8,9 and cholesterol levels.10,11 In the landmark CARDIA study, 
blacks were 20 times more likely to develop heart failure before the age of 50, than 
whites, with a persistent disparity in uncontrolled blood pressure as a key antecedent.6 
Not surprisingly, the disparity in cardiovascular mortality is the major contributor to the 
disparity in life expectancy in the United States,86 with blacks 2-3 times more likely than 
whites to die from heart diseases at any given age.4 
 
 Medicare Part D, signed into law in 2003 and implemented in 2006, aimed to 1) 
expand access to prescription drugs by reducing the financial out-of-pocket burden 
associated with them, and 2) improve the quality of medication use by requiring drug 
plans to offer medication therapy management (MTM) services to their eligible Medicare 
enrollees.38,39 Cost-related non-adherence, which motivated the introduction of Part 
D,36,40 decreased among Medicare enrollees following Part D implementation in 2006, 
though not among the most vulnerable, e.g. those with low-income or poor health.41-43 
Part D also increased drug use and reduced out-of-pocket expenditure.44,45 Among 
patients with cardiovascular diseases, Part D improved medication adherence in 
hypertension, hyperlipidemias, and heart failure.46 Some have suggested that this 
improvement has led to a significant (about 4%) reduction in hospitalizations for acute 
myocardial infarction (MI), angina, and congestive heart failure (CHF).47 The Part D 
coverage gap, the “donut hole”, however, was associated with some reduction in 
adherence to cardiovascular medications.48-51 While optimal design and delivery of MTM 
services and the eligibility threshold are still active areas of research,52 early evaluations 
of MTM among beneficiaries in 2010 show the versatility of MTM for improving the 
quality of medication use process and its outcomes, including medication adherence in 
clinically complex patients.53 
 
 In addition to its general goals and provisions, Medicare Part D also aimed to 
further support the low-income population, among whom racial/ethnic minorities are 
overrepresented, by creating the low-income subsidy (LIS). The LIS effectively 
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eliminated cost-sharing for beneficiaries below 150% of the federal poverty line, 
automatically including those who are dually eligible for Medicare and Medicaid as well 
as those receiving Supplemental Security Income.55 Recent evidence indicates that LIS 
recipients are doing better on medication use quality metrics, including medication 
adherence in a number of chronic conditions.56-58 
 
 Taken together, the goals and impact of Part D coverage on the general Medicare 
and LIS populations suggest that it may have reduced the racial/ethnic disparities in 
medication adherence. Testing this hypothesis in a formal impact evaluation is still an 
open empirical question. This evaluation is further motivated by the increasing 
vulnerability among minorities who may not be receiving as much benefit from Part D as 
their white majority counterparts. This concern is supported by studies showing that, 
compared to whites, minorities have had more difficulties navigating the Part D program, 
due in part to health literacy and socioeconomic disadvantage,59 and have been more 
unaware of and confused by their Part D benefits.60 Further, given the greater burden of 
cardiovascular diseases among minorities, particularly blacks, any potential unintended 
consequences of Part D benefit designs and delivery structure may have especially 
negative consequences for these already burdened minority beneficiaries. Very scant 
literature has formally examined the impact of Part D on drug-related disparities, 
generally, and to the best of our knowledge, none has focused specifically on the impact 
of Part D on adherence disparities. In one pre-post study of elderly beneficiaries,61 Part D 
was associated with a larger decrease in out-of-pocket expenditure and unmet drug needs 
among black non-dually eligible beneficiaries, and a larger decrease in unmet drug needs 
only among Hispanic dual-eligibles, relative to their white counterparts. In a difference-
in-difference evaluation by Mahmoudi and Jensen,62 Part D was associated with a 
reduction of white-Hispanic disparities in expenditure and use of prescription drugs, but 
increased white-black disparity in total drug expenditure.  
 
The goal of this study was to investigate, using nationally representative data, 
how Part D introduction affected the time course of adherence disparities in the Medicare 
population, controlling for the secular trends that would have prevailed in the absence of 
Part D. By investigating the impact of Part D, we sought to answer two interrelated 
questions: 1) whether adherence behavior among blacks and Hispanics was further 
increased or reduced as a result of Part D coverage, and 2) to what extent the potential of 
Part D to reduce adherence disparities has been realized. Such an impact evaluation can 
inform future policy endeavors, by reinforcing our knowledge of what works and what 
does not work for disparities reduction, including further recognition of the potential of a 
policy change to exert unintended effects on both the absolute outcomes, adherence 
among minorities in our case, as well as, from a social justice perspective, the state of 
disparities. 
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Methods 
 
Data and Population 
 
 We analyzed the annual data files, linked to the Medical Conditions files and 
Prescribed Medicines event files, of the Household Component of the Medical 
Expenditure Panel Survey (MEPS-HC; MEPS for short) from 2002 to 2010. MEPS is an 
annual, nationally representative survey of healthcare access, use, and expenditure by the 
US civilian non-institutionalized population, with oversampling of minorities, 
administered by the US Agency for Healthcare Research and Quality (AHRQ). Each year 
MEPS panel participants are sampled from the previous year’s respondents to the 
National Health Interview Survey. Each panel is then interviewed for five rounds over 
two and a half years, providing data for two calendar years. MEPS annual files (known as 
Full Year Consolidated Data Files) combine data from the two panels that overlap in the 
particular year a file covers: rounds 3, 4, and 5 of the previous year’s panel and rounds 1, 
2, and 3 of the current year’s panel. By combining data from the overlapping panels, 
these annual files provide nearly double the sample size of individual panels and cover 
the entire calendar year for each respondent. Although all MEPS data are reported by 
respondents during computer-assisted personal interviewing, further detailed health 
service use data, including on prescription drugs, are collected from a sample of 
providers with respondents’ permission. Specifically of relevance to this study, the 
quality of MEPS prescription drug data, as well as Medicare Part D enrollment has been 
shown to be comparable to that of claims data.87,88 Additionally, MEPS provides very 
rich data on respondents’ sociodemographics, health and chronic conditions, as well as 
experience with providers and the healthcare system, allowing a thorough study of 
adherence as shaped by these determinants. 
 
The study sample included respondents who were: 1) continuously included in all 
MEPS survey rounds for a calendar year. This excludes respondents who went “out of 
scope” because of death, institutionalization, or other reasons. 2) Medicare beneficiaries 
65 years and older (the "treated" group) as of January 1st of survey year, and non-
Medicare but otherwise insured individuals 60-64 years old (near-elderly, the control 
group) as of December 31st of survey year. This latter date serves to exclude individuals 
who may become eligible for Medicare during survey year. The near-elderly were used as 
the control group, since they are presumably closest in characteristics to the elderly and, 
for the most part, have seen minimal policy changes in their drug coverage in the study 
period.47 3) Self-reported being non-Hispanic white (henceforth “white”), non-Hispanic 
black (henceforth “black”), or Hispanic. We could not include other racial/ethnic groups 
or further distinguish Hispanic subgroups due to their small sample sizes. 4) Had at least 
one of the following six conditions: hypertension, hyperlipidemia, angina, congestive 
heart failure, myocardial infarction, and stroke. Clinical Classification Codes and 3-digit 
ICD-9 codes in MEPS were used to identify respondents with these conditions in MEPS 
Medical Conditions Files. Appendix Table A-1 lists all the conditions and their 
associated codes. 5) Had at least one refill during the survey year of a maintenance 
cardiovascular drug of the following therapeutic classes: ACE Inhibitors, Angiotensin II 
Receptor Blockers (ARBs), HMG-CoA Reductase Inhibitors (Statins), Beta-blockers, 
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Calcium Channel Blockers, Diuretics, or combination products of these medications. 
Appendix Table A-2 lists the specific medications included and their Multum Lexicon® 
class information. 
 
Since the study population represents only a small portion of MEPS respondents 
each year, it was necessary to pool the annual files to ensure adequate sample size for the 
analyses we conducted. Survey design variables in annual files 2002 and following years 
provide a correctly specified common variance structure to calculate the appropriate 
standard errors with pooling.89 For our impact evaluation, we considered MEPS years 
from 2002-2005 to cover the pre-Part D period, whereas data from 2007-2010 covered 
the post period. We excluded 2006 from the post period since it was a transition year for 
both individuals and health plans under Part D, and thus, if used in the post-Part D 
period, it is likely that Part D effects might be under-estimated.39,47 We test this 
hypothesis in a sensitivity analysis. 
 
 
Measurement of Adherence 
 
 Using drug refill records for each included respondent, we measured adherence to 
each medication class as the proportion of days covered (PDC) by refills for any 
medication from that class, expressed as a percentage and capped at 100%. ACE 
inhibitors and ARBs were considered a single class for this purpose. Also, component 
medications of combination products were counted towards their respective classes. A 
follow-up period specific to each drug class was calculated for each respondent, starting 
from an index date corresponding to the first day of the interview round in which the first 
refill (of that class) occurred. The end date was the last day of survey year, December 
31st. While the majority of index refills (60-65%) for any class occurred in rounds 3/1 
(resulting in January 1 as the index date), some respondents did not have refills for one or 
more classes until rounds 4/2 or 5/3; in this case, the index date was set to the start date of 
the specific round in which the refill occurred. More than 91% of index refills had 
occurred in the first two rounds of a calendar year. In addition to calculating class-
specific PDCs, we calculated an average PDC to summarize adherence to all drug classes 
an individual was taking. We then classified respondents as adherent if they had PDC of 
at least 80% over the follow-up period. The main outcome variable was the overall binary 
adherence classification. Class-specific adherence classifications were examined in 
secondary analyses. 
 
 Although all MEPS years in our analysis have extensive data on prescription 
refills, including dispensed quantity, strength, dosage form, and therapeutic 
class/subclass, data on days of supply were not available in years prior to 2010. We used 
2010 data to characterize the patterns of observed days’ supply as they relate to dispensed 
quantities of drug refills. In so doing, we identified the most frequent number of supply 
days furnished by each level of dispensed quantity. Next, we derived a scheme to 
smoothly approximate the distribution of refill supply days for use in prior years of 
MEPS (where actual days of supply data are not available). For comparison, we also 
more coarsely approximated days of supply by discretizing the distribution of dispensed 
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quantities on the basis of some rough “rules of thumb” (e.g. dispensed quantities ≤ 45 
pills give 30 days of supply, quantities >45 but ≤ 75 pills cover 60 days, and quantities 
>75 provide 90 days of supply). Then, in 2010 data, we measured adherence, both as a 
continuous PDC and as a dichotomous classification as explained above, using the actual 
and the approximated days’ supply distributions.  
 
To assess the validity of our derivations, we used Lin’s concordance 
coefficient90,91 to compare the approximate continuous distributions of supply days and 
estimated PDC to their actual counterparts. We also used Kappa and C-statistics to 
compare dichotomous adherence classifications produced using approximate PDC 
distributions against those produced using the actual PDC distribution. Finally, using the 
most valid method for approximating refill days of supply from dispensed quantities, we 
calculated days of supply for refills in years prior to 2010. The validity of computing 
refill days of supply in earlier years using the pattern of days’ supply vis-à-vis dispensed 
quantities in 2010 hinges on the potentially plausible assumption (based on discussions 
with two cardiologists with more than 20 years of practice experience) that the dosing 
frequency of a given strength of a specific cardiovascular drug has been stable over 2002-
2010 in a specific patient population (for example: for the same patient population, if a 
30-pill refill of 40-mg simvastatin covers 30 days in 2010, on average, this would have 
also been true in 2002).  
 
 
Conceptualizing Adherence Disparities 
 
 In most empirical research on healthcare disparities, authors have typically 
estimated the disparity as the difference in outcome levels across racial/ethnic groups, 
after adjusting for the entire set of covariates, including socioeconomic status (SES) and 
other measures of race-related disadvantage.67 Typically, the magnitude of disparity is 
viewed as the coefficient of the race indicator variable in a multivariable linear model or 
the odds ratio in a logistic regression. Although not expressly stated, the normative 
judgment underlying this approach to estimating disparities posits that racial disparities 
are the differences due to race-related factors other than the control variables already 
accounted for. This is because, in a multivariable model that adjusts for measured racial 
disadvantage, such as income and education, the race variable only captures variation in 
the remaining manifestations of racism that are not accounted for, such as 
discrimination.69 McGuire and colleagues termed this disparity the residual direct effect 
(RDE) of race.92 This traditional approach to estimating disparities ignores the 
contributions of other inextricable features of racial disadvantage, such as low SES, 
potentially leading to false conclusions regarding the existence of disparities.67,92 When 
race is viewed as a complex, multidimensional lived experience involving both material 
and psychosocial disadvantage, racial disparities in health outcomes must include all 
differences due to every relevant dimension of racial inequality.65,93 This argument also 
applies to ethnic disparities. In the interest of parsimony, and since race captures most 
aspects of ethnicity and the two categorizations are not meaningful to disentangle in a 
society with inequitable race relations,65,94 we use the term “race” here to refer to race 
and ethnicity together. 
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 In its 2002 landmark report, “Unequal Treatment,” the Institute of Medicine 
(IOM) provided a framework to define racial disparities in healthcare, distinguishing 
disparities, which insinuate inequity and injustice, from benign differences in healthcare 
that might be more legitimate.66,92 According to the IOM, racial healthcare disparities 
correspond to the racial differences in healthcare that are justified neither by the clinical 
appropriateness and health status needs, nor by the preferences and attitudes towards 
medical care, assuming that those preferences were formulated under “full and accurate 
understanding of treatment options.”66 Healthcare disparities arise through two broad 
mechanisms:66 1) The operative legal, and regulatory environment in which healthcare 
systems function, including policies and practice patterns, insurance coverage, SES, and 
other differential factors that constrain healthcare use disproportionately for minorities,92 
and 2) discrimination at the patient-provider level, which may take the form of prejudice, 
stereotyping, or statistical discrimination under clinical uncertainty.95  
 
To illustrate differences vs. disparities: if, for instance, Hispanics are on average 
younger and thus healthier, the age-related difference in healthcare use between them and 
whites should not be counted towards a disparity. On the other hand, if the health status 
among blacks is worse than whites, but they are not receiving healthcare commensurate 
with their health needs because of inequitable factors, then this difference in healthcare 
use is indeed a disparity. In essence, the IOM framework attempts to isolate the 
contributions of the current structural and fundamental impediments to achieving equity 
in the health system, which are extrinsic to individuals and potentially ameliorable 
through appropriate interventions. While it is true that the differentials in health status 
and chronic disease burden have been shaped by historical racism, selectively adjusting 
for health status allows examining differences between two clinically comparable groups 
that, in the absence of racialized social factors such as poverty, stress, and limited access 
to resources, would have exhibited similar rates of healthcare utilization and health-
related behaviors. Not only does the IOM framing of disparities and their potential 
sources provide an organizing heuristic to guide empirical research on disparities, 
particularly by being explicit about value judgments, it also acknowledges the 
contributions of multiple relevant dimensions of racial disadvantage to healthcare 
disparities  
 
 In this study, we applied the IOM framework to examine disparities in medication 
adherence and the impact of Medicare Part D on these disparities. Adherence behavior is 
shaped by complex interactions of multiple factors, pertinent to the patient, the condition, 
the drug regimen, the provider and the health system, as well as the social and economic 
environments.17,77 MEPS offers a wide array of variables that we used to characterize 
these determinants. We made a priori classifications for each predictor/determinant of 
adherence as potentially contributing to disparities, on the basis of how it correlates with 
race and socioeconomic disadvantage. Specifically, as we show in Figure 2-1, which is 
similar in spirit to the IOM framework,66 the racial difference in adherence can be 
decomposed into disparities and “non-disparities.”  
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Figure 2-1. Conceptualizing adherence disparities in the light of the IOM 
framework 
* Measured in MEPS Self-Administered Questionnaire (SAQ)  
† Proxy for language in clinical encounter  
‡ We do not adjust for drug copay since it is on the causal pathway between Part D and 
adherence. Adjusting for copay biases down Part D effects.  
§ Discrimination in the clinical encounter is roughly captured by the experience with 
provider variables, to the left.  
| | Measured by the D’Hoore’s version of the Charlson comorbidity index96 using MEPS 
3-digit ICD-9 codes, excluding respondent-specific cardiovascular conditions. Conditions 
included in the index are not further adjusted for.  
# Defined using depression ICD-9 codes 296 and 311. 
HMO: Health Maintenance Organization; IOM: Institute of Medicine; RDE: Residual 
Direct Effect. 
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Adherence disparities arise due to disparate SES across racial groups, racial 
discrimination, as well as racial differences in the experience with the healthcare system, 
including having a usual source of care, health/drug insurance, language in the clinical 
encounter (proxied by the interview language), satisfaction with care, and the quality of 
patient-provider relationship. Differences in adherence that arose due to differences in 
health status were not counted towards the disparity. As explained above, although health 
differentials have been shaped by historical disadvantage, our goal was to compare 
adherence behavior across racial groups of comparable health status so as to produce 
disparity estimates that incorporate how the social and health-system factors in their 
current form perpetuate these disparities. Following the IOM, we also do not count 
differences in adherence due to preferences/beliefs, instantiated in MEPS by respondents’ 
attitudes towards risk, insurance, and medical care, towards disparities. 
  
We discuss below the statistical details of how we empirically implemented our 
Figure 2-1-conceptualization of disparities. Each of the conceptual stipulations we make 
as to what constitutes a disparity in adherence and what does not is a hypothesis that can 
be formally tested. To evaluate how our conclusions about disparities might change 
depending on classification of particular factors, we conducted a series of sensitivity 
analyses that ranged from counting only demographic differences towards disparities, to 
fully adjusting disparity estimates for all covariates in hand (i.e. estimating RDE 
disparities). 
 
 
Statistical Analysis 
 
We used a difference-in-differences (DID) design (Figure 2-2) to evaluate the 
impact of Part D introduction on the racial disparities in adherence to cardiovascular 
medications. DID is a quasi-experimental evaluation strategy that uses the mean outcome 
in the control group observed after the treatment as an estimate of the counterfactual 
outcome that would have been observed in the treated group, in the absence of treatment. 
 
The key identifying assumption for a valid DID analysis is that the treated and 
control groups exhibit parallel trends in the mean outcome in the absence of treatment 
(policy implementation). With such a valid control group, the DID estimate of the 
treatment effect thus equals what’s left after taking the difference across time and across 
groups in the mean outcome, which serves to eliminate the secular time trend that is 
common to both groups and unrelated to the treatment, as well as the systematic 
differences due to time-invariant group characteristics (e.g. adherence is systematically 
higher among the near-elderly than among the elderly), respectively.97 In regression 
analysis, DID estimation is done using a set of binary indicator variables for groups, time 
period, and their interaction term. To estimate the impact on disparities, we added race 
indicator variables and their interaction terms with group and time indicators to the basic 
DID setup, as shown in Equation 2-1. We apply the DID framework to pooled cross-
sectional MEPS data on Medicare seniors and the near-elderly before and after Part D.  
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Figure 2-2. Difference-in-Difference (DID) evaluation of Part D effect on racial 
disparities in adherence  
Change in Disparities in Medicare (Tx Group)   = Δb – Δa 
Change in Disparities in the near-elderly (Ctrl Group)  = Δd – Δc 
DID Effect of Part D on Disparities    = (Δb – Δa) – (Δd – Δc). 
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Using logistic regression, we model adherence, as a dichotomous outcome 
variables (at or above 80% PDC cutoff) as a function of the DID setup as well as the 
aforementioned predictors of adherence. In notation,  
 
Pr?PDC≥80%?x?=g-1(α?+?Xk.βk?
K
k=1
+ γ1?.Post + γ2? .Medicare + γ12? .Medicare×Post 
+ γ3? .Black + γ4? .Hispanic + γ13? .Black×Post + γ14? .Hispanic×Post 
+ γ23? .Black×Medicare + γ24? .Hispanic×Medicare 
+ γ123? .Black×Medicare×Post + γ124? .Hispanic×Medicare×Post) (Eq. 2-1) 
 
Where, g-1 is the inverse of the logistic function that relates that the outcome (on 
the probability scale) to the covariates. Pr[] is the population average probability of 
adherence, conditional on covariates. X represents the individual characteristics that 
predict adherence behavior, including demographics, health, SES, insurance, and 
experience with the healthcare system, as listed in Figure 2-1. We also included the 
interactions of SES and race indicators. Post, Medicare, Black, and Hispanic, are binary 
indicator variables, each equals one for the post-Part D period (2007-2010), being a 
Medicare senior, self-identifying as black, or Hispanic, respectively, and zero otherwise. 
The interaction terms serve to capture the heterogeneity of average adherence across the 
three dimensions of comparison: time, treated/control groups, and race. The coefficients 
of the two triple interaction terms,?γ123?  and γ124? , provide an estimate of the effect of Part 
D on adherence, comparing minorities to whites, i.e. the effects of Part D on the racial 
disparities in adherence.  
 
To implement our IOM conceptualization of adherence disparities within this DID 
framework, we defined adherence disparities as the differences in mean adherence across 
clinically comparable racial groups that arise due to inequitable social and health-system 
factors, including SES, insurance coverage, access to primary care, and discrimination in 
the clinical encounter (Figure 2-1). To make racial groups clinically comparable, we 
selectively adjusted our race-specific outcomes predictions for perceived health status, 
comorbidity, and clinical need (including the use of other prescription drugs). We also 
adjusted for beliefs/preferences (including geographic location), per the IOM definition. 
For brevity, we collectively label the factors that are potential sources of disparities (the 
left two thirds of Figure 2-1) by the letter S, for SES and denote factors we adjust for by 
H, for health (right side of Figure 2-1), reflecting that SES and health are at the heart of 
the two groups of factors we conceptually distinguish.68 
  
For empirical implementation, we followed Cook, McGuire, and colleagues68,69,92 
in using a rank-and-replace procedure to estimate disparities. Briefly, we first estimated 
our multivariable logistic DID model as above (Equation 2-1), controlling for all the 
aforementioned covariates. The adequacy of model fit was tested using a modified 
Hosmer-Lemeshow test for complex survey data.98 Next, we generated a composite score 
of H factors for each individual in the dataset by calculating the linear combination of 
each individuals’ observed value of each H variable multiplied by the pertinent 
coefficient in the multivariable model, i.e. the H-score ?? ?????????????  ; simply, it is the 
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sum of the Xβ products for all K H variables, for each individual i. Next, we ranked 
individuals in each racial group by their H-score, generating a percentile rank for each 
individual within their race-specific H distribution. Then, to match minority and white 
distributions of H variables, we replaced the value of each H variable for each minority 
individual by the value of that variable in the white individual with the corresponding H-
based percentile rank. Replacing minority with white distributions this way preserves the 
joint associations among H variables and is superior to other methods for ranking and 
replacement.69 This replacement creates a counterfactual minority group that still 
preserves its observed distributions of social and health-system exposures (the S 
variables), while now possessing the white distributions of health, clinical need, and 
preferences (H variables). Then, we predicted average marginal adherence levels in 
counterfactual minority and factual white groups using our estimated DID model 
(Equation 2-2). Finally, we computed racial disparities as the differences in predicted 
average adherence between each counterfactual minority group (blacks, Hispanics) and 
the reference (factual) white group. In simple notation, the disparity Δ is given by 
 
∆=AdherenceFactual Whites-AdherenceCounterfactual Minority 
∆=?????????????R=W, S=W, H=W) 
- ?????????????R=M, S=M, H=W) (Eq. 2-2) 
 
Where, R is race, M minority, W white, and S and H take on the same designation 
as above. To calculate the DID effect of Part D on the disparities, we used predictive 
margins99 to compute Δ before and after Part D in the treated and control groups and took 
the double difference across time and groups (see notes of Figure 2-2).  
 
Finally, since there were high rates of missing data for the (categorical) variables 
on beliefs and experience with providers (highest rate 4.4%, leading to up to 25% sample 
reduction if only complete cases were included), we used multiple imputation using 
chained equations (MICE) to impute the missing data for each of these variables.100 
Following recent recommendations in the imputation literature,100,101 we imputed the 
variables with missing data in 5 imputation datasets, adjusting for survey design in the 
imputation model. Using Stata –MI- set of commands, we carried out our analyses, 
including ranking-and-replacement and estimating predictive margins, across all 
imputation datasets and produced a single set of point estimates and standard errors that 
took into account the uncertainty due to imputation. All analyses accounted for MEPS 
complex survey design using Taylor series linearization in STATA® 13 (StataCorp; 
College Station, TX).  
 
 Analogous to the main analysis, we also conducted a series of sensitivity and 
subgroup analyses to assess robustness of our findings to the conceptual and empirical 
decisions made, and to assess potential heterogeneity of Part D effects across policy-
relevant groups. First, we assessed the robustness of our DID-based predictions to a 
series of empirical adjustments, using the rank-and-replace procedure, for demographics, 
health, concurrent drug therapy, and beliefs/preferences. These various adjustments 
reflect different value judgments regarding how differences in each of these factors 
originated and how they contribute to producing adherence disparities. We also estimated 
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Part D impact on RDE disparities directly from our multivariable DID model. Second, we 
graphically assessed the plausibility of the parallel trend assumption necessary for the 
validity of DID estimation. We further considered how our DID estimates would change 
if we included 2006 data in post-Part D year, and if we restricted the treated group to a 
population more comparable to the near-elderly controls (i.e. Medicare elderly 65-70 
years old).102 Third, we analyzed the effect of Part D on disparities in adherence to each 
of the five cardiovascular medication classes we considered, in addition to evaluating 
effects by gender and dual-eligibility status. 
 
 
Results 
 
 
Sample Characteristics 
 
 The main study sample included 14,221 and 3,456 MEPS respondents, nationally 
representative of 19.7 and 5.3 million Medicare seniors and non-Medicare near-elderly 
individuals, respectively. Thus, our total sample size was 17,677 respondents, 
representing a total of 25 million individuals nationwide. As shown in Table 2-1, over 
the entire study period (2002-05, 2007-2010), Medicare seniors and the near-elderly had 
comparable adherence behaviors, with overall adherence rates hovering around 40%. 
Black seniors in Medicare had the lowest overall adherence rate (36.59%). In comparison 
with the near-elderly controls, Medicare seniors were more likely to be females and less 
likely to be married. They also had worse health status, more physical/cognitive 
limitations and comorbidities, and a higher burden of cardiovascular disease, particularly 
the advanced stages of coronary heart disease, congestive heart failure, myocardial 
infarction, and stroke. They were also less likely to be current smokers, obese, or to 
exercise. Seniors were also more likely to be poor or low-income, and less likely to have 
completed high school or college education. As expected, seniors were less likely to have 
private or employer-sponsored insurance coverage, but concurrently used more 
medications, visited physicians more often, and were more likely to have had 
hospitalizations during survey year. Seniors’ experience with providers was comparable 
to that of their near-elderly counterparts, but they tended to more positively rate their 
satisfaction with the healthcare system.  
 
 In both treated and control groups, blacks and Hispanics were more likely than 
whites to have no spouse/significant other, and to live in urban areas. Across regions, 
blacks were heavily concentrated in the South while Hispanics also concentrated in the 
West. Both groups were less likely to live in the Midwest. Minorities had worse health 
status and comorbidity, as well as a higher burden of hypertension and diabetes. 
However, they had either lower or comparable prevalence rates of other conditions, such 
as hyperlipidemia, cardiovascular complications (CHD and AMI), and depression. 
Minorities were also less likely to exercise and to be obese. Relative to whites, smoking 
was higher among blacks while lower among Hispanics. Invariably, minorities had lower 
education and income, and expectedly were more likely to receive Medicaid coverage 
and less likely to have private or employer-sponsored insurance. Blacks were more likely
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Table 2-1. Characteristics of treated and control groups by race 
 
Characteristics 
Medicare Elderly (65 years or older)  Near-Elderly Controls 
White Black Hispanic Overall  White Black Hispanic Overall 
Sample Size 10,311 2,300 1,610 14,221  2,519 547 390 3,456 
Weighted 
Population 16,722,679 1,767,117 1,164,105 19,653,901  4,469,185 498,497 284,937 5,252,619 
% (unless otherwise noted) 
Adherence to CV Medications 
Overall 39.93 36.59 38.51 39.54  40.61 41.13 41.53 40.71 
ACEIs/ARBs 47.02 43.55 47.81 46.75  47.67 47.78 49.17 47.78 
Statins 44.08 45 43.49 44.11  43.74 41.15 48.74 43.8 
Beta-Blockers 48.42 43.58 48.8 48.04  47.34 45.35 45.68 47.02 
Ca Channel 
Blockers 41.36 40.68 37.53 41  41.07 48.78 56.84 43.24 
Diuretics 48.01 43.92 43.52 47.32  49.82 46.05 53.09 49.51 
Demographics 
Age 
(Mean±SD) 
74.69 
±6.36 
73.54 
±6.25 
73.63 
±5.91 
74.53 
±6.34  
61.97 
±1.38 
62.05 
±1.42 
61.74 
±1.35 
61.96 
±1.38 
Female Gender 57.85 63.37 60.8 58.52  51.17 53.67 57.98 51.78 
Married 57.38 34.05 46.84 54.66  77.25 47.35 62.34 73.6 
Urban 
Residence 77.67 86.25 92.73 79.33  78.33 91.55 92.47 80.36 
Census Region 
Northeast 21.05 18.73 14.89 20.47  20.2 21.16 23.04 20.45 
Midwest 25.42 17.25 6.02 23.54  26.65 17.44 9.48 24.84 
South 35.21 56.75 43.35 37.63  35.51 53.47 31.2 36.98 
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Table 2-1.      (Continued) 
 
Characteristics 
Medicare Elderly (65 years or older)  Near-Elderly Controls 
White Black Hispanic Overall  White Black Hispanic Overall 
West 18.32 7.28 35.75 18.36  17.64 7.93 36.28 17.73 
Self-Reported Health 
Excellent 14.54 9.23 7.54 13.65  16.6 6.34 7.49 15.13 
Very Good 29.52 21.82 16.83 28.08  35.79 26.08 18.07 33.9 
Good 33.41 33.66 31.96 33.35  31.26 34.55 31.89 31.61 
Fair 16.62 26.66 32.69 18.48  11.31 24.64 27.85 13.47 
Poor 5.9 8.63 10.99 6.45  5.04 8.39 14.7 5.88 
Any Physical 
Limitation * 62.19 63.61 65.45 62.51  39.09 48.87 43.07 40.23 
Any Cognitive 
Limitation * 9.05 14.86 15.15 9.93  3.6 6.41 10.21 4.22 
Conditions (over survey year) 
Charlson Comorbidity Score 
1st/2nd Quartiles 57.06 47.07 44.27 55.41  64.63 54.1 45.52 62.6 
3rd Quartile 31.91 38.25 40.96 33.02  28.56 33.49 43.66 29.85 
4th Quartile 11.02 14.68 14.77 11.57  6.81 12.41 10.82 7.56 
Comorbidity 
Count, † 
Median(IQR) 
6(3,8) 4(2,6) 5(3,7) 5(3,8)  4(3,7) 4(2,6) 4(2,6) 4(2,7) 
Hypertension 81.96 92.89 90.23 83.43  77.13 94.55 91.38 79.55 
Hyperlipidemia 59.82 48.15 51.53 58.28  64.34 47.45 56.64 62.32 
Angina/CHD 17.25 11.71 16.09 16.68  9.54 7.36 8.53 9.27 
CHF 4.66 5.12 2.89 4.59  1.86 2.14 0.41 1.81 
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Table 2-1.      (Continued) 
 
Characteristics 
Medicare Elderly (65 years or older)  Near-Elderly Controls 
White Black Hispanic Overall  White Black Hispanic Overall 
AMI 6.88 5.12 5.15 6.62  3.96 4.17 3.39 3.95 
Stroke 5.49 5.94 5.3 5.51  2.28 2.62 4.75 2.45 
Depression 11.78 5.61 11.87 11.23  13.02 7.11 13.49 12.48 
Diabetes 22.08 35.49 40.7 24.39  20.89 32.38 39.58 22.99 
Asthma 9.03 11.03 10.53 9.3  11.79 14.06 12.4 12.04 
Emphysema 7.27 3.95 3.07 6.72  4.08 2.79 1.39 3.81 
Arthritis 61.04 63.98 58.83 61.17  48.99 55.6 47.72 49.55 
Beliefs & Behaviors 
More likely to 
take risks 14.44 14.27 16.39 14.54  16.04 12.6 18.6 15.85 
Can overcome 
illness without 
medical care 
9.89 8.26 7.56 9.61  12.68 7.94 8.89 12.03 
Does not need 
health insurance 3.65 3.92 6.4 3.84  2.59 1.77 7.07 2.75 
Behaviors          
Current Smoker 8.35 10.52 5.6 8.38  14.49 19.76 9.72 14.73 
Moderate/ 
Vigorous 
Exercise 
46.85 38.56 40.62 45.74  57.07 43.59 45.14 55.14 
Obese 
(BMI≥30) 27.86 40.26 32.69 29.26  39.85 50.07 44.38 41.06 
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Table 2-1.      (Continued) 
 
Characteristics 
Medicare Elderly (65 years or older)  Near-Elderly Controls 
White Black Hispanic Overall  White Black Hispanic Overall 
Socioeconomic Status 
Income: ‡ 
Poor/Near-Poor  13.39 31.57 32.54 16.16  6.83 20.94 25.88 9.2 
Low-Income 18.34 26.36 24.75 19.44  6 14.6 13.89 7.24 
Middle-Income  31.4 25.8 27.52 30.67  26.33 27.45 28.13 26.54 
Education: Less 
than High 
School 
22.5 47.94 67.62 27.46  10.77 32.33 55.23 15.23 
High School 
Diploma 50.8 38.02 22.2 47.95  43.19 44.63 29.76 42.6 
Language: 
Interview Not 
in English 
0.28 0.06 51.21 3.28  0.22 0.59 41.25 2.48 
No English at 
Home 1.18 1.01 57.81 4.52  1.02 1.32 52.12 3.82 
Insurance (over survey year) 
Employer-
Sponsored 34.48 28.06 16.14 32.82  82.77 68.48 54.76 79.9 
Medicaid 5.47 25.44 37.36 9.16  3.89 20.92 31.64 7.01 
Private- Non 
HMO 42.73 24.22 14.14 39.37  62.28 44.09 25.39 58.55 
Private- HMO 9.29 9.13 6.87 9.13  31.2 31.18 36.32 31.47 
Healthcare Use (over survey year) 
No. of concurrent CV Medications § 
0-1 39.63 36.28 40.02 39.35  47.74 35.19 42.14 46.24 
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Table 2-1.      (Continued) 
 
Characteristics 
Medicare Elderly (65 years or older)  Near-Elderly Controls 
White Black Hispanic Overall  White Black Hispanic Overall 
2-3 53.74 54.51 54.25 53.84  46.97 56.37 49.91 48.02 
≥4 6.63 9.21 5.74 6.81  5.29 8.44 7.95 5.74 
No. of other concurrent medications 
0-1 11.49 14.94 13.62 11.92  15.31 15.83 18.72 15.54 
2-4 48.13 47.02 49.89 48.14  53.96 49.22 46.09 53.08 
≥5 40.38 38.04 36.49 39.94  30.73 34.95 35.2 31.38 
No. of 
Pharmacies 
Used, 
Median(IQR) 
1(1,2) 1(1,1) 1(1,1) 1(1,2)  1(1,2) 1(1,1) 1(1,1) 1(1,2) 
Average Copay 
for CV Drugs 
($2010), 
Median(IQR) 
19.92 
(8.60,43.41) 
13.36 
(4.00,31.48) 
9.62 
(2.67,27.66) 
18.59 
(7.63,41.72)  
17.07 
(9.62,32.69) 
13.93 
(6.27,25.58) 
12.18 
(3.32,25.45) 
16.53 
(9.01,31.81) 
Had a Usual 
Source of Care 97.59 96.4 96.55 97.42  96.79 96.99 92.71 96.59 
Had  ≥1 Any 
Inpatient Stay 19.78 20.88 16.45 19.68  12.91 15.78 12.75 13.17 
Quintiles of ambulatory physician visits (range) 
Q 1 (0-2) 15.35 22.59 20.4 16.3  23.78 27.85 27.79 24.38 
Q 2 (3-4) 17.78 21.75 19.19 18.22  23.44 23.92 20.01 23.3 
Q 3 (5-7) 20.52 22.63 22.71 20.84  21.35 17.72 22.8 21.08 
Q 4 (8-12) 22.73 18.31 20.02 22.17  18.21 19.07 14.55 18.09 
Q 5 (≥13) 23.62 14.72 17.68 22.47  13.22 11.44 14.85 13.14 
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Table 2-1.      (Continued) 
 
Characteristics 
Medicare Elderly (65 years or older)  Near-Elderly Controls 
White Black Hispanic Overall  White Black Hispanic Overall 
Experience with Providers 
Always Listens 65.13 74.42 70.81 66.3  62.11 69.97 67.29 63.14 
Always 
Explains Care 60.91 71.38 66.12 62.16  62.45 72.23 61.69 63.34 
Always 
Respects 67.59 75.92 72.53 68.63  65.8 75.99 65.08 66.73 
Satisfaction with Healthcare 
Dissatisfied-
Neutral 7.59 10.86 10.03 8.03  8.03 11.55 14.33 8.71 
Satisfied 29.47 29.14 23.24 29.07  34.21 28.5 31.8 33.54 
Very Satisfied 62.95 60 66.73 62.91  57.76 59.95 53.86 57.75 
 
Boldface estimates are statistically significant at the 5% level and represent pairwise comparisons relative to reference groups: 
overall proportions among Medicare elderly were compared to the near-elderly controls, and minorities were compared to their 
white counterparts (within treated/control groups).  
* Physical limitations included functional or sensory limitations, or limitation in the Instrumental Activities of Daily Living or 
in the Activities of Daily Living. Cognitive limitations included confusion, dementia, problems making decisions, or needing 
supervision for own safety. 
† Excluded respondent-specific cardiovascular conditions. Charlson Score based on D’Hoore’s version suing 3-digit ICD-9 
codes.96 
‡ Poor/Near-Poor: <125% FPL; Low-Income: ≥125 to <200 %FPL; Middle-Income ≥200 to <400% FPL; High Income 
(reference): ≥400% FPL.  
§ Same-pill combination products were counted as one drug 
CV: Cardiovascular; ACEI/ARB: Angiotensin-Converting Enzyme Inhibitors/Angiotensin II Receptor Blockers; SD: Standard 
Deviation; IQR: Interquartile Range; CHD: Coronary Heart Disease; CHF: Congestive Heart Failure; AMI: Acute Myocardial 
Infarction; BMI: Body Mass Index; FPL: Federal Poverty Line; HMO: Health Maintenance Organization.  
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to concurrently take multiple cardiovascular medications than whites, although they were 
not seeing physicians as much (in Medicare). Interestingly, both blacks and Hispanics 
tended to rate their relationship with providers more positively than whites. 
 
 
Adherence Measurement and Validation 
 
 In validating our approach to derive refill days of supply from dispensed 
quantities, we compared continuous PDC and dichotomous adherence calculated using 
the derived distribution of supply days to those calculated using the actual days of supply 
data in the 2010 sub-sample of our study sample. As shown in Table 2-2, we found the 
PDC measurements based on derived days of supply to be in substantial agreement with 
PDC measurements based on actual days of supply. Agreement was highest when a 
refined approach was followed to derive days of supply from dispensed quantities 
(Discretization 3 in Table 2-2; Lin’s concordance coefficient 0.97, κ-statistic 0.94). This 
level of agreement was also consistent across drug classes, and at all stages of PDC 
measurement. Using the “Discretization 3” scheme, we calculated PDCs for our entire 
sample.  
 
 
Multivariable DID Logistic Regressions  
 
To substantiate our DID analysis, we graphically assessed the adjusted trends in 
adherence disparities across treated and control groups from 2002 to 2010. Since 
Medicare seniors and the near-elderly were different in important ways, particularly 
health and socioeconomic status, examining trends adjusted for covariates was a more 
appropriate approach to assess the common trend assumption central to the validity of 
DID analysis. Figure 2-3 provides visual evidence to suggest that adherence disparities 
in both groups were on similar trajectories until around 2005 when, interestingly, 
adherence trends started to change among both seniors and their near-elderly 
counterparts, even before the formal implementation of Part D in 2006. 
 
 In the main sample and subgroups, we estimated multivariable logistic models of 
adherence as a function of the DID interactions, as well as the full set of covariates. The 
magnitude of the DID coefficients, specifically the triple interactions of race, Medicare 
coverage, and post-Part D, remained relatively stable to sequential adjustment for 
covariates. This observation is illustrated in Appendix Figure A-1. Coefficient estimates 
expressed in terms of odds ratios for all models, are listed Appendix Table A-3 and A-4. 
All models had non-significant P values in Hosmer-Lemeshow modified Goodness-of-Fit 
tests, indicating adequate fit for the data.  
 
 
Ranking-and-Replacing H Distributions in the Main Analysis 
 
Using the rank-and-replace procedure, we adjusted the marginal adherence 
predictions (specifically, average probabilities of adherence) based on our estimated 
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Table 2-2. Derivation of refill days of supply and validation of adherence measurement in the 2010 sub-sample (n= 
1,282) 
 
Deriving refill days of supply from dispensed 
quantities of pills 
 Agreement between the original PDC distribution based on actual 
days of supply vs. PDC distributions derived via discretization of 
dispensed quantities of refills 
Scheme Dispensed Quantity  
Corresponding 
Days of Supply 
 Continuous PDC  Binary Adherence Classification 
 Pearson 
Correlation 
Lin's 
Concordance 
 Observed 
Agreement 
κ 
Statistic 
C-
Statistic 
Discretization 1 ≤45 30  0.94 0.94  94.07% 0.88 0.94 
>45 but ≤75 60   
>75 90   
Discretization 2 ≤75 30  0.96 0.95  95.71% 0.91 0.96 
>75 90   
Discretization 3 0-7 Same  0.98 0.97  96.96% 0.94 0.97 
8 16   
9-14 Same   
15-16 30   
20-44 Same   
45 90   
46-75 30   
76-119 90   
120 30   
>120 90   
 
Discretizations 1 and 2 are rather crude and have no concrete empirical basis. Discretization 3 is a refinement based on the 
actual empirical distributions of days of supply vis-à-vis dispensed quantities, where “Corresponding Days of Supply” was the 
most frequent (usually >90% of the time) days of supply observed for each quantity dispensed
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Figure 2-3. Graphical assessment of the common trend assumption of adherence 
disparities among Medicare seniors and near-elderly controls 
Disparity is on the Y-axis and is empirically equal to the difference by race in the 
adjusted average probability of overall cardiovascular medication adherence 
(Pr(PDC≥80%)). PDC: Proportion of days covered; Tx: Treated; Ctrl: Control  
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models with full covariate specification, for the H variables, namely: demographics, 
health status, clinical need, and beliefs/preferences (including geography). By replacing 
the distributions of H variables of minorities with those of their white counterparts, we 
created counterfactual minority groups that possessed whites’ H distributions while 
keeping their observed distributions of SES and other S variables. In essence, this is 
similar to a hypothetical experiment where two clinically similar groups are randomly 
assigned a treatment: here, the groups are the factual whites and the counterfactual 
minorities, and the “treatment” is minority race with all the relevant facets of 
disadvantage it typically involves. As Figure 2-4 shows, after ranking-and-replacement, 
H distributions of minorities became virtually identical to those of whites. 
 
 
Effect of Part D on Adherence Disparities in the Main Analysis  
 
 Table 2-3 shows the results of the main analysis. Following Part D introduction, 
rates of adherence to cardiovascular medications improved a significant 59% among 
Hispanic Medicare seniors (29% to 46%), 47% among whites (32% to 47%), and only 
9% among blacks (35% to 38%). Among the near-elderly, adherence levels also 
improved in 2007-2010, but with smaller magnitudes and significantly favored whites 
over minorities. Prior to Part D, disparities in adherence were non-significant among 
seniors. Over the same period (2002-2005), adherence was significantly better among 
Hispanics than whites in the near-elderly population.  
 
Following Part D implementation, there was a significant increase in white-black 
disparities among seniors (+11 percentage points, P<0.01), and no significant change 
among the near-elderly (+5% points, P>0.05). On the other hand, while there was no 
statistically significant change in white-Hispanic disparities among seniors (-2% points, 
P>0.05), there was a significant upsurge in these disparities among the near-elderly 
(+14% points, P<0.05). Taking the trends in the treated and control groups together, we 
estimated that Part D was associated with a significant 16%-point reduction in white-
Hispanic disparities. There was however no statistically significant DID change due to 
Part D in black-white disparities in overall cardiovascular medication adherence. These 
findings are summarized in Figure 2-5.  
 
 
Subgroup Analyses 
 
 In addition to estimating the overall average effect of Part D, we also assessed its 
impact on the racial disparities among men, women, the dually eligible for Medicaid, and 
the non-dually eligible. Additionally, we evaluated how results would change if we 
included 2006 data or restricted the treated group to seniors 65-70 years of age. As shown 
in Figure 2-6, the average DID estimate of Part D on adherence disparities in each of 
these groups. Including 2006 data in the post-Part D period pushed the increase in black-
white disparities further towards the null (+0.03 vs. +0.06% points in the main analysis, 
P>0.05 for both), while yielding virtually the same reduction in white-Hispanic  
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Figure 2-4. Observed and replaced distributions of the H linear predictor and 
conditions count for whites and blacks 
P values for Kolmogorov-Smirnov tests for the equality of black and white distributions:  
Xβ distributions: observed white & black: P<0.001, observed white vs. replaced black: 
P=1.000;  
Condition Count: observed white & black: P<0.001, observed white vs. replaced black: 
P=0.903. 
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Table 2-3. Overall cardiovascular medication adherence levels and disparities in 
the treated/control groups before and after Medicare Part D 
 
Outcome  
Medicare Elderly  Near Elderly Controls 
Pre-Part D  
(2002-05) 
 Post-Part D 
(2007-10) 
 Pre-Part D  
(2002-05) 
 Post-Part D  
(2007-10) 
Estimate [95% CI] 
Average Adherence 
White 0.32 [0.30,0.34]  
0.47 
[0.45,0.48]  
0.30 
[0.26,0.34]  
0.47 
[0.43,0.51] 
Black 0.35 [0.30,0.39]  
0.38 
[0.35,0.42]  
0.34 
[0.28,0.40]  
0.46 
[0.39,0.53] 
Hispanic 0.29 [0.24,0.33]  
0.46 
[0.42,0.50]  
0.39 
[0.31,0.46]  
0.42 
[0.35,0.49] 
Adherence Disparities 
White-Black -0.03 [-0.07,0.02] 
 0.08 
[0.04,0.12] 
 -0.04 
[-0.12,0.03] 
 0.01 
[-0.09,0.07] 
White-Hispanic 0.03 [-0.01,0.08] 
 0.01 
[-0.04,0.05] 
 -0.09 
[-0.17,-0.01] 
 0.05 
[-0.03,0.13] 
Change in Disparities over Time 
White-Black 0.11 [0.05,0.17]  0.05 [-0.05,0.15] 
White-Hispanic -0.02 [-0.08,0.04]  0.14 [0.03,0.25] 
Difference-in-Differences  
White-Black 0.06 [-0.06,0.18] 
White-Hispanic -0.16 [-0.29,-0.03] 
 
Boldface denotes P<0.05. 
Estimates are probability-scale predictions, adjusted for health status/clinical need using 
the rank-and-replace procedure. Disparities are the differences in the average probability 
of adherence by race. Standard errors underlying confidence intervals were estimated via 
Taylor series linearization and combined across 5 multiply imputed datasets.  
 
  
 30 
 
 
 
 
Figure 2-5. The impact of Part D impact on adherence disparities in overall 
cardiovascular medication adherence 
Pr(PDC≥80%) is the average probability of adherence. Capped spikes represent 95% 
confidence intervals. Point estimates and 95% CIs are provided in the last four rows of 
Table 2-3. PDC: Proportion of days covered; Tx: Treated; Ctrl: Control; DID: 
Difference-in-differences 
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Figure 2-6. The impact of Part D on adherence disparities in subgroups 
Pr(PDC≥80%): average probability of adherence. Capped spikes represent 95% 
confidence intervals. PDC: Proportion of days covered; DID: Difference-in-differences 
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disparities as the main analysis. Among seniors 65-70 years old, Part D had the same 
effect on white-black disparities, whereas the reduction in white-Hispanic disparities was 
lower in magnitude and statistically non-significant (-9% points).  
 
Further, as in Figure 2-6, while Part D was associated with a non-significant 
change (-4%, P>0.05) in the disparity between white and black women, we found a 
significant increase in white-black disparities among men (+21% points, P<0.05). DID 
effects of Part D on white-Hispanic disparities by gender were statistically non-
significant .Similarly, Part D effects on disparities by dual eligibility status were all non-
significant. 
 
We also investigated the DID effects of Part D on the disparities in adherence to 
each cardiovascular medication class. As in the main analysis, Part D was associated with 
no statistically significant changes in white-black disparities in adherence to each 
medication class. White-Hispanic disparities followed the same direction as in the main 
analysis, with beta-blocker adherence disparities showing a large, statistically significant 
decrease (-30% points, P<0.05). Other changes in white-Hispanic disparities by 
medication class were not significant. For reference, Appendix Table A-5 (Column 1) 
lists all DID point estimates and confidence intervals for all subgroups. 
 
 
Current Racial Disparities in Adherence in Medicare 
 
 While Part D was implemented to expand access to prescription drugs and 
improve the quality of medication use, our data suggest that the policy may have had 
some unintended consequences. In fact, as Figure 2-7 shows, large and statistically 
significant disparities in adherence between white and black seniors remain in the post-
Part D era. Over 2007-2010, the white-black disparity in overall adherence was 8% 
points in the entire sample, 11% points among men, 7% points among women, 8% points 
among the non-dually eligible, and a high 19% points among the dually eligible (P<0.01 
for all). White-Hispanic disparities, on the other hand, were much smaller (and 
statistically non-significant), except among the dually eligible: 15% points (P<0.01).  
 
We also examined levels of disparities in adherence to each drug class, over 2007-
2010. While we did not detect statistically significant white-Hispanic disparities in 
adherence to each medication class (all below 5% points, P>0.05), we found larger white-
black disparities in adherence to ACE inhibitors/ARBs (6% points, P<0.05), beta-
blockers (8% points, P<0.01), and diuretic agents (8% points, P<0.01). All point 
estimates and 95% CIs for adherence disparities in Medicare over 2007-2010 are listed 
for reference in Appendix Table A-5 (Column 2). 
 
 
Sensitivity of Results to Disparity Definitions 
 
 Finally, we assessed the robustness of our estimates to various definitions of 
disparities, starting from racial differences in crude, unadjusted adherence proportions to  
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Figure 2-7. Racial disparities in overall cardiovascular medication adherence 
among Medicare seniors in 2007-2010 by subgroup 
Pr(PDC≥80%) is the average probability of adherence, predicted for each group using the 
main logistic model and adjusted for H variables using the rank-and-replace procedure. 
Capped spikes represent 95% confidence intervals.  
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fully adjusted RDE disparities. Appendix Table A-6 lists the results of these analyses, 
both DID estimates as well as estimates of disparities in the post-Part D period (2007-10). 
 
When we estimated the DID effect of Part D on the racial differences in 
unadjusted adherence proportions, we found no statistically significant change in white-
black differences (+5% points, P>0.05) while white-Hispanic differences decreased by 
18% points (P<0.01). Further, regardless of the level of adjustment of disparities to 
various factors (e.g. demographics, health, beliefs, SES, etc), the DID effect of Part D 
remained virtually the same: no statistically significant effect on white-black disparities, 
and a 16%-point decrease in white-Hispanic disparities. As with our earlier analyses, the 
magnitude of adherence disparities among seniors in the 2007-2010 period was not 
sensitive to the how we empirically defined disparity (Appendix Table A-6, Column 2).  
 
 
Discussion 
 
 Part D introduction was associated with a 59% improvement in cardiovascular 
medication adherence among Hispanics, 47% among whites, and only 9% among blacks. 
This finding largely agrees with a recent study, by Mahmoudi and Jensen, of the effects 
of Part D on disparities in drug use and expenditure (also used MEPS data in a 
difference-in-differences evaluation),62 which found that Part D significantly reduced 
white-Hispanic disparities. These authors also reported Part D had no significant effect 
on white-black disparities in measures of drug use and expenditure, except on the 
disparity in total drug expenditure, which may have increased following Part D.62  
 
The net reduction in white-Hispanic disparities is numerically the result of a 
modest decrease in this disparity in the Medicare population and a large increase among 
the near-elderly controls in the 2007-2010 period. There are a number of potential 
explanations for the reduction in white-Hispanic disparities. First, our data and recent 
literature59 show that after 2006, Hispanics were primarily covered by Part D Medicare 
Advantage prescription drug (MA-PD) plans, significantly more so than whites and 
blacks (41%, vs 33 and 29% among blacks and whites, respectively, in our sample). Most 
MA-PD plan enrollees were enrolled in an MA plan prior to 2006;103 these beneficiaries 
generally experienced a smoother transition to drug coverage with the advent of Part D 
thanks to the subtle integration of the new benefit into the already existing managed care 
structure.59 Further, these plans have been offering more generous drug coverage than 
Part D stand-alone prescription drug plans (PDP),103 and their design is associated with 
much less disparities in access to drugs and benefit information,59 as well as better 
coordination of care.104  
 
Hispanic seniors were more likely to be automatically eligible for the low-income 
subsidy than blacks and whites (46%, vs. 30 and 8% among blacks and whites, 
respectively, in our sample). They may also have been better primed for Part D given 
their presumably higher participation rates in the pre-Part D drug discount card program 
from 2004-2005 (this program was started by the Centers for Medicare and Medicaid 
Services (CMS) to subsidize drug costs for non-dually eligible low-income beneficiaries, 
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with income up to 135% of the federal poverty line, in anticipation of Part D 
implementation).105 This could as well explain the decline in white-Hispanic adherence 
disparities in Medicare starting in 2005, even before Part D launch in 2006.  
 
Among the near-elderly, where 80% receive employer-sponsored insurance, 
adherence disparities increased. As in Table 2-3, over 2007-2010, adherence rates rose 
most for near-elderly whites, rose modestly for blacks, and least for Hispanics; 
particularly worsening the disparity between whites and Hispanics. Our data show that 
rates of prescription drug coverage declined 11% among near-elderly Hispanics, 7% 
among blacks, and only 2% among whites, perhaps as a result of differential loss of 
employment and employer-sponsored coverage. The economic recession and rising 
unemployment rates that loomed in the 2007-2008 fiscal year might thus offer a potential 
explanation for the increase in adherence disparities among the near-elderly controls. 
 
Except among men, where Part D was associated with a significant 21%-point 
increase in the white-black disparity, Part D was not associated with significant changes 
in white-black disparities. For those over 65, however, average adherence to all 
cardiovascular medications actually worsened 11% points more among blacks relative to 
their white counterparts. A number of factors might explain this widening of the white-
black adherence disparity. First,  black seniors,60 especially non-duals and even those 
enrolled in MA-PD plans59 found it much harder to get necessary information about their 
covered prescription drugs compared to whites and Hispanics. Second, blacks were more 
likely to enroll in Part D stand-alone PDPs, where they were more prone to significant 
disparities compared to whites in accessing medications and benefit information,59 and to 
lower overall adherence levels,106 relative to MA-PD plans. It is worth noting here that 
the greater enrollment in MA-PD plans among Hispanics compared to blacks may be a 
direct consequence of the disparate geographic concentration of these two groups: e.g. 
Hispanics in the West enjoy greater access to these plans since Western states have much 
higher market penetration by managed care plans.107 
 
Third, our data show as above that black seniors were generally less likely than 
Hispanics to be automatically signed up for the LIS. Black females, however, were more 
likely than males to be eligible for the LIS, and, in fact, were more likely to enroll in Part 
D coverage from the outset.60 This could explain why Part D was associated with a 
significant increase in white-black disparities among men but not women. Fourth, blacks 
are more likely than whites and Hispanics to have complex cardiovascular regimens, e.g. 
concurrently taking multiple drugs (Table 2-1), which could be predisposing them to 
persistently lower adherence rates compared to whites.  
 
Our results, as in the literature,28-31 expectedly show that racial disparities in 
adherence continue to exist in Medicare. White-black disparities were significant, while 
white-Hispanic disparities were significant only among the dually eligible. The disparate 
experiences we discussed above between minority seniors and their white counterparts 
undoubtedly account for a sizable portion of these disparities. Three more Part D-related 
issues set racial groups further apart. First, among non-Medicaid seniors who were still 
eligible for the LIS (below 150% of the poverty line), minorities are less likely to be 
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aware of this benefit,103 and predictably less likely to receive it. Second, these 
beneficiaries (non-Medicaid, LIS-eligible minorities), especially high users, might be 
more likely to fall in the coverage gap (so-called “donut hole”) further exacerbating their 
medication-taking behavior.48 Third, recent evidence has shown that minorities are less 
likely to meet Part D utilization-based eligibility criteria for medication therapy 
management (MTM) services.63,64 This deprives scores of minority patients from a 
benefit that is well-equipped to help them with their complex medication-related issues, 
including adherence behavior.53 
 
While it is important to identify access/quality issues that may disparately 
compromise adherence behavior among minorities, it is at least equally as important to 
envision adherence as a reflection of the structural, physical, and psychosocial 
disadvantage racial minorities typically live in. Poverty, low educational attainment, 
disordered physical and social environments, and policies that institutionalize racism are 
systematically causal antecedents to almost every poor health outcome among 
minorities.108 While achieving equity in these fundamental determinants of health must 
remain a long-term goal for society, collaborative, creative, and holistic interventions by 
healthcare professionals can provide some quick remedies in the short-run. In Medicare, 
MTM programs can offer a platform to empower minorities to adhere to their appropriate 
medication regimens and lifestyle recommendations, improve their health literacy, and 
enhance their self-efficacy, central to a variety of self-management behaviors.109 Delivery 
of MTM in collaborative/referral networks that bring together providers, pharmacists, 
social workers, and community/home health workers can proactively identify and tackle 
issues compromising medication adherence (and potentially other aspects of healthcare). 
Further research110 is needed on how to optimize MTM delivery for minority and low-
SES patients.  
 
For effective interventional research on how to reduce adherence disparities, 
greater appreciation of the complexity of adherence is warranted. Adherence should be 
understood as a series of behaviors that start with keeping doctor’s appointments to actual 
administration of medications, involving steps such as regularly filling prescriptions, 
using reminders, exercising, and maintaining healthy diet.111 These contiguous behaviors 
arise from complex interactions among multiple factors, pertinent to the patient and the 
environment. Given this complexity, we need to build a deeper mechanistic 
understanding of how this intricate system works and how/where it engenders disparities. 
Parsing out this intricacy, through complex systems science and simulation approaches, 
enables us to identify novel “leverage points” for effective intervention that were 
potentially otherwise unidentifiable.112 Studying adherence this way can also help us 
answer interesting clinical questions, some of which does arise in this study, such as why 
the magnitude of adherence disparity differ by medication class (for example, why 
disparities are larger in adherence to beta-blockers more than other classes, and only 
among blacks).  
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Limitations 
 
The results of this study should be understood in the light of its limitations. First, 
our derivation of refill days of supply from dispensed quantities was based on 2010 data 
of MEPS, without validation against an external standard, claims data for example. Given 
that previous research has demonstrated that MEPS prescription drug data are of 
comparable quality to Medicare claims data,87 we believe benchmarking our analysis 
solely to MEPS 2010 is credible. An alternative to “manually” deriving refill days of 
supply from dispensed quantities would have been to formally impute days of supply in 
earlier years of MEPS using a multiple imputation regression model informed by refill- 
and respondent-level covariate data in the 2010 sample. We found however that 
dispensed quantities overwhelmingly accounted for the variation in days of supply, with 
all possible covariates explaining as little as 1% of the variation in days of supply (based 
on R2 calculations). To do multiple imputation properly on missing data of this magnitude 
(nine tenths of the data are missing, essentially), we would have needed to impute over 
more than 90 datasets, which is computationally intensive and would require technically 
challenging handling in subsequent analyses. Notwithstanding these caveats, the 
substantial level of agreement we detected between adherence measures based on actual 
vs constructed days of supply, consistently at all stages of adherence measurements and 
across drug classes, reinforces the validity of our approach. 
 
While data on dispensed quantities were 100% complete for all refills from 2002-
2010, a large proportion of 2010 refills had missing days of supply data (about 33%). We 
found the pattern of missing data to be very consistent across drug class and respondent 
characteristics, indicating that a missing-completely-at-random (MCAR) assumption is 
likely plausible. As such, we examined the pattern of refill days of supply vis-à-vis 
dispensed quantities only among individuals with complete days of supply data for all 
their listed refills. We also assumed that the patterns of supply days vis-à-vis dispensed 
quantities in 2010 would hold in earlier years of MEPS. Although we believe this 
assumption is likely true on average, changes in treatment guidelines and generic 
availability might have affected the prescribed total daily doses of some cardiovascular 
medications, especially in earlier years of our study period (for example, in 2002 and 
2003 before the 7th Joint National Committee (JNC-7) guidelines on hypertension 
management were issued/adopted). 
 
Since we used the annual files of MEPS, sampled individuals were mostly 
prevalent, rather than incident, users of the study medications, as it was not possible to 
ascertain medication use in the year prior to the index refill. Although MEPS had dates 
for when a drug was first taken, these dates were missing for about 80% of refills and no 
inference could be made on whether respondents were new or prevalent users of 
medications on the basis of these dates. Another complication of using the annual files is 
that many covariates were not available at baseline (i.e. the first interview round), but, 
rather at other time points (e.g. physical activity available in last round of the year). This 
temporal ambiguity might have affected the identification of covariate associations with 
adherence. We were primarily interested, however, in the identification of DID effects, 
which we properly assessed over the pooled cross-sections before and after Part D. We 
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used covariates to make the DID assumptions more plausible and to fine-tune our 
definitions of disparities.  
 
We encountered the rather surprising finding that predicted disparity estimates 
were not sensitive to various levels of adjustment using the rank-and-replace procedure. 
It is unclear whether this is a statistical consequence of covariate assessment, outcome 
variable construction, or it is indeed the case that our covariates could explain little about 
adherence disparities. In the 2010 sample, we compared coefficient estimates from 
models of adherence using: 1) actual vs constructed days of supply data and 2) using only 
covariates temporally antecedent to adherence (e.g. first-round covariates on the right-
hand side with adherence in the remaining two rounds as the outcome) vs simultaneous 
outcome-covariate models. We found no statistically significant differences in coefficient 
estimates across these models.  
 
An alternative to using the annual files would have been to use the longitudinal 
two-year panel version of MEPS. This, however, would have cut our sample in half 
(since annual files pool the two overlapping panels of the year), further inflating the 
standard errors and rendering point estimates unstable and untrustworthy. We encounter 
this problem to some extent in subgroup analyses (e.g. in the dually eligible sub-sample), 
where quite large estimates are statistically no different from zero! 
 
Based on previous research,47 we used the near-elderly as the control group that 
provides the counterfactual scenario that would have prevailed in Medicare had Part D 
not been implemented. Two issues challenge the validity of this control group. First, the 
Medicare Modernization Act of 2003, which created Part D, also established the pre-Part 
D drug discount card program for transitional assistance of low-income beneficiaries105 
and further subsidized MA plans to expand their benefits, in 2004-2005.62 With minority 
seniors taking advantage of these two changes together, the trend of adherence disparities 
among seniors started to partially deviate from being parallel to its near-elderly 
counterpart before Part D implementation in 2006. Further, growing enrollment of 
minority beneficiaries in MA plans after Part D62 could also mean that some of the 
observed changes in disparities might actually be attributed to changes in Medicare 
Advantage and not directly to Part D. Second, the near-elderly experienced the shock of 
the economic recession and job loss that loomed in 2007-2008. This has likely set the 
trend of disparities among the near-elderly on an ascending path that would not have been 
necessarily experienced by seniors in the absence of Part D (about 60% of the near-
elderly were employed vs only 14% of seniors). Nonetheless, since the perfect control 
group is lacking in this policy space (that is, 65-year plus old seniors without Medicare), 
the near-elderly make a reasonable control group to study changes in healthcare delivery 
and financing in Medicare. Despite the aforementioned limitations, findings in this study 
are consistent with the published literature and can be readily accounted for by the 
observed changes in healthcare access and delivery among Medicare seniors and the 
near-elderly.  
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Conclusion 
 
In a nationally representative sample from MEPS, we used a quasi-experimental 
difference-in-differences design to evaluate Medicare-wide effects of Part D introduction 
on the racial disparities in adherence to cardiovascular medications. We took a nuanced 
approach to conceptualizing and estimating adherence disparities according to the IOM 
framework, and performed multiple subgroup and sensitivity analyses to assess the 
robustness of our conclusions. Our results suggest that following Part D, the overall 
cardiovascular medication adherence disparity between white and Hispanic seniors has 
narrowed by 16% points, whereas there was no statistically significant change in the 
white-black disparity, except among men where it increased by 21% points.. Significant 
adherence disparities continue to remain among the elderly in Medicare, especially 
among dually eligible beneficiaries. Differential awareness of and access to benefits, such 
as the LIS among the non-dually eligible, as well as the institutionalized disparity in 
access to MTM services may be immediate targets for policy interventions to improve 
adherence behavior and the overall quality of medication therapy in Medicare. Research 
on the determinants of adherence disparities and on optimizing the delivery of 
interventions, such as MTM, to answer the needs of minority beneficiaries is much 
needed.  
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CHAPTER 3.    RACIAL DISPARITIES IN ADHERENCE TO 
CARDIOVASCULAR MEDICATIONS AMONG THE ELDERLY IN 
MEDICARE: LOOKING BEYOND THE MEAN 
 
 
Background 
 
 In cardiovascular diseases, adherence to evidence-based medication regimens is 
key to achieving the goals of pharmacotherapy and slowing disease progression.15,74 
Lower medication adherence rates exist among racial/ethnic minorities, relative to whites, 
even in settings with equitable access to prescription drugs.11,33 In the Medicare program, 
where Part D introduction enhanced adherence by improving the affordability and quality 
of use of medications,41,45,46,53 adherence disparities continue to persist. After Part D 
implementation, Holmes et al reported that among Medicare seniors with uncomplicated 
hypertension, blacks and Hispanics were about 45% less likely to be adherent to their 
antihypertensive medications, including alpha- and beta-blockers, angiotensin-converting 
enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), Calcium channel 
blockers (CCBs), diuretics and vasodilators.28 Zhang et al examined adherence to ACE 
inhibitors/ARBs and diuretics among seniors with heart failure, and found blacks, 
Hispanics, and Native Americans to be about 40% less likely to achieve adherence than 
whites.29 Zhang et al also reported that black and Hispanic seniors surviving acute 
myocardial infarction (AMI) were 20-30% less likely to adhere to beta-blocker, ACE 
inhibitor, or statin therapy for 6 months or a year post-infarction.30 In an analysis across 
race and gender of AMI survivors, Lauffenburger et al reported that black and Hispanic 
women were least likely (having about 30-36% lower odds), compared with white men, 
to be adherent to these post-AMI preventive therapies.31 In a meta-analysis of published 
studies, Lewey et al estimated that generally patients of non-white race were at about 
50% higher odds of non-adherence to statins than whites.32 
 
Substantial disparities exist between whites and racial minorities in the control of 
blood pressure and cholesterol levels,10,113-115 and predictably in cardiovascular disease 
progression and mortality.3,4,6,7 Among the multiple social and behavioral factors that 
might explain the disparities in these risk factors,8,12-14 the disparities in cardiovascular 
medication adherence are repeatedly identified as a key culprit.7,8,12,15 Although extant 
evidence documents adherence disparities, a full understanding of these disparities is still 
lacking. One missing piece in this puzzle is a greater appreciation of how these disparities 
vary across the distribution of adherence where different adherence levels may represent 
populations with distinct patterns of behavior. Current literature have predominantly 
documented disparities in the probability of 80% adherence, which has been the 
traditional cutoff for adherence classification. Apart from the arbitrary nature of this 
cutoff and its apparent lack of a clear clinical rationale,16,116,117 it represents only one 
level of adherence behavior and indiscriminately lumps potentially distinct patterns of 
behavior below and above 80% medication possession. 
 
 Studying disparities in the probability of 80% adherence (or some other cutoff), 
albeit informative, thus risks ignoring disparities among populations at other levels of 
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adherence, which may be driven by potentially different factors and amenable to distinct 
interventions. Further, studying adherence (as a continuous outcome) in typical 
regression frameworks falls prey to a similar phenomenon, where the modeled outcome 
is mean adherence conditional on the included set of control variables. Because of the 
nature of the mean as a summary statistic of central tendency, disparities at other 
locations in the adherence distribution will only “show up” in the mean if they are 
relatively large. Thus, using a single cutoff or a continuous measure of adherence may 
obscure disparities that occur at other locations in the adherence distribution, even ones 
that may be significant and policy-relevant. 
 
Quantile regression70,118-120 is a powerful technique that allows assessment of how 
predictors (e.g. race in this study’s context) influence the central and non-central 
locations, scale, and shape of the outcome distribution.121 Widely applied in labor 
economic evaluations, such as in the study of wage inequality,120 applications of quantile 
regression to study health disparities have increased in recent years,122-127 including a few 
applications in the context of adherence disparities.128,129 Besides enabling the 
investigation of the heterogeneity of adherence disparities across the distribution, quantile 
regression is well suited to accommodate the quasi-continuous left-skewed distributions 
of medication possession measures.128 In one interesting example, Gebregziabher and 
colleagues128 showed that black-white disparities in medication adherence among type 2 
diabetes patients persisted across the distribution of the medication possession ratio 
(MPR) and particularly around 60% MPR, whereas white-other race disparities were 
significant only at the lowest quantile (corresponding to ~ 40% MPR) and were not 
detectable at the mean. Juarez et al129 also examined disparities in adherence to anti-
diabetic and lipid-lowering medications between Pacific Islander and white Americans in 
Hawaii. She found that disparities relative to whites were largest and most significant at 
the 25th percentile of the PDC (proportion of days covered; a variant of the MPR) 
distribution and decreased monotonically towards the higher percentiles of the 
distribution. These findings point to sub-populations where adherence disparities may be 
most amplified and potentially deserving priority intervention. 
 
 In this study, we sought to explore the heterogeneity of racial disparities across 
the distribution of adherence to cardiovascular medications, among Medicare seniors 
after 2006. We used a versatile unconditional quantile regression estimator, recently 
developed by Firpo, Fortin, and Lemieux.70 As we further explain in the “Statistical 
Analysis” section, in multivariable regression settings where predictors may have 
interactive effects on the outcome, making the assumption of additive covariate effects 
unrealistic, unconditional quantile regression directly provides the appropriate estimates 
of marginal effects of covariates on outcome quantiles.130 
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Methods 
 
 
Data Source 
 
We used longitudinal data from the household component of the Medical 
Expenditure Panel Survey (MEPS), panels 11 to 14 spanning years 2006 to 2010. MEPS 
is an annual overlapping panel survey of the US civilian non-institutionalized population, 
administered by the US Agency for Healthcare Research and Quality (AHRQ).131 The 
primary focus of MEPS is on healthcare access, use, and expenditure in the United States, 
enabling calculation of national impact estimates for a wide variety of health policy 
changes. Each year MEPS panel participants are sampled from the previous year’s 
respondents to the National Health Interview Survey (NHIS), with oversampling of 
minorities and other policy-relevant groups (such as adults with functional limitations 
and low-income households).131 Each panel is then prospectively followed for two 
calendar years and their data are collected over five rounds of computer-assisted personal 
interviewing. Rounds 1 and 2 fall in the first year, rounds 4 and 5 fall in the second year, 
while round 3 spans the end of the first and the beginning of the second year. AHRQ 
provides two types of main data files that can be linked to Medical Conditions and event 
files: longitudinal and annual/cross-sectional (known as Full Year Consolidated Data) 
files. For this study, we linked the longitudinal panel files to the Medical Conditions and 
Prescribed Medicines event files. Although all MEPS data are reported by respondents 
during round interviews, further detailed health service use data, including on 
prescription drugs, are collected from a sample of providers (e.g. medical and pharmacy) 
with respondents’ permission. Then these data are used to supplement respondents’ self-
reports of health service use and expenditure. Of particular relevance to this study, the 
quality of MEPS prescription drug data, as well as Medicare Part D enrollment has been 
shown to be comparable to that of claims data.87,88 MEPS also provides very rich data on 
respondents’ sociodemographics, health and chronic conditions, as well as experience 
with providers and the healthcare system, allowing a thorough study of adherence as 
shaped by these determinants. 
 
 
Cohort Identification 
 
We included MEPS respondents who were: 
1) Continuously included in all MEPS survey rounds for the two panel years, 
excluding those who went “out of scope” because of death, institutionalization, or 
other reasons.  
2) Medicare beneficiaries 65 years or older as of Round 1, who reported receiving 
Medicare until the end of the second year (Round 5).  
3) Non-Hispanic white (henceforth “white”), non-Hispanic black (henceforth 
“black”), or Hispanic. We excluded other racial/ethnic groups and did not further 
distinguish Hispanic subgroups as their small sample sizes limited such 
inferences. MEPS ascertains race/ethnicity as follows:132 first, respondent’s self-
report of their race/ethnicity is the primary way to procure this data. Then, if not 
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available, race/ethnicity is obtained from the originally collected NHIS data in the 
year prior to joining the MEPS panel. Finally if not available either way, MEPS 
assigns race/ethnicity based on respondent’s relationship to other members of 
his/her household starting with blood relatives in the immediate family. MEPS 
survey questions assessing race/ethnicity have been consistent since 2002.132  
4) Had at least one of the following six prevalent conditions in both year 1 and year 
2: hypertension, hyperlipidemia, angina, congestive heart failure, myocardial 
infarction, or stroke, listed in the linked Medical Conditions file. Clinical 
Classification Codes and 3-digit ICD-9 codes in MEPS were used to identify 
respondents with these conditions.133 Appendix Table A-1 (Chapter 2) lists all 
the conditions and their associated codes. Identified respondents had at least one 
event (inpatient, outpatient, or prescription drug) associated with one or more of 
these conditions. 
5) Were prevalent users of at least one chronic cardiovascular medication of the 
following classes: ACE Inhibitors, Angiotensin II Receptor Blockers (ARBs), 
HMG-CoA Reductase Inhibitors (Statins), Beta-blockers, Calcium Channel 
Blockers, Diuretics, or combination products of these medications. Use was 
defined as having at least one refill for the same medication class in both years. 
Second-year refills were used to estimate adherence. 
 
Since our study sample only included a small portion of MEPS respondents, we 
pooled MEPS panels 11-14 by year to create one analytical file with adequate sample size 
for our analyses. Pooling MEPS data is commonly practiced and survey design variables 
in MEPS files for our study period specify a common variance structure that takes into 
account pooling when calculating standard errors.89 Our final analytical file contained 
pooled data for year 1 (2006-2009), the baseline year, and year 2 (2007-2010) where 
adherence was estimated. 
 
 
Adherence Measurement 
 
 Using refill records for included respondents in the second year, we measured 
adherence to each medication class as the proportion of days covered (PDC) by refills for 
any medication from that class, expressed as a percentage and capped at 100%. Thus, in 
the case of overlapping refills for two beta-blockers, for example, only one refill was 
counted towards calculation of the beta-blocker-specific PDC. ACE inhibitors and ARBs 
were also considered a single class for this purpose. Component medications of 
combination products were also counted towards their respective classes. Since MEPS 
does not collect refill dates, an index date specific to each medication class was identified 
for each respondent as the first day of the round in which the first refill (for the specific 
class) occurred. These rounds were either the fourth, the fifth, or the portion of the third 
round that had fallen in the second year. Respondents were then followed until the last 
day of the fifth round, which corresponded to December 31st of the second year in the 
panel for all participants. Inpatient days were excluded from the follow-up period. For all 
classes, while a majority of respondents (55-60%) had January 1st of the second year (i.e. 
the part of round 3 that fell in year 2) as the class-specific index date, more than 95% of 
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index refills had occurred by March of the second year. To summarize adherence over all 
medication classes, we calculated a respondent-specific PDC that was the average of all 
his/her class-specific PDCs. The main outcome variable was the overall continuous PDC. 
We explored class-specific adherence in sub-group analyses. 
 
 Although MEPS provides extensive data on prescription refills, including 
dispensed quantity, strength, dosage form, and therapeutic class/subclass, data on days of 
supply were not routinely collected until 2010. We used 2010 data, which was the second 
year of Panel 14 in our sample, to characterize the patterns of observed days’ supply as 
they relate to dispensed quantities of drug refills. In so doing, we identified the most 
frequent number of supply days furnished by each level of dispensed quantity. Next, we 
derived a scheme to smoothly approximate the distribution of days of supply for use in 
prior years of MEPS (where actual days of supply data are not available). Then, in 2010 
data, we calculated PDCs as explained above using the actual and constructed days of 
supply distributions. To assess the validity of our derivation, we used Lin’s concordance 
coefficient90,91 to compare the constructed distribution of days of supply as well as the 
PDC based on it, to the actual distribution and its associated PDC. (We also derived 
binary adherence at PDC≥80% based on the two distributions, and compared them using 
C-statistics). Then, we used our validated scheme to construct refill days of supply from 
dispensed quantities in all panels. The validity of computing refill days of supply in 
earlier years using the pattern of days of supply vis-à-vis dispensed quantities in 2010 
hinges on the potentially plausible assumption (based on discussions with two 
cardiologists with more than 20 years of practice experience) that the dosing frequency of 
a given strength of a specific cardiovascular drug has been stable over 2007-2010 in a 
specific patient population. (For example: for the same patient population, if a 30-pill 
refill of 40-mg simvastatin covers 30 days in 2010, on average, this would have also been 
true in 2007).  
 
 
Covariates 
 
We modeled the PDC distribution as a function of a series of baseline covariates 
assessed over the first year of the MEPS panel. In addition to race/ethnicity identifiers, 
which were the primary predictors of interest, we used data on respondents’ demographic 
characteristics; geographic location; self-reported health and functional (physical/ 
cognitive) status; depressive symptoms;134 cardiovascular conditions and other comorbid 
conditions; beliefs regarding health, risk, and insurance; income and poverty status, and 
educational attainment; health behaviors; type of primary insurance coverage for 
prescription drugs; financial and pill burden associated with medications; access to/use of 
primary care and other health services; and experience with providers and satisfaction 
with the healthcare system.  
 
In addition to binary indicators of which cardiovascular condition(s) respondents 
had in the baseline year, we also enumerated other comorbid conditions, such as diabetes, 
asthma, and cancer, and calculated a modified version of the Charlson comorbidity score 
(excluding respondent-specific cardiovascular conditions and depression) adapted for use 
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with 3-digit ICD-9 codes in MEPS.96 For socioeconomic status (SES), we used MEPS-
provided categories of income as a percent of the Federal Poverty Line (FPL) and 
categorized years of education into three levels: less than high school, high school 
diploma (12 years), and above high school. High-income and having education beyond 
high school served as the reference categories.  
 
For drug coverage status, we used a series of variables on insurance status as well 
as amounts paid by each payer for prescription drugs over the first year to ascertain drug 
coverage for each respondent. We identified three principal categories of coverage, as of 
December 31st of the first year: those who had no evidence of drug coverage by any 
payer, those who had Medicare Part D, and those who had a private source of drug 
coverage including employer-sponsored. Among Part D enrollees, we identified those 
who were concurrently enrolled in Medicare managed care and those who were not. Thus 
we were able to further split Part D recipients into those who had Medicare Advantage 
Part D plans (MA-PD) and those who were just enrolled in stand-alone Part D plans 
(PDPs) with no evidence of enrollment in MA. Further, we created an indicator for 
whether a Part D respondent was deemed eligible for auto-enrollment for the low-income 
subsidy (LIS), which included dually eligible beneficiaries and beneficiaries receiving 
Supplemental Security Income (SSI) (both variables were available in MEPS).55,57 Other 
LIS-recipients who are not automatically enrolled but their income is below 150% FPL 
and have limited assets must apply to receive the LIS.54 Although we validated the 
characteristics of these sub-categories of Part D recipients against the 
literature,54,56,58,59,103 ascertaining drug plan type or actual receipt of the LIS is not 
possible in MEPS. 
 
 
Disparity Definition 
 
 In the primary multivariable analysis, we defined disparities in adherence 
following the Institute of Medicine’s (IOM) framework for assessing healthcare 
disparities.66,92 The IOM contends that racial healthcare disparities are differences in 
healthcare that are not justified by the clinical appropriateness, health status needs, or by 
patients’ informed preferences and attitudes towards medical care.66 Healthcare 
disparities arise through two broad mechanisms:66 first, the legal and regulatory 
environment in which healthcare systems operate, including policies and practice 
patterns, insurance coverage, SES, and other differential factors that constrain healthcare 
use disproportionately for minorities,92 and second, discrimination at the patient-provider 
level, which may take multiple forms.95 As such, the IOM framework attempts to identify 
the contributions of the current structural impediments to achieving equity in the 
healthcare system, which are extrinsic to patients and potentially amenable to appropriate 
policy and clinical practice interventions.  
 
Accordingly, we defined racial disparities in adherence as the differences in 
adherence across clinically comparable racial groups that arise due to inequitable social 
and health-system factors, including SES, insurance coverage, access to primary care, 
and potential discrimination in the clinical encounter. Clinical comparability enables 
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isolating the disparities potentially engendered by social and health system factors, 
similarly to a hypothetical experiment where there are two groups with identical health 
profiles but only one receives racial disadvantage (socioeconomic and otherwise) as the 
treatment. Since the two groups possess identical health and disease burdens, their 
different rates of healthcare use (medication, in our case) must then be attributable to the 
“treatment,” that is racial disadvantage.  
 
We took a straightforward approach67,122,125,126 to empirically study adherence 
disparities as defined above, where we adjusted the association between race/ethnicity 
and adherence only for the effects of demographics, geographic location, health status 
and medical conditions, and beliefs. Only controlling for these variables balances out 
health characteristics of minority and white groups and allows the effects of variables 
potentially mediating disparities, such as SES variables, to be reflected in the 
race/ethnicity coefficients. This is also consistent with the empirical principle that if one 
wishes to estimate the total effect of a variable, race/ethnicity in our case, one should not 
adjust for intermediate variables on the causal pathway between the variable of interest 
and the outcome.135 Notwithstanding our a priori empirical definition of adherence 
disparities, we explored in secondary analyses the sensitivity of our primary findings to 
various definitions of disparities, through sequentially adjusting for groups of covariates 
up to full adjustment for all available covariates. 
 
 
Statistical Analysis 
 
We used unconditional quantile regression to explore how racial disparities 
change across the distribution of adherence. Quantile regression118,120 is analogous to 
ordinary least squares (OLS) regression except that it models conditional outcome 
quantiles instead of conditional means. Originally started as median regression, quantile 
regression allows exploration of the dependence of the outcome on covariates at other 
locations of the distribution, i.e. other quantiles. Mathematically, as Equation 3-1 shows, 
the qth conditional quantile of an outcome variable Y on covariates X can be written as, 
 
Qq?Y?X?=αq?+? Xk?qKk=1 .βkq?  (Eq. 3-1) 
 
where 0 < q < 1 is the modeled quantile, indicating that the proportion of the sample 
modeled is below the quantile q. This is not to say that quantile regression runs on a 
subset of the population. It means that the distance of data points from the quantile line, 
βk, is measured as a weighted sum of the absolute vertical distances (deviations) from the 
line, and the weight is (1-q) for the observations below the line and (q) for those above 
the line.121 For example, the 70th quantile regression can be thought of as a plane that 
passes through the sample, weighing observations above it by 0.70 and observations 
below it by 0.30.126 βk is estimated by minimizing these weighted absolute deviations. 
 
 Typical quantile regression applications have used conditional quantile 
regression, as described above. The quantile regression coefficient of a variable is an 
estimate of the effect of that variable on the conditional outcome quantile. As in linear 
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regression, when there are no covariates or when covariate effects are assumed to be 
independent of the values of other covariates (that is, no interaction/effect modification), 
these coefficients are also consistent estimators of the effect on the unconditional mean of 
the outcome distribution.130 This latter property of regression coefficients is what makes 
them interpretable as population-level effects, which are of primary interest in most 
empirical research.130 When covariate effects are realistically not additive/parallel but 
rather interactive (for example, the association between race and adherence may differ by 
geographic region), conditional and unconditional effects start to diverge.130 In such 
(fairly typical) cases, quantile regression coefficients do not provide consistent estimates 
of covariate effects on the unconditional distribution. In mean regressions, such as 
generalized linear models and logistic regression, unconditional (average) marginal 
effects can be recovered as recycled predictions following model estimation.99,136 In the 
case of quantile regression, however, conditional effects captured by coefficients are very 
complicated to convert to unconditional effects.  
 
 Firpo, Fortin, and Lemieux70 recently developed a computationally simple 
approach that directly estimates unconditional quantile regression coefficients. Their 
approach relies on modeling a quantity known as the re-centered influence function (RIF) 
of outcome quantiles directly instead of the outcome quantiles themselves. The influence 
function (IF) is a mathematical tool that assesses the “influence” of a particular 
observation on a distributional statistic without having to recalculate that statistic.70 The 
RIF is obtained by adding the IF of the statistic to the statistic itself. An interesting 
property of the RIF is that its expected value is equal to the statistic. For example, if we 
regress RIF of mean PDC in a linear regression on X variables, the IF would basically be 
the residual (difference between observed y and estimated μ PDC) at a particular PDC 
value (the observation of interest). Estimated RIF gives the mean PDC itself. As shown in 
Equation 3-2, in simple notation,  
 
IF?y; μ?=?y-μ? 
RIF?y; μ?=μ+?y-μ?=y (Eq. 3-2) 
 
We would also get precisely the same coefficients as in the standard case of 
regressing the mean itself instead of its RIF. Using this approach, Firpo, Fortin, and 
Lemieux70 demonstrated that modeling the RIF of each outcome quantile as a function of 
explanatory covariates in OLS regression yields coefficient estimates that are essentially 
the effects of covariates on the unconditional outcome distribution. Racial disparity 
would thus directly equal to the coefficient of the race variable, without the need to do 
any further computation. 
 
 Using the -rifreg- STATA routine,137 and following the recommendations on 
estimating RIF and the probability density function at each quantile,70,130 we estimated 
unconditional quantile regressions of PDC at the 10th, 20th, up to the 70th quantile (where 
adherence was almost perfect, PDC ~ 100%) as a function of race/ethnicity indicators as 
well as other covariates as explained above. All analyses accounted for MEPS survey 
design by including longitudinal weights and design variables as appropriate. We 
estimated standard errors using 5,000 block bootstrap replications, to account for 
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clustering of survey data in primary sampling units. Since rates of missing data in some 
covariates (e.g. belief and experience with providers) were as high as 13%, we used 
multiple imputation using chained equations (MICE) to impute missing data for each of 
these variables.100 Regression analyses were estimated separately in each imputation 
dataset and then point estimates and standard errors were combined using Rubin’s 
rules138 to produce a single set of estimates that took into account uncertainty due to 
imputation. All analyses were carried out in STATA® 13 (StataCorp; College Station, 
TX). 
 
 
Results 
 
 
Sample Characteristics 
 
The study sample included 3,749 MEPS respondents, nationally representing  
20.7 million Medicare seniors with cardiovascular diseases. Average length of follow-up 
for adherence measurement was 342 days. Table 3-1 lists characteristics of sampled 
respondents by race. Compared with their white counterparts, black seniors were more 
likely to be female, less likely to be married, and substantially more likely to reside in the 
South. Hispanic seniors were also less likely to be married and substantially more likely 
to reside in urban areas and in the West. Both black and Hispanic seniors had worse self-
rated health and higher rates of cognitive limitation than whites. They were also more 
likely to have hypertension and diabetes but less likely to have hyperlipidemia. 
Interestingly, blacks were only half as likely to be diagnosed with depression but twice as 
likely to screen positive for depressive symptoms using the Patient Health Questionnaire 
ver. 2 (PHQ-2).134 Hispanics were also about twice as likely as whites to report 
depressive symptoms on the PHQ-2 scale, but no more likely than whites to be diagnosed 
with depression. Both minority groups were also much less likely to believe they did not 
need medical care to manage illness. Both were less likely to exercise and more likely to 
be obese.  
 
Black and Hispanic seniors were much more likely to be at the lowest levels of 
income and education. For more than 50% of Hispanics, English was not the primary 
language spoken at home or with others. For drug coverage, nearly 19% of the cohort had 
no evidence of drug coverage in MEPS, including from federal sources. Nonetheless, 
rates of plan enrollment were very similar to what the Kaiser Family Foundation (KFF) 
reported for January 2010.54  Overall Part D enrollment was 61.8%. In our sample of 
elderly beneficiaries with cardiovascular diseases, the overall rate of auto-enrollment in 
the LIS was ~10% (15.5% among Part D enrollees in the sample). Whites were more 
likely than either minority group to have no drug coverage, and less likely to be eligible 
for automatic receipt of the LIS. While Hispanics were more likely to have MA-PD 
coverage, blacks were more likely to be enrolled in PDPs. Both minority groups were, 
however, less likely than whites to have employer-sponsored or other private coverage. 
These findings were also consistent with the literature on drug coverage by race.59,103,139 
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Table 3-1.  Characteristics of sampled Medicare seniors by race 
 
 Characteristics White Black Hispanic Overall 
 % (unless otherwise noted) 
Demographics     
Age (Mean±SD) 75.42±6.34 74.55±6.13 74.51±6.04 75.28±6.31 
Female 56.69 63.41 58.74 57.44 
Married 56.08 31.31 45.14 53.08 
Urban/MSA 79.34 84.06 91.77 80.60 
Census Region     
Northeast 21.24 18.22 13.67 20.46 
Midwest 25.70 15.41 6.95 23.50 
South 34.48 59.88 42.84 37.36 
West 18.57 6.49 36.53 18.68 
Self-Reported Health     
Excellent 13.40 7.65 6.66 12.42 
Very Good 31.32 23.72 17.08 29.67 
Good 33.61 35.31 35.00 33.86 
Fair 16.58 25.64 30.41 18.34 
Poor 5.09 7.68 10.84 5.71 
Any Physical 
Limitation* 62.29 63.48 66.69 62.69 
Any Cognitive 
Limitation* 9.78 18.24 17.03 11.04 
Medical Conditions     
Quartiles of Charlson Comorbidity Score 
1st/2nd Quartiles 56.35 46.43 43.37 54.57 
3rd Quartile 31.53 39.52 40.54 32.86 
4th Quartile 12.12 14.05 16.09 12.56 
Count of Comorbid 
Conditions,† 
Median(IQR) 
5 (3, 8) 4 (2, 6) 4 (2, 7) 5 (3, 7) 
Hypertension 82.57 93.65 89.86 84.07 
Hyperlipidemia 66.24 56.95 58.53 64.88 
Angina/CHD 21.79 17.38 21.26 21.35 
CHF 4.02 3.54 2.80 3.90 
AMI 8.89 7.21 7.63 8.65 
Stroke 6.00 6.14 4.86 5.94 
Depression Diagnosis 10.85 5.35 11.30 10.38 
Depressive Symptoms 7.41 14.69 16.42 8.68 
Diabetes 22.42 36.50 41.71 25.00 
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Table 3-1.      (Continued) 
 
 Characteristics White Black Hispanic Overall 
 % (unless otherwise noted) 
Asthma 8.40 11.35 9.98 8.78 
Emphysema 6.90 5.12 3.12 6.48 
Arthritis 60.21 66.25 57.22 60.56 
Beliefs     
More Likely to Take 
Risks 16.45 14.13 12.84 16.00 
Can overcome illness 
without medical care 11.31 7.05 7.11 10.64 
Does not need health 
insurance 4.45 5.01 5.81 4.60 
Behaviors     
Current Smoker 8.30 10.91 6.10 8.39 
Had 
Moderate/Vigorous 
Exercise 
47.43 37.43 38.65 45.92 
Obese (BMI≥30) 28.53 36.67 35.39 29.73 
Socioeconomic Status 
Income: ‡ 
Poor/Near-Poor  15.38 32.56 31.51 18.03 
Low-Income 15.95 20.71 21.05 16.73 
Middle-Income  31.44 31.15 30.54 31.35 
High-Income 37.23 15.58 16.89 33.89 
Education:  
Less than High School 19.73 47.42 65.57 25.31 
High School Diploma 52.97 39.00 22.77 49.68 
College and Beyond 27.30 13.59 11.66 25.01 
Language:  
Interview Not in 
English 
0.13 0.00 52.00 3.61 
No English at Home 1.13 1.02 59.91 5.08 
Primary Drug Coverage- End of Year 1 
No Known Rx 
Coverage 19.85 12.99 11.77 18.68 
Part D: PDPs 35.96 43.66 39.55 36.91 
Part D: MA-PD 23.00 30.37 41.72 24.93 
Employer/Other Private 21.19 12.97 6.96 19.49 
Auto Eligible for PD 
Low-Income Subsidy 5.72 25.92 38.99 9.81 
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Table 3-1.      (Continued) 
 
 Characteristics White Black Hispanic Overall 
 % (unless otherwise noted) 
Use of CV Drug Classes in Year 2 
ACE Inhibitors/ARBs 58.17 59.68 69.16 59.05 
Statins 60.11 49.56 48.71 58.38 
β-blockers 41.67 37.08 44.33 41.43 
Ca Channel Blockers 19.72 36.54 29.71 21.93 
Diuretics 43.85 54.65 35.29 44.26 
Healthcare Use at Baseline 
No. of concurrent CV Medications § 
0-1 34.95 32.53 37.34 34.89 
2-3 56.26 55.27 55.94 56.15 
≥4 8.78 12.21 6.72 8.96 
No. of concurrent medications overall 
0-1 9.96 14.13 12.82 10.54 
2-4 44.51 44.51 48.76 44.80 
≥5 45.53 41.37 38.42 44.67 
No. of Pharmacies 
Used, Median(IQR) 1 (1, 2) 1 (1, 1) 1 (1, 1) 1 (1, 2) 
Average Copay for CV 
Drugs ($2010), 
Median(IQR) 
15.62 
(6.70, 
31.84) 
9.17 
(3.07, 21.31) 
6.67 
(2.38, 21.19) 
14.44 
(5.79, 30.69) 
Had a Usual Source of 
Care 97.43 95.58 95.13 97.11 
Any Inpatient Stay- 
Previous Year 17.23 17.88 14.81 17.13 
Any Emergency 
Department Visit- 
Previous Year 
17.33 21.06 20.12 17.86 
Quintiles of ambulatory physician visits (range) 
Q 1 (0-2) 17.99 28.83 24.92 19.45 
Q 2 (3-4) 18.12 21.21 22.09 18.67 
Q 3 (5-7) 20.47 21.75 19.62 20.53 
Q 4 (8-12) 22.18 13.14 17.85 21.07 
Q 5 (≥13) 21.23 15.08 15.51 20.29 
Experience with Providers 
Very Satisfied with 
Received Healthcare 58.67 53.87 52.69 57.83 
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Table 3-1.      (Continued) 
 
Characteristics  White Black Hispanic Overall 
 % (unless otherwise noted) 
Provider Always 
Explained  56.79 58.28 50.71 56.52 
Provider Always 
Listened 61.24 62.36 54.69 60.90 
Provider Always 
Respected 63.11 64.49 56.91 62.82 
Sample Size 2,585 703 461 3,749 
Weighted Population 17,447,543 1,891,319 1,396,116 20,734,978 
 
Boldface estimates have P<0.05 for pairwise comparisons relative to whites.  
* Physical limitations included functional or sensory limitations, or limitation in the 
Instrumental Activities of Daily Living or in the Activities of Daily Living. Cognitive 
limitations included confusion, dementia, problems making decisions, or needing 
supervision for own safety. 
† Excluded respondent-specific cardiovascular conditions.  
‡ Poor/Near-Poor: <125% FPL; Low-Income: ≥125 to <200 %FPL; Middle-Income ≥200 
to <400% FPL; High Income (reference): ≥400% FPL.  
§ Same-pill combination products were counted as one drug 
CV: Cardiovascular; SD: Standard Deviation; IQR: Interquartile Range; CHD: Coronary 
Heart Disease; CHF: Congestive Heart Failure; AMI: Acute Myocardial Infarction; BMI: 
Body Mass Index; FPL: Federal Poverty Line; PDP: stand-alone prescription drug plan; 
MA-PD: Medicare Advantage Prescription Drug plan; PD: Part D; ACE: Angiotensin-
Converting Enzyme; ARB: Angiotensin II Receptor Blocker  
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Exposure to ACE inhibitors was highest among Hispanics and was similar among 
whites and blacks. Statin use was much less among minorities compared to whites, 
perhaps reflecting the lower prevalence of (diagnosed) hyperlipidemia. The use of 
Calcium channel blockers was higher among minorities than among whites. Blacks were 
the most exposed to diuretics whereas Hispanics were exposed the least. Black seniors 
were more likely to concurrently take multiple cardiovascular medications, but 
nonetheless more likely to take less medications concurrently overall. Both blacks and 
Hispanics were less likely to report having a usual source of care and were more likely to 
have fewest ambulatory physician care. No statistically significant differences were 
present in rating the experience with providers or satisfaction with healthcare by race. 
 
 
Adherence Validation 
 
 In the 2010 sub-cohort, we studied refill days of supply vis-à-vis dispensed 
quantities to build a scheme that would allow us to derive days of supply from dispensed 
quantities in earlier panels of MEPS, where days of supply data were not available. Based 
on identifying the most frequent number of supply days furnished by each level of 
dispensed quantity, we found the following scheme to work best for constructing days of 
supply from dispensed quantities, (quantity vs days of supply): [8: 16; 15-16: 30; 45: 90; 
46-75: 30; 76-119: 90; 120: 30; >120: 90; all other quantities: identical days of supply]. 
This scheme also worked equally well across medication classes. Comparing the PDC 
distribution that is based on constructed days of supply versus the one based on actual 
days of supply in the 2010 sub-sample gave a Lin’s concordance coefficient of 0.97, 
indicating substantial agreement. Figure 3-1 shows how the two PDC distributions were 
almost identical. (We also observed agreement of similar proportions when we compared 
binary adherence classifications (at PDC≥80%) based on the two distributions: C-statistic 
0.97).  
 
 
Adherence Distribution by Race 
 
Figure 3-2 and Table 3-2 compare the observed distributions of the average 
overall PDC by race. Relative to whites, the PDC distribution for black seniors was 
shifted to the left at central and non-central quantiles, with higher density than whites at 
the lower quantiles (where adherence is poor). For Hispanics, the disparity relative to 
whites was not apparent at the center of the distribution, and fluctuated across the 
quantiles below the median. Adherence among white seniors was predominantly more 
likely to fall in upper PDC quantiles than either minority group. 
 
 
Adjusted Adherence Disparity Estimates  
 
 In the primary quantile regression analyses, we adjusted the association between 
race/ethnicity and PDC for health/clinical need, including demographics, health 
status/medical conditions, and the number of concurrently used medications, as well as  
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Figure 3-1. Comparing distributions of average overall adherence calculated 
using actual vs. constructed days of supply in the 2010 sample (n= 556) 
 
 
 
 
 
 
Figure 3-2. Observed distributions of average overall adherence by race 
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Table 3-2. Quantiles of the distributions of average overall adherence by race 
 
PDC White Black Hispanic Overall 
Mean ±SD 72.78±25.15 68.08±26.84 71.57±27.05 72.27±25.47 
Q10 32.97 26.47 28.93 32.88 
Q20 49.45 43.27 46.7 49.45 
Q30 59.91 53.57 58.54 58.95 
Q40 70.05 61.43 68.68 69.41 
Q50 77.59 72.73 77.14 77.29 
Q60 86.29 81.5 85.66 85.43 
Q70 93.2 89.2 94.12 92.83 
Q80 99.27 97.47 98.9 99.17 
 
PDC: proportion of days covered; SD: standard deviation; Q: quantile. 
 
 
beliefs and geographic location. Appendix Table B-1 lists regression coefficients for all 
primary unconditional quantile regressions. Figure 3-3 plots black and Hispanic 
coefficients from each unconditional quantile regression, graphically illustrating the 
heterogeneity of disparities across the adherence (PDC) distribution. Black-white 
disparities were large and statistically significant, starting with a spike of -9.05 PDC 
percentage points at the 30th percentile (PDC≈60%), and then monotonically decreased to 
-3.28% points as overall adherence approached its highest levels at the top quantile 
(PDC=100%). Hispanic-white disparities of -4.07% points and -1.40% points were 
statistically significant at the 20th and 40th percentiles (PDC≈48% and 74%), respectively.  
 
Similarly to disparities in overall adherence, disparities in adherence to ACE 
inhibitors/ARBs were large below the 30th percentile, as listed in Appendix Table B-2. 
In contrast, black-white disparities in adherence to statins and diuretics were only notable 
at the 40th and 50th percentiles (PDC ≈ 73-89% and 58-70%, respectively). Blacks were 
less adherent to beta-blocker therapy than whites across all percentiles, with largest 
disparity (-10.39% points) at the 20th percentile. Hispanics were significantly much less 
adherent to diuretics than whites at every modeled quantile. Both black and Hispanic 
seniors were in fact much less adherent to diuretics than whites, with disparities as large 
as -19 and -15% points, respectively, at the 40th percentile (PDC ≈ 73%). 
 
Regardless of how we empirically defined disparity, through various levels of 
adjustment for covariates, the recurring pattern was consistent with the primary findings 
above, despite a few changes in the statistical significance of estimates. Sensitivity of 
findings to various levels of covariate adjustment is illustrated in Appendix Table B-3 
and Appendix Figure B-1. Interestingly, full adjustment for all covariates resulted in 
larger disparity estimates than all other paradigms of adjustment, particularly in the case 
of black-white disparities. 
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Figure 3-3. Heterogeneity in adjusted racial disparities across the distribution of 
average overall adherence (entire sample, n=3,749)  
Quantiles 10, 20, 30, 40, 50, 60, and 70 correspond to PDC values of 30, 48, 63, 74, 82, 
95, and 100%, respectively. 
 
 
Racial Disparities by Gender and LIS Status 
 
As Figure 3-4 illustrates, elderly black men had lower adherence levels relative to 
their white counterparts at all PDC percentiles (i.e. their adherence distribution was 
significantly left-shifted), with largest disparities manifesting at the lowest percentiles 
(PDC below 60%). Among women, elderly blacks had significantly lower adherence 
rates starting at the 30th percentile (PDC≈61%). The disparity then declined as overall 
adherence approached 100% at the 70th percentile, notwithstanding a large disparity that 
re-emerged at the 60th percentile (PDC≈94%). Hispanic-white disparities, on the other 
hand, were not statistically significant across all modeled quantiles among both genders.  
 
Figure 3-5 shows the pattern of disparities across the adherence distribution by 
LIS status. The lower panel shows the pattern among those who were auto-eligible for the 
LIS, including dually eligible beneficiaries as well as beneficiaries receiving SSI. The 
upper panel is for essentially the rest of the sample, who were not eligible for auto-
enrollment in the LIS, including those below 150% FPL who might be receiving the LIS 
but not identifiable in MEPS. Not surprisingly, black-white disparities in the upper panel 
showed the same pattern observed in the overall sample, although Hispanic-white 
disparities were not significant across all percentiles. Among the auto-enrolled LIS 
population, disparities took interesting courses. Black-white disparities started with a 
peak of -15.7% points at the 10th percentile (PDC<30%) and then declined steadily until 
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Figure 3-4. Pattern of adjusted racial disparities across the adherence 
distributions among men (n=1,569) and women (n=2,180) 
Quantiles 10, 20, 30, 40, 50, 60, and 70 correspond to PDC values: 28, 49, 60, 72, 81, 95, 
and 99% among men, and 29, 51, 61, 74, 84, 94, and 100% among women, respectively. 
 
 
 
 
 
Figure 3-5. Adjusted racial disparities across the adherence distribution among 
auto-recipients of Part D LIS (n=617) and the rest of the sample (n=3,132) 
Quantiles 10, 20, 30, 40, 50, 60, & 70 equal PDC values: 28, 47, 63, 73, 81, 94, & 100%. 
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the 50th percentile, where they disappeared and then re-emerged at the 60th percentile 
(PDC>90%). Hispanic-white disparities, though exhibited a similarly interesting trend, 
they were only significant at the 20th and 30th percentiles.  
 
 
Discussion 
 
In a nationally representative sample of Medicare seniors with cardiovascular 
conditions, we used unconditional quantile regression to unravel the heterogeneity of 
racial disparities across the distribution of average adherence to 5 cardiovascular 
medication classes. The most salient finding of our analysis was that disparities were 
generally largest at the lower quantiles of the adherence distribution, around the 20th to 
the 40th, corresponding to adherence levels of ~ 50 to 73% PDC. Notwithstanding a few 
exceptions where disparities existed even among those with adherence ~ 90%, generally 
speaking, as one moved towards the upper percentiles, race appeared to matter less as a 
determinant of adherence behavior, that is: disparities declined among the populations 
with increasingly better adherence. Statistically, these findings suggest that the adjusted 
distribution of adherence behavior among minorities is most left-shifted from whites’ 
distribution at the lower quantiles. These findings align with the two other studies we 
could identify which studied adherence disparities using quantile regression.128,129  
 
Although more research is needed to identify the specific drivers of disparities 
across the adherence distribution, available literature offer a number of possible 
explanations for our findings. One interesting observation we found was that although 
minorities were less likely to have healthcare events associated with depression, they 
were twice as likely as whites to suffer depressive symptoms (Table 3-1). Depression is 
known to compromise medication adherence and impair individuals’ self-efficacy,140 
which is a key psychobehavioral determinant of adherence and a range of other self-
management behaviors.109 Self-efficacy refers to an individual’s conviction that s/he can 
successfully carry out the behavior required to produce a desired outcome.141 Screening 
minority patients for depression and promoting their self-confidence provides an 
invaluable opportunity for providers to proactively address these key culprits in poor 
adherence.142,143 Also, the lack of sufficient social support is a relevant barrier. Family 
members, caregivers, friends, and providers can offer various forms of support, such as 
easing depression, anxiety, and stress, helping with reminders to take medications, and 
positively encouraging and reassuring patients of their ability to self-manage their 
health.144 Unfortunately, no data on social support was available in MEPS. 
 
A quality patient-provider relationship is crucial for helping patients with poor 
adherence.142 Beyond behavioral support, provider communication can address patients’ 
beliefs and concerns about how medications work and their side effects (such as frequent 
urination and impotence); issues identified to be barriers to adherence among 
hypertensive blacks.144 Better communication with providers may particularly help with 
minorities’ especially problematic adherence to diuretics and beta-blockers, as we report 
in this study. Another potential barrier to adherence peculiar to blacks is their higher 
likelihood to concurrently use multiple cardiovascular medications (Table 3-1). While 
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understandably this may be due to clinical need, black seniors are less likely to have a 
written list (record) of their medications and more likely to have medication-related 
problems, such as suboptimal monitoring.145 They are also less likely to have adequate 
health literacy.145,146 Further, elderly minorities who were not aware of Part D benefits 
were found to be less adherent to their antihypertensive medications.147 Medicare Part D 
Medication Therapy Management (MTM) programs148 provide an excellent mechanism 
to address these drivers of poor adherence among minority seniors. Through 
comprehensive medication reviews, collaboration with patient’s providers, and 
establishing an empowering collaborative relationship with the patients themselves, 
pharmacists providing MTM can properly educate patients about their medications, 
address their medication-related problems and concerns, and promote their self-
management behavior.52,53,149 Towards this end, current evidence suggest that minorities’ 
adherence to cardiovascular medications significantly improves when there is race and 
language concordance between them and their providers, which should be sought 
whenever possible.150,151 
 
 The large magnitude of disparities towards the lower end of the adherence 
distributions suggests that these barriers may be particularly pronounced among poorly 
adherent minority patients. Two issues need to be addressed, however, before we can 
effectively eliminate these barriers. First, although one could delineate the characteristics 
of these populations, identifying them in routine clinical practice is challenging. This is a 
result of the lack of alignment between the empirical refill-based measures of adherence 
typically employed in research, and the measures that can be used to assess patient 
adherence in routine clinical practice.117,152 Second, although using quantile regression 
enabled us to get a more comprehensive picture of the adherence distribution, we still 
lump adherence into a single number without further parsing out the underlying 
behavioral details. Instead of using the PDC or MPR to summarize patient adherence 
over (say) a year, a more informative alternative would be to examine the developmental 
trajectories of adherence over time using group-based trajectory models.153 This would 
enable us to capture more details about regimen execution, i.e. patterns of how the 
prescribed compares to the actual regimen taken, and persistence over time.18,21 
Identifiable patterns such as brief lapse in therapy due to occasional dose omissions, 
longer drug holiday but then continuation, periodic gaps in therapy, and early 
discontinuation provide a basis for more meaningful classification of adherence behavior 
with implications for intervention and for studying disparities. It is worth noting here that 
some recently developed questionnaire instruments, which can be administered in 
practice settings, can help identify these distinct patterns as well, and can thus offer a 
closer insight into real-world settings.152,154 
 
 
Limitations 
 
This study is not without limitations. First, our derivation of refill days of supply 
from dispensed quantities was based on the 2010 data in our MEPS sample, without 
validation against an external standard, e.g. Medicare claims data. Given that previous 
research documented the validity of MEPS prescription drug data against Medicare 
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claims,87 we believe benchmarking our analysis solely to MEPS 2010 is sufficient. While 
data on dispensed quantities were complete for all refills in the study period, a large 
proportion of 2010 refills had missing days of supply data (about 30%). We found the 
pattern of missing data to be very consistent across drug class and respondent 
characteristics, indicating that a missing-completely-at-random (MCAR) assumption is 
likely plausible. As such, we examined the pattern of refill days of supply vis-à-vis 
dispensed quantities only among individuals with complete days of supply data for all of 
their listed refills. 
 
We also assumed that the patterns of days of supply vis-à-vis dispensed quantities 
in 2010 would hold in earlier years of MEPS. Although we believe this assumption is 
likely true on average, changes in treatment guidelines, generic availability, and coverage 
tier classifications of drugs might have affected the prescribed total daily doses of some 
cardiovascular medications. Since MEPS did not have refill dates, a reasonable choice for 
the index date was the first day of the MEPS round in which the refill occurred. We 
might have thus underestimated adherence for respondents who started late in the round, 
although it is not possible to identify them. If a respondent had too few refills over a 
round (3-4 months), it might also be the case that they skipped refills and not necessarily 
they started taking the medication later in the round. 
 
Our approach to estimating disparities might have suffered from omitted variable 
bias. As we adjusted the association between race and adherence for health-related 
covariates in concordance with the IOM definition, we assumed that omitted variables, 
such as income and education, would reflect predominantly in the race coefficients. It is 
well-known, however, that these and other omitted variables are correlated with health 
and demographics as well, and as such, race coefficients might not have necessarily 
captured the entirety of race-related disadvantage as we had hoped. Given the technical 
complexity of the analyses we undertook, it was more tractable to take this rather simple 
approach to estimate disparities. Our sensitivity analyses involving various levels of 
adjustment further confirmed the robustness of our primary findings. Last, although we 
ensured that sample sizes for all analyses were well above the minimum recommended 
by AHRQ, (n=100), we believe that small sample sizes may have contributed to the lack 
of statistical significance in some of our sub-group analyses, especially those involving 
Hispanics.  
 
 
Conclusion 
 
Using a nationally representative sample of Medicare seniors with cardiovascular 
conditions in MEPS, we have found racial disparities to be more pronounced at the lower 
end of the distribution of cardiovascular medication adherence. Among patient 
populations with overall better adherence, disparities declined (although retaining their 
statistical significance in the case of black-white disparities). The higher magnitude of 
disparities among poorly adherent populations suggests that currently known barriers to 
adherence, such as depression, low self-efficacy, lack of social support, and knowledge 
and beliefs about medications, may be worse among minorities in these populations than 
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among minorities in populations with better adherence. It may also suggest that other 
peculiar barriers might be at play among these minority patients. Either way, our results 
indicate that minority patients in poorly adherent populations may be deserving of 
priority intervention. There is a considerable need to understand the specific barriers that 
make these patients significantly lagging behind their white counterparts in adhering to 
their cardiovascular medications. 
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CHAPTER 4.    EXPLAINING THE BLACK-WHITE GAP IN ADHERENCE TO 
CARDIOVASCULAR MEDICATIONS AMONG MEDICARE SENIORS: A 
DISTRIBUTION-WIDE APPLICATION OF OAXACA-BLINDER 
DECOMPOSITION 
 
 
Background 
 
Poor adherence to cardiovascular medications is a strong risk factor for falling 
short of drug therapy goals, such as blood pressure and cholesterol levels, with negative 
consequences for cardiovascular morbidity and mortality, and healthcare costs.15,73,74,155 
Several studies have found adherence levels among racial minorities, particularly black 
Americans, to be significantly lower than whites, even where equal access to prescription 
drugs is guaranteed.11,33 Among elderly recipients of Medicare, the advent of Part D was 
an important step towards reducing the financial out-of-pocket burden of prescription 
drugs and improving the quality of medication use, thus eventually reducing the negative 
consequences of poor adherence.36,37 Despite the relative success of Part D,41,45,46,53 black 
seniors have continued to experience disproportionately lower levels of adherence. 
Among seniors with uncomplicated hypertension, Holmes and colleagues found blacks to 
be 47% less likely to be adherent to their antihypertensive medications, including alpha- 
and beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II 
receptor blockers (ARBs), Calcium channel blockers (CCBs), diuretics and 
vasodilators.28 Zhang et al estimated that blacks with heart failure were 39% less adherent 
to ACE inhibitors/ARBs and diuretics than whites.29 In the year following acute 
myocardial infarction, black seniors were also about 25%-35% less likely to adhere to 
beta-blocker, ACE inhibitor, or statin therapy.30,31 In Chapter 2 of this dissertation, 
analyses of the Medical Expenditure Panel Survey data on elderly Medicare beneficiaries 
(2007-2010) have estimated an average black-white disparity of 8 percentage points 
(~17%) in the probability of adherence (≥80% medication possession) to ACE 
inhibitors/ARBs, statins, beta-blockers, CCBs, and diuretics. Further, in Chapter 3, as 
other studies have reported,129 black-white disparities were most prominent towards the 
lower end of the adherence distribution (around the 30th percentile), namely, among those 
who were poorly adherent.  
 
Not only does the black-white disparity appear to be the largest among racial 
disparities in cardiovascular medication adherence, it also appears to be especially 
consequential. Blacks bear the largest burden of cardiovascular morbidity, leading to 2-3 
times higher likelihood of death due to cardiovascular disease at any given age.3,4 This 
disparity in cardiovascular death accounts for the largest share (34%) of the black-white 
all-cause mortality differential in the United States, with the disparity in uncontrolled 
hypertension making up most of that share (44%).5 In the CARDIA study, Bibbins-
Domingo et al found adult blacks to be 20 times more likely than their white counterparts 
to develop heart failure before the age of 50, pursuant to a striking disparity in 
uncontrolled blood pressure that persisted over more than 10 years of follow-up.6 Based 
on an analysis of the National Health and Nutrition Examination Survey, Fiscella et al 
estimated that bringing the blood pressure level among blacks to that among whites could 
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save more than 7,000 lives annually from death due to heart disease or stroke.7 Among 
the social and behavioral factors that might explain the disparities in uncontrolled blood 
pressure and other risk factors,8,12-14 the lower level of cardiovascular medication 
adherence among blacks stands out as a proximal culprit that is amenable for healthcare 
intervention.7,8,12,15 
 
Adherence is shaped by the interplay of multiple patient-, environment-, disease-, 
regimen-, provider-, and health system-related factors.77,156 Understanding how each of 
these factors influences adherence behavior disparately among whites and blacks brings 
us closer to comprehending adherence disparities. With a more concrete understanding of 
how these disparities develop, we would become better able to tailor interventions to 
reduce them. Despite a large literature on adherence behavior among blacks, the specific 
drivers of adherence disparities are still largely ambiguous. For example, in a review of 
the recent literature, Ogedegbe and colleagues have noted that self-efficacy, which is an 
individual’s confidence that s/he can accomplish a desired outcome, particularly predicts 
medication adherence among blacks.142 Depressive symptoms and younger age, on the 
other hand, appeared to reduce the likelihood of adherence.142 Also, better provider 
communication, especially in race-concordant relationships, was reportedly associated 
with better adherence.142,150,151 Other studies have also shown a link between poor 
adherence and inadequate health literacy.145,146 The evidence on the degree to which 
social support and sociodemographic characteristics affected adherence among blacks 
remains inconclusive.142 Among the elderly in Medicare, a national survey in 2003 found 
racial disparities only in cost-related non-adherence, whereas there were no differences in 
non-adherence due to experience with or beliefs about medications.81 Another study 
among the elderly reported disparities in following provider recommendation but not in 
forgetting to take medications.85 A systematic, deliberate comparison of how different 
predictors operate differently among black and white seniors to produce the observed 
patterns of adherence remains a critical gap in the literature. 
 
In this study, we combined two powerful empirical techniques, Oaxaca-Blinder 
decomposition with unconditional quantile regression, to quantify the contributions of 
each predictor to the racial differences in cardiovascular medication adherence in a 
nationally representative sample of white and black Medicare seniors. As we explain 
below, these techniques enabled us to provide quantitative, “bottom-line,” estimates of 
how much the differences in the distribution of individual characteristics as well as the 
differences in how these characteristics influenced adherence among blacks and whites, 
contributed to the observed racial differences in adherence. To our knowledge, this study 
is the first application of decomposition analysis in the adherence literature. This study 
contributes to the literature by identifying which predictors of adherence matter most, 
from a disparity-reduction point of view, and also among which population sub-groups. 
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Methods 
 
 
Data Source 
 
We used longitudinal data from the household component of the Medical 
Expenditure Panel Survey (MEPS), panels 11 to 14 spanning years 2006 to 2010. MEPS 
is an annual overlapping panel survey of the US civilian non-institutionalized population, 
administered by the US Agency for Healthcare Research and Quality (AHRQ).131 The 
primary focus of MEPS is on healthcare access, use, and expenditure in the United States, 
enabling calculation of national impact estimates for a wide variety of health policy 
changes. Each year MEPS panel participants are sampled from the previous year’s 
respondents to the National Health Interview Survey (NHIS), with oversampling of 
minorities and other policy-relevant groups (such as adults with functional limitations 
and low-income households).131 Each panel is then prospectively followed for two 
calendar years and their data are collected over five rounds of computer-assisted personal 
interviewing. Rounds 1 and 2 fall in the first year, rounds 4 and 5 fall in the second year, 
while round 3 spans the end of the first and the beginning of the second year. AHRQ 
provides two types of main data files that can be linked to Medical Conditions and event 
files: longitudinal and annual/cross-sectional (known as Full Year Consolidated Data) 
files. For this study, we linked the longitudinal panel files to the Medical Conditions and 
Prescribed Medicines event files. Although all MEPS data are reported by respondents 
during round interviews, further detailed health service use data, including on 
prescription drugs, are collected from a sample of providers (e.g. medical and pharmacy) 
with respondents’ permission. Then these data are used to supplement respondents’ self-
reports of health service use and expenditure. Of particular relevance to this study, the 
quality of MEPS prescription drug data, as well as Medicare Part D enrollment has been 
shown to be comparable to that of Medicare claims data.87,88 MEPS also provides very 
rich data on respondents’ sociodemographics, health and chronic conditions, as well as 
experience with providers and the healthcare system, allowing a thorough study of 
adherence as shaped by these determinants. 
 
 
Cohort Identification 
 
We included MEPS respondents who were: 
1) Continuously included in all MEPS survey rounds for the two panel years, 
excluding those who went “out of scope” because of death, institutionalization, or 
other reasons.  
2) Medicare beneficiaries 65 years or older as of Round 1, who reported receiving 
Medicare until the end of the second year (Round 5).  
3) Non-Hispanic white (henceforth “white”) and non-Hispanic black (henceforth 
“black”). MEPS ascertains race/ethnicity as follows:132 first, respondent’s self-
report of their race/ethnicity is the primary way to procure this data. Then, if not 
available, race/ethnicity is obtained from the originally collected NHIS data in the 
year prior to joining the MEPS panel. Finally if not available either way, MEPS 
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assigns race/ethnicity based on respondent’s relationship to other members of 
his/her household starting with blood relatives in the immediate family. MEPS 
survey questions assessing race/ethnicity have been consistent since 2002.132  
4) Had at least one of the following six prevalent conditions in both year 1 and year 
2: hypertension, hyperlipidemia, angina, congestive heart failure, myocardial 
infarction, or stroke, listed in the linked Medical Conditions file. Clinical 
Classification Codes and 3-digit ICD-9 codes in MEPS were used to identify 
respondents with these conditions.133 Appendix Table A-1 (Chapter 2) lists all 
the conditions and their associated codes. Identified respondents had at least one 
event (inpatient, outpatient, or prescription drug) associated with one or more of 
these conditions. 
5) Were prevalent users of at least one chronic cardiovascular medication of the 
following classes: ACE Inhibitors, ARBs, HMG-CoA Reductase Inhibitors 
(Statins), Beta-blockers, CCBs, Diuretics, or combination products of these 
medications. Use was defined as having at least one refill for the same medication 
class in both years. Second-year refills were used to estimate adherence. 
 
Since our study sample only included a small portion of MEPS respondents, we 
pooled MEPS panels 11-14 by year to create one analytical file with adequate sample size 
for our analyses. Pooling MEPS data is commonly practiced and survey design variables 
in MEPS files for our study period specify a common variance structure that takes into 
account pooling when calculating standard errors.89 Our final analytical file contained 
pooled data for year 1 (2006-2009), the baseline year, and year 2 (2007-2010) where 
adherence was estimated. 
 
 
Adherence Measurement 
 
 Using refill data for sampled respondents in the second year, we measured 
medication class-specific adherence as the proportion of days covered (PDC) by refills 
for any medication from that class, expressed as a percentage and capped at 100%. In the 
case of overlapping refills for two statins, for example, only one refill was counted 
towards calculation of the statin-specific PDC. ACE inhibitors and ARBs were counted 
as one class for this purpose. Component medications of combination products were also 
counted towards their respective classes. As refill dates were not available in MEPS, we 
determined the follow-up index date specific to each medication class for each 
respondent as the first day of the round in which the first refill (for the specific class) 
occurred. These rounds were either the fourth, the fifth, or the portion of the third round 
that had fallen in the second year. Respondents were then followed until the last day of 
the fifth round, which corresponded to December 31st of the second year in the panel for 
all participants. Inpatient days were excluded from the follow-up period. For all classes, 
while over 50% of respondents had January 1st of the second year (i.e. the part of round 3 
that fell in year 2) as the class-specific index date, more than 96% of index refills had 
occurred by March of the second year. The main outcome variable was an overall 
continuous PDC summarizing adherence over all medication classes, calculated for each 
respondent as the average of all his/her class-specific PDCs. Dichotomous adherence 
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classification based on having a PDC of at least 80% was explored in a secondary 
analysis. 
 
 Although MEPS provided extensive data on prescription refills, including 
dispensed quantity, strength, dosage form, and therapeutic class/subclass, data on days of 
supply were not routinely collected until 2010. We used 2010 data, which was the second 
year of Panel 14 in our sample, to characterize the patterns of observed days’ supply as 
they related to dispensed quantities of drug refills. In so doing, we identified the most 
frequent number of supply days furnished by each level of dispensed quantity. Next, we 
derived a scheme to smoothly approximate the distribution of days of supply for use in 
prior years of MEPS (where actual days of supply data are not available). Then, in 2010 
data, we calculated PDCs as explained above using the actual and constructed days of 
supply distributions. To assess the validity of our derivation, we used Lin’s concordance 
coefficient90,91 to compare the constructed distribution of days of supply as well as the 
PDC based on it, to the actual distribution and its associated PDC. We also compared 
dichotomous adherence based on actual vs. constructed days of supply distributions using 
C-statistics. Then, we used our validated scheme to construct refill days of supply from 
dispensed quantities in all panels. The validity of computing refill days of supply in 
earlier years using the pattern of days of supply vis-à-vis dispensed quantities in 2010 
hinges on the potentially plausible assumption (based on discussions with two 
cardiologists with more than 20 years of practice experience) that the dosing frequency of 
a given strength of a specific cardiovascular drug has been stable over 2007-2010 in a 
specific patient population. (For example: for the same patient population, if a 30-pill 
refill of 40-mg simvastatin covers 30 days in 2010, on average, this would have also been 
true in 2007).  
 
 
Covariates 
 
We modeled the PDC distribution for each racial group as a function of a series of 
baseline covariates assessed over the first year of the MEPS panel. We used data on 
respondents’ demographic characteristics; geographic location; self-reported health and 
functional (physical/ cognitive) status; depressive symptoms;134 cardiovascular conditions 
and other comorbid conditions; beliefs regarding health, risk, and insurance; income and 
poverty status, and educational attainment; health behaviors; type of primary insurance 
coverage for prescription drugs; financial and pill burden associated with medications; 
access to/use of primary care and other health services; and experience with providers 
and satisfaction with the healthcare system.  
 
In addition to binary indicators of which cardiovascular condition(s) respondents 
had in the baseline year, we also incorporated other comorbid conditions, such as 
diabetes, asthma, and cancer, in a modified version of the Charlson comorbidity score 
(excluding respondent-specific cardiovascular conditions and depression) adapted for use 
with 3-digit ICD-9 codes in MEPS.96 For socioeconomic status (SES), we used MEPS-
provided categories of income as a percent of the Federal Poverty Line (FPL) and 
categorized years of education into three levels: less than high school, high school 
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diploma (12 years), and above high school. High-income and having education beyond 
high school served as the reference categories.  
 
For identifying respondents’ primary type of drug coverage, we used a series of 
variables on insurance status as well as amounts paid by each payer for prescription drugs 
over the first year to ascertain drug coverage for each respondent. We identified three 
principal categories of coverage, as of December 31st of the first year: those who had no 
evidence of drug coverage by any payer, those who had Medicare Part D, and those who 
had a private source of drug coverage including employer-sponsored. Among Part D 
enrollees, we identified those who were concurrently enrolled in Medicare managed care 
and those who were not. Thus we were able to further split Part D recipients into those 
who had Medicare Advantage Part D plans (MA-PD) and those who were just enrolled in 
stand-alone Part D plans (PDPs) with no evidence of enrollment in MA. Further, we 
created an indicator for whether a Part D respondent was deemed eligible for auto-
enrollment for the low-income subsidy (LIS), which included dually eligible beneficiaries 
and beneficiaries receiving Supplemental Security Income (SSI) (both variables were 
available in MEPS).55,57 Other LIS-recipients who are not automatically enrolled but their 
income is below 150% FPL and have limited assets must apply to receive the LIS.54 
Although we validated the characteristics of these sub-categories of Part D recipients 
against the literature,54,56,58,59,103 ascertaining drug plan type or actual receipt of the LIS is 
not possible in MEPS. 
 
 
Statistical Analysis 
 
 We used Oaxaca-Blinder decomposition (OBD)157-159 to quantify the 
contributions of each covariate to the (unadjusted) racial difference in adherence. In 
contrast to earlier work in this dissertation, where we defined inequitable racial 
disparities and did a priori classification of covariates as to whether they represented 
sources of disparities or not, this decomposition analysis explores unadjusted racial 
differences in fitted levels of adherence allowing an empirical evaluation of how each 
covariate contributes to the adherence difference. OBD has been a popular analytical tool 
in labor economics, providing insights into the potential drivers of race and gender gaps 
in wages.71 In prescription drug research, examples of OBD application include 
decomposition of the racial difference in prescription drug utilization and spending 
among Medicare beneficiaries,160 the racial differences in anti-obesity medication use 
among US adults,161 and the sources of regional variation in Medicare Part D drug 
spending.162 Also, the study of racial differences in access to primary healthcare is 
another notable application of OBD in the US health services literature.163  
 
Most commonly, OBD starts with estimating a separate regression model for each 
racial group, which is then used to estimate the outcome level for each individual in the 
dataset. Next, the difference in average estimated outcomes between the two racial 
groups is calculated. Finally, this unadjusted difference is broken down into 1) an 
“explained” component due to the difference in the distribution of individual 
characteristics, or “endowments” as termed in Blinder’s original work,158 and 2) an 
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“unexplained” component due to how these characteristics are associated with the 
outcome (as captured by their model coefficients) differently across racial groups.71,159,164 
This is termed two-fold decomposition. The explained component is interpreted as the 
expected change in the outcome difference had the two groups had the same overall 
composition or distribution of characteristics. For example, in decomposing the 
difference in adherence, the explained component is an estimate of the expected change 
in the adherence difference had blacks possessed the same demographic, social, health, 
etc characteristics as whites. The unexplained component is interpreted as the expected 
change in the outcome difference had the two groups had the same return on the outcome 
due to their characteristics. Again, the unexplained component of the adherence 
difference quantifies how much that difference would change had characteristics (e.g. 
education, insurance, depression) worked the same way to determine adherence among 
blacks and whites. Assuming no relevant covariates were left out of the model, the 
unexplained component is traditionally interpreted as indicating discrimination in the 
environment where covariates determine outcome levels (for instance, the healthcare or 
broader social environment where the same insurance plan works better for whites than 
blacks resulting in improved adherence for whites but not for blacks). A three-fold 
decomposition can also be formulated, in which a third component that captures the 
simultaneous effects of endowments and returns is calculated.159 
 
Breaking down outcome differences into just the aggregate explained and 
unexplained components is known as aggregate decomposition. For estimation of these 
aggregate components, we have to invoke a conditional independence assumption, where 
no relevant covariates were omitted/unobserved, or at least an ignorability assumption, 
where unobservable characteristics correlated with controlled covariates in the same way 
across the two groups compared. By further assuming that the aggregate components are 
composed of additively separable linear functions, they can be further decomposed into 
the contributions of each individual covariate. This further breakdown is known as 
detailed decomposition.71  
 
As the counterfactual language for interpreting decomposition components above 
entails, one must decide which group would serve as the viewpoint group for the 
analysis.159,164 Three potential alternatives exist: the lower-outcome group, the higher-
outcome group, or the pooled average of the two groups. For example, decomposing the 
racial difference from the viewpoint of whites confers the following interpretation on the 
explained component: how much would adherence level of whites change were they to 
have the characteristics of blacks? Alternatively, a black-viewpoint analysis would make 
the explained component interpretable as the expected change in black’s adherence level 
were they to have the same characteristics as whites. Choosing the pooled average would 
mean that group-specific outcome estimates would come from a pooled regression model 
instead of a separate group-specific model as described earlier. Results of the 
decomposition analysis accordingly depend on which group is chosen, in what is termed 
as an “index number problem.”165 
 
 OBD analyses have originally been based in the linear ordinary least squares 
(OLS) regression framework, for both continuous and binary outcomes (using a linear 
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probability model in this latter case). More generalized nonlinear extensions have been 
developed over the years, including for example decompositions based on logit, probit, 
and count regressions, such as Poisson and negative binomial.166-168 Nonlinear 
decompositions work better when the racial difference is located in the tails of the 
distribution or when there are large differences between the covariates that the linear 
model’s prediction would fall outside a meaningful range (e.g. predicting probabilities 
>1). In all these cases, decomposition of mean differences is carried out. Although 
studying differences in mean outcomes is informative, policy-relevant differences might 
exist elsewhere in the distribution but might be undetectable in the mean. In the case of 
the racial differences in adherence, our analyses as well as other studies in the 
literature128,129 have demonstrated the existence of large, significant disparities in the 
lower percentiles of the adherence distribution. Conducting OBD across the adherence 
distribution, by estimating race-stratified quantile regressions, can reveal the potential 
heterogeneity in covariate contributions to the racial adherence gap. 
 
Recently, OBD has been extended to quantile regression. Quantile regression is 
analogous to OLS, except that conditional outcome quantiles as opposed to the 
conditional mean are modeled, thus revealing how the outcome depends variably on the 
covariates at different locations of the distribution. Quantile regression does not run on a 
subset of the sample, but rather differentially weights the observations in the sample 
above and below the modeled quantile. For example, the 70th quantile regression can be 
thought of as a plane that passes through the sample, weighing observations above it by 
0.70 and observations below it by 0.30.126 Coefficient estimates are then estimated by 
minimizing weighted absolute deviations (as opposed to least squares in OLS). 118,120 
Typical quantile regression modeling involves estimating covariate effects on conditional 
outcome quantiles. The conditional outcome distribution is expectedly different from the 
unconditional distribution, with the latter being integrated over all covariates.130 As noted 
above, OBD breaks down the difference in estimated, unconditional outcome levels 
across groups. OBD is not possible in the context of conditional quantile regression,71 
except with computationally intensive calculations to generate the unconditional outcome 
quantiles.169 Firpo, Fortin, and Lemieux70 have developed a simple approach to 
estimating unconditional quantile regression, by first estimating a quantity known as the 
re-centered influence function (RIF) for the desired outcome quantile and then regressing 
it on the covariates in an OLS regression. This serves to readily generate the 
corresponding unconditional outcome quantile, which is then used to generate detailed 
OBD estimates as described above.71 While we found no application of RIF-
unconditional quantile regression-based OBD in the health services literature, recent 
applications involved studying rural-urban inequality in education in Senegal,170 and 
racial inequality in wages and occupation in the United States and Brazil.171,172 
 
 In this study, we used RIF-unconditional quantile regression, as implemented in 
STATA® by Fortin137, together with the OBD routine –oaxaca- developed by Jann,159 
to perform OBD on racial differences in adherence across the distribution of continuous 
PDC, namely 10th, 20th, to the 80th percentile, as a function of the full set of covariates 
described above. As Equation 4-1 shows, RIF-based OBD starts with estimating the τth 
unconditional PDC quantile from race-stratified Qτth RIF-OLS models: 
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QB
τ?=XBτ??? . βBτ?, for blacks 
 
and  
 
QW
τ? =XWτ???? . βWτ???for whites  
 
and the racial difference in the τth PDC quantile, ∆?QPDCτ , would be 
 
∆?QPDCτ =QB
τ? -QW
τ? =XBτ??? . βBτ?-XWτ???? . βWτ?  
 
which can be decomposed, in a two-fold black-viewpoint analysis, into: 
 
∆?QPDCτ =QB? τ-QW? τ= ?XB
τ???-XWτ???? ?. βBτ?????????
Difference in
Composition
+ ? βBτ?- βWτ??.XWτ???? ?????????
Difference in 
Returns to Composition
 (Eq. 4-1) 
 
 For sensitivity analysis, we conducted a two-fold decomposition using βτ?  from 
pooled RIF-unconditional quantile regressions. For comparability with the literature, we 
also estimated OBD of differences in mean PDC in OLS as well as differences in the 
average probability of 80% adherence in logit and linear probability models. All analyses 
accounted for MEPS complex design by using survey design variables. Standard errors 
were estimated by balanced repeated replications173 using MEPS provided weights and 
half-sample indicators.174 Since rates of missing data in some covariates (e.g. beliefs and 
experience with providers) were as high as 13%, we used multiple imputation using 
chained equations (MICE) to impute missing data for each of these variables.100 
Regression analyses were estimated separately in each imputation dataset and then point 
estimates and standard errors were combined using Rubin’s rules138 to produce a single 
set of estimates that took into account uncertainty due to imputation. Estimates with alpha 
less than 5% were considered statistically significant. All analyses were carried out in 
STATA® 13 (StataCorp; College Station, TX). 
 
 
Results 
 
 The study sample included 3,288 MEPS respondents, nationally representative of 
about 19 million white and black Medicare seniors with cardiovascular disease. Each 
respondent was followed for an average period of 342 days. Table 4-1 lists overall 
sample characteristics and Appendix Tables C-1 and C-2 list respondent characteristics 
across PDC quantile categories (10th to 80th percentiles). Overall, black seniors were 
more likely to be female, less likely to be married, and less likely to live in the Midwest 
or the West, while more likely to live in the South. Blacks were also less likely to rate 
their health status as “excellent” or “very good”, while more likely to rate it as “fair” or 
“poor.” The prevalence rates of cognitive limitations and depressive symptoms, as 
measured by the Patient Health Questionnaire (PHQ)-2,134 were higher among blacks  
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Table 4-1. Overall characteristics of sampled Medicare seniors, by race 
 
 Characteristics White Black Overall  
 %, unless otherwise noted 
Demographics    
Female 56.69 63.41 57.34 
Married 56.08 31.31 53.66 
Urban/MSA 79.34 84.06 79.80 
Census Region    
Northeast 21.24 18.22 20.95 
Midwest 25.70 15.41 24.69 
South 34.48 59.88 36.97 
West 18.57 6.49 17.39 
Self-Reported Health Status   
Excellent 13.40 7.65 12.84 
Very Good 31.32 23.72 30.58 
Good 33.61 35.31 33.78 
Fair 16.58 25.64 17.46 
Poor 5.09 7.68 5.34 
Any Physical Limitation* 62.29 63.48 62.41 
Any Cognitive Limitation* 9.78 18.24 10.61 
Depressive Symptoms 7.41 14.69 8.13 
Cardiovascular Conditions & Comorbidity  
Hypertension 82.57 93.65 83.65 
Lipidemia 66.24 56.95 65.33 
Angina/CHD 21.79 17.38 21.35 
CHF 4.02 3.54 3.98 
AMI 8.89 7.21 8.72 
Stroke 6.00 6.14 6.02 
Count of Comorbid 
Conditions,† Mean ±SD 5.61 ±3.53 4.57 ±3.13 5.51±3.51 
Charlson Comorbidity Score† 
Q1-2 56.35 46.43 55.38 
Charlson Comorbidity Score† 
Q3 31.53 39.52 32.31 
Charlson Comorbidity Score† 
Q4 12.12 14.05 12.31 
Beliefs    
More Likely to Take Risk 16.45 14.13 16.22 
Can Overcome Illness 
without Medical Care 11.31 7.05 10.89 
No Need for Health Insurance 4.45 5.01 4.51 
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  Table 4-1.      (Continued) 
 
 Characteristics White Black Overall  
 %, unless otherwise noted 
Behaviors    
Current Smoker 8.30 10.91 8.56 
Moderate / Vigorous Exercise 47.43 37.43 46.45 
Obese (BMI≥30) 28.53 36.67 29.32 
Socioeconomic Status   
Income:‡  
Poor/Near Poor 15.38 32.56 17.06 
Low-Income 15.95 20.71 16.42 
Mid-Income 31.44 31.15 31.41 
High-Income (Ref) 37.23 15.58 35.11 
Education:  
Less than High School 19.73 47.42 22.43 
High School Diploma 52.97 39.00 51.60 
Above High School (Ref) 27.30 13.59 25.96 
Primary Drug Coverage at Baseline  
No Known Rx Coverage 
(Ref) 19.85 12.99 19.18 
Part D: PDPs 35.96 43.66 36.71 
Part D: MA-PD 23.00 30.37 23.72 
Employer/Other Private 21.19 12.97 20.39 
Auto Eligible for PD Low-
Income Subsidy 5.72 25.92 7.70 
Use of CV Drugs in Year 2  
ACEI/ARBs 58.17 59.68 58.31 
Statins 60.11 49.56 59.08 
Beta-Blockers 41.67 37.08 41.22 
CCBs 19.72 36.54 21.36 
Diuretics 43.85 54.65 44.90 
Healthcare Use at Baseline   
No. of Concurrent CV Medications §  
0-1 34.95 32.53 34.72 
2-3 56.26 55.27 56.17 
≥4 8.78 12.21 9.12 
No. of concurrent medications overall  
0-1 9.96 14.13 10.37 
2-4 44.51 44.51 44.51 
≥5 45.53 41.37 45.12 
No. of Pharmacies Used 1.33 ±0.54 1.17 ±0.44 1.31±0.53 
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Table 4-1.      (Continued) 
 
 Characteristics White Black Overall  
 %, unless otherwise noted 
Average Copay for CV Drugs 
($2010)  
25.21 
±31.34 17.30 ±24.8 24.44±30.85 
Had a Usual Source of Care 97.43 95.58 97.25 
Had any Inpatient Stay? 17.23 17.88 17.29 
Had any ER visit? 17.33 21.06 17.70 
Quintiles of ambulatory physician visits (range)  
Q 1 (0-2) 17.99 28.83 19.05 
Q 2 (3-4) 18.12 21.21 18.43 
Q 3 (5-7) 20.47 21.75 20.59 
Q 4 (8-12) 22.18 13.14 21.30 
Q 5 (≥13) 21.23 15.08 20.63 
Experience with the Healthcare System  
Very Satisfied with Health 
Care 58.67 53.87 58.20 
Provider Always Explained 56.79 58.28 56.94 
Provider Always Listened 61.24 62.36 61.35 
Provider Always Respected 63.11 64.49 63.25 
Sample Size 2,585 703 3,288 
Weighted Population 17,447,543 1,891,319 19,338,862 
 
Boldface estimates have P<0.05 for pairwise comparisons relative to whites.  
Refer to Appendix Tables C-1 and C-2 for characteristics by race across PDC quantiles 
10th-80th. 
* Physical limitations included functional or sensory limitations, or limitation in the 
Instrumental Activities of Daily Living or in the Activities of Daily Living. Cognitive 
limitations included confusion, dementia, problems making decisions, or needing 
supervision for own safety. 
† Excluded respondent-specific cardiovascular conditions.  
‡ Poor/Near-Poor: <125% Federal Poverty Line (FPL); Low-Income: ≥125 to <200 
%FPL; Middle-Income ≥200 to <400% FPL; High Income (reference): ≥400% FPL.  
§ Same-pill combination products were counted as one drug 
MSA: Metropolitan Statistical Area; CHD: Coronary Heart Disease; CHF: Congestive 
Heart Failure; AMI: Acute Myocardial Infarction; SD: Standard Deviation; Q: Quantile; 
BMI: Body Mass Index; PD: Part D; PDP: stand-alone prescription drug plan; MA-PD: 
Medicare Advantage Prescription Drug plan; ACE: Angiotensin-Converting Enzyme; 
ARB: Angiotensin II Receptor Blocker  
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than whites. While hypertension was more prevalent among black seniors, 
hyperlipidemia was more prevalent among whites. Although blacks had less comorbid 
conditions in addition to cardiovascular disease, they were more likely to have higher 
severity of illness, as measured by the Charlson comorbidity score.96 Blacks were also 
less likely to believe they could overcome illness without medical care. They were also 
less likely to exercise and more likely to be obese.  
 
Black seniors were highly represented in lower SES categories, such as being 
poor/low-income or having no high-school diploma. While blacks were less likely to go 
without drug coverage, including greater enrollment in Part D MA-PD and PDP plans as 
well as being auto-enrolled in the LIS, they were less likely than whites to have 
employer-sponsored or private coverage. Blacks were less likely to use statins, while 
more likely to use CCBs or diuretics. Blacks were also more likely to concurrently use 4 
or more cardiovascular medications, albeit using a smaller number of medications 
overall. Blacks had smaller copays for their cardiovascular medications. While whites 
were more likely to have a usual source of care, blacks were more likely to use the 
emergency department and much less likely to frequent ambulatory care. No significant 
differences were observed in rating of providers or satisfaction with care. With a few 
exceptions, such as blacks at the 30th PDC percentile being more likely to have a usual 
source of care or being substantially more likely to smoke at the 40th percentile, the 
patterns of association of characteristics with race seemed to hold across PDC quantile 
categories.  
 
 
Adherence Validation 
 
 In the 2010 sub-sample where refill days of supply data were available, we 
studied days of supply vis-à-vis dispensed quantities so as to build a scheme to derive 
days of supply from dispensed quantities in earlier panels of MEPS (where days of 
supply data were not available). Based on identifying the most frequent number of supply 
days furnished by each level of dispensed quantity, we found the following scheme to 
perform best in constructing days of supply from dispensed quantities, (quantity vs days 
of supply): [8: 16; 15-16: 30; 45: 90; 46-75: 30; 76-119: 90; 120: 30; >120: 90; all other 
quantities: identical days of supply]. This scheme also worked equally well across 
medication classes. Comparing the PDC distribution that is based on constructed days of 
supply versus the one based on actual days of supply in the 2010 sub-sample gave a Lin’s 
concordance coefficient of 0.98, indicating substantial agreement. Figure 4-1 shows how 
the two PDC distributions were virtually identical. We also observed similarly substantial 
agreement between dichotomous adherence classifications (at PDC≥80%) based on the 
two distributions: C-statistic 0.98).  
 
 
Racial Differences in Adherence 
 
 Estimated RIFs of PDC quantiles were used in OBD to calculate the racial 
difference across the PDC distribution. Appendix Tables C-3 and C-4 list coefficients  
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Figure 4-1. Comparing distributions of average overall adherence calculated 
using actual vs. constructed days of supply in the 2010 sample (n= 485) 
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estimated in each of the RIF unconditional quantile regressions used in OBD. Figure 4-2 
shows both the observed and fitted (unadjusted) differences in PDC across the 
distribution. Racial differences were largest below the median, spiking at the 40th 
percentile to about 9 percentage points, and then declining as one moves up the PDC 
distribution. 
 
 
Decomposition of the Racial Differences in Adherence 
 
 Tables 4-2 and 4-3 list the results of OBD of the racial difference across the 
unconditional 10th-40th and 50th-80th of the PDC distribution, respectively. Black-white 
differences were significant at all percentiles, except at the 50th and 80th percentile, and as 
shown in Figure 3-2, they spiked at the 40th percentile to 9 percentage points. Except at 
the 40th percentile, the aggregate contributions of the racial differences in composition 
and the returns of compositional characteristics on adherence were not significant. 
Among seniors at the 40th percentile of the PC distribution (PDC ~ 69%), if the way 
covariates predicted adherence among blacks were identical to how they worked among 
whites, the black-white PDC difference would have been reduced by about 12 percentage 
points (~130%).  
 
 
 Demographics. The differences in neither the distribution of age, gender, urban 
residence, or geographic location were associated with the racial difference in adherence. 
Similarly for marital status, except at the 30th percentile. Had marriage been associated 
with adherence the same way among blacks and whites, the racial difference in adherence 
at the 30th percentile would have increased by 7.5 percentage points (~ 96%). In 
Appendix Table C-2, being married was significantly associated with a large 
improvement in adherence among blacks but not among whites. 
 
 
 Health. Two health-related factors appeared to matter for the racial difference in 
adherence: hyperlipidemia and activity limitation. As in Table 4-2, holding everything 
else constant, had the prevalence of hyperlipidemia been equal among whites and blacks 
at the 10th percentile of the PDC distribution, the racial difference in adherence would 
have increased by 0.93 percentage points (~15%). On the other hand, had the effect of 
having hyperlipidemia among blacks been similar to that among whites, the racial 
difference in adherence would have dropped by 9.7 percentage points (~150%). In 
Appendix Table C-2, we have underlined the coefficients of hyperlipidemia in the black 
and white RIF-Q10 models. Evidently, being black and hyperlipidemic reduced (i.e. left- 
shifted) the 10th PDC quantile significantly by about 13 percentage points, an effect that 
was much larger and opposite in direction to its counterpart among whites. 
 
Another notable health-related factor was having activity limitation (Table 4-3). 
Among seniors at the 50th percentile of the PDC distribution (PDC ~77%), had physical 
limitation among blacks been associated with the adherence the same way as among 
whites, the racial difference in adherence would have increased by 7.32 percentage points 
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Figure 4-2. Comparing observed and fitted black-white differences across 
quantiles of the proportion of days covered (PDC) 
Fitted values were estimated using race-stratified RIF-unconditional quantile regressions. 
See Panel-A of Table 4-2 and 4-3 for point estimates and standard errors of the fitted 
values. 
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Table 4-2. Oaxaca-Blinder decomposition of black-white differences in adherence across PDC quantiles, 10th-40th, from the 
viewpoint of black seniors 
 
 Outcome QPDC 10th QPDC 20th QPDC 30th QPDC 40th 
 Estimate (Standard Error) 
 Panel A: Fitted Adherence Levels and Differences 
QPDC, Blacks 27.10 (2.72) 42.99 (2.71) 52.69 (2.29) 61.59 (2.51) 
QPDC, Whites 33.50 (1.26) 49.77 (1.16) 60.51 (1.30) 70.60 (1.10) 
Difference -6.40 (3.14) -6.78 (3.05) -7.82 (2.76) -9.00 (2.84) 
 Panel B: Portion of Adherence Difference Due to: 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Aggregate 
Contribution -1.40 (5.34) -5.00 (6.04) -1.74 (4.71) -5.04 (5.33) 1.59 (3.83) -9.41 (4.83) 2.94 (4.43) -11.95 (5.42) 
Age 70-75 -0.71 (0.46) -1.91 (1.82) -0.06 (0.42) 1.07 (1.72) 0.11 (0.42) 1.38 (1.64) 0.02 (0.39) 0.61 (1.60) 
Age 75-80 0.21 (0.31) -1.50 (1.93) 0.05 (0.17) 0.52 (1.52) -0.01 (0.17) 0.66 (1.43) -0.01 (0.17) 0.56 (1.45) 
Age ≥ 80 0.51 (0.56) -0.42 (2.71) 0.17 (0.51) 0.93 (2.64) -0.21 (0.44) 2.68 (2.25) -0.20 (0.49) 2.43 (2.47) 
Female -0.07 (0.54) 0.38 (4.22) 0.53 (0.52) 4.90 (4.02) 0.19 (0.41) 2.93 (3.29) -0.26 (0.45) -0.50 (3.44) 
Married 0.61 (2.07) -0.36 (4.68) -0.79 (1.83) 4.25 (4.20) -1.87 (1.58) 7.50 (3.80) -0.96 (1.71) 3.95 (3.90) 
Urban Residence 0.23 (0.42) 3.90 (6.30) -0.14 (0.40) -2.73 (6.42) -0.17 (0.40) -2.40 (5.70) -0.05 (0.45) 0.67 (6.71) 
Census Region: 
Midwest -0.62 (0.85) 1.10 (2.23) -1.50 (0.87) 2.96 (2.20) -0.20 (0.83) -1.08 (2.31) -0.83 (0.93) 1.75 (2.47) 
South 0.99 (1.86) 3.55 (3.08) 1.87 (1.88) 3.34 (2.76) 0.19 (1.52) 0.67 (2.56) 0.86 (1.91) 2.47 (3.03) 
West 1.90 (2.31) -1.96 (3.79) 0.86 (1.81) -1.49 (2.89) 0.67 (1.36) -1.44 (2.29) 0.68 (1.52) -1.18 (2.50) 
Health Status: 
Very Good 0.02 (1.05) -2.32 (4.32) -0.15 (0.97) -1.23 (3.98) -0.38 (0.78) 0.24 (3.48) 0.07 (0.93) -2.12 (4.01) 
Good 0.01 (0.36) -1.61 (4.52) 0.02 (0.32) -1.85 (4.08) -0.01 (0.26) -1.91 (3.38) -0.03 (0.33) -2.94 (4.17) 
Fair -0.09 (1.50) -2.37 (2.66) 0.73 (1.31) -0.71 (2.27) 0.92 (1.03) 0.50 (2.01) 0.35 (1.20) -0.63 (2.30) 
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 Table 4-2.      (Continued) 
 
 Characteristics QPDC 10th QPDC 20th QPDC 30th QPDC 40th 
 Estimate (Standard Error) 
 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Poor 0.02 (0.51) -0.24 (0.85) 0.34 (0.47) 0.38 (0.81) 0.29 (0.39) 0.54 (0.73) 0.23 (0.49) 0.56 (0.85) 
Any Physical 
Limitation 0.07 (0.23) 2.00 (4.37) 0.03 (0.19) 3.20 (4.20) -0.08 (0.20) -0.34 (3.94) 0.08 (0.21) 3.94 (3.97) 
Any Cognitive 
Limitation -0.88 (0.68) -0.45 (0.83) 0.05 (0.64) 0.49 (0.86) 0.55 (0.59) 1.05 (0.84) 0.59 (0.62) 0.88 (0.76) 
Depressive 
Symptoms -0.81 (0.78) -0.27 (0.83) -1.25 (0.73) -0.89 (0.70) -0.62 (0.62) -0.38 (0.66) -0.44 (0.60) -0.13 (0.64) 
Hypertension -0.76 (1.29) -9.90 (10.24) -0.59 (1.35) -7.54 (10.27) 0.87 (1.09) 1.78 (9.13) 0.69 (1.07) 1.30 (8.76) 
Hyperlipidemia 0.93 (0.47) -9.70 (3.82) 0.30 (0.42) -3.59 (4.15) -0.06 (0.34) -0.54 (3.79) -0.41 (0.40) 3.00 (4.02) 
Angina/CHD -0.24 (0.31) 1.64 (1.58) -0.32 (0.36) 1.93 (1.75) -0.20 (0.27) 0.51 (1.52) -0.19 (0.26) 0.67 (1.46) 
CHF 0.00 (0.10) -0.16 (0.50) 0.03 (0.13) -0.51 (0.54) -0.00 (0.08) 0.06 (0.45) -0.02 (0.10) 0.28 (0.49) 
AMI -0.03 (0.31) -0.26 (1.09) 0.22 (0.33) -1.22 (1.13) 0.20 (0.27) -1.00 (0.90) 0.12 (0.28) -0.80 (0.97) 
Stroke 0.03 (0.18) 0.55 (0.69) 0.02 (0.16) 0.60 (0.71) 0.01 (0.12) 0.42 (0.56) -0.00 (0.15) 0.16 (0.75) 
Count of 
Comorbid 
Conditions 
-1.61 (1.11) 8.72 (6.71) -1.05 (1.00) 5.26 (6.29) -0.30 (0.87) 3.43 (5.37) -0.14 (0.96) 1.79 (5.75) 
Charlson 
Comorbidity 
Score Q3 
0.14 (0.55) 1.19 (2.34) 0.41 (0.55) 2.33 (2.06) 0.59 (0.45) 2.36 (1.89) 0.57 (0.50) 2.24 (1.79) 
Charlson 
Comorbidity 
Score Q4 
-0.00 (0.24) 0.37 (1.38) 0.10 (0.27) 0.95 (1.34) 0.19 (0.26) 1.13 (1.22) 0.24 (0.28) 1.59 (1.28) 
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 Table 4-2.      (Continued) 
 
 Characteristics QPDC 10th QPDC 20th QPDC 30th QPDC 40th 
 Estimate (Standard Error) 
 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
More Likely to 
Take Risks -0.09 (0.19) 0.44 (1.27) -0.17 (0.24) 1.59 (1.15) 0.03 (0.17) -0.17 (1.23) 0.14 (0.21) -0.77 (1.46) 
Can overcome 
illness without 
medical care 
0.09 (0.68) -0.27 (1.45) 0.17 (0.65) -0.67 (1.41) 0.63 (0.62) -1.42 (1.28) 0.58 (0.68) -1.25 (1.37) 
Does not need 
health insurance -0.07 (0.19) 0.04 (0.61) -0.08 (0.17) 0.01 (0.67) 0.01 (0.14) 0.44 (0.62) 0.06 (0.17) 0.90 (0.67) 
Current Smoker 0.17 (0.23) 0.67 (0.59) 0.02 (0.29) 0.37 (0.69) -0.03 (0.21) 0.22 (0.60) 0.06 (0.24) 0.13 (0.64) 
Had Moderate / 
Vigorous 
Exercise 
-0.05 (0.60) 0.73 (3.31) 0.42 (0.64) -0.34 (3.10) 0.14 (0.55) 1.48 (2.77) 0.12 (0.58) 0.90 (3.08) 
Obese (BMI≥30) 1.36 (0.66) 4.56 (1.98) 1.09 (0.56) 3.03 (1.77) 1.17 (0.53) 3.52 (1.66) 0.85 (0.58) 2.19 (1.81) 
Income: 
Poor/Near-Poor  -0.95 (1.48) -0.58 (1.49) -2.33 (1.60) -2.04 (1.44) -0.39 (1.29) -0.46 (1.26) -1.17 (1.52) -1.32 (1.44) 
Low-Income -0.28 (0.41) -0.81 (1.33) -0.63 (0.47) -2.56 (1.46) -0.26 (0.40) -0.71 (1.26) -0.57 (0.54) -1.95 (1.53) 
Middle-Income  0.01 (0.22) -2.62 (3.03) 0.01 (0.28) -3.87 (3.19) 0.01 (0.20) -1.74 (2.63) 0.01 (0.31) -2.85 (3.26) 
Education:  
Less than High 
School 
-2.06 (1.70) -1.03 (1.31) 1.01 (2.10) 1.14 (1.63) 0.17 (2.00) 0.17 (1.61) 0.51 (2.06) 0.01 (1.55) 
High School 
Diploma 1.93 (0.92) -7.28 (4.01) 0.12 (1.04) 1.74 (4.55) 0.37 (1.09) -0.53 (4.86) 0.28 (1.17) -1.48 (5.04) 
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 Table 4-2.      (Continued) 
 
 Characteristics QPDC 10th QPDC 20th QPDC 30th QPDC 40th 
 Estimate (Standard Error) 
 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Drug Coverage 
Plan:  
Part D: PDPs 
2.38 (1.38) 8.78 (4.55) 1.38 (1.16) 4.51 (4.17) 0.75 (0.88) 2.22 (3.28) 1.00 (0.93) 4.11 (3.23) 
Part D: MA-PD 1.42 (0.85) 4.86 (2.98) 0.87 (0.73) 2.41 (2.68) 0.83 (0.58) 2.25 (2.22) 0.89 (0.67) 2.66 (2.25) 
Employer/Other 
Private -1.65 (1.11) 4.42 (2.95) -1.59 (1.09) 3.71 (2.81) -1.82 (0.89) 4.37 (2.14) -2.39 (0.99) 6.30 (2.10) 
Auto Eligible for 
PD Low-Income 
Subsidy 
-2.78 (1.86) -1.05 (0.50) -2.76 (1.62) -0.76 (0.43) -2.63 (1.43) -0.83 (0.42) -0.93 (1.51) -0.22 (0.42) 
Average Copay 
for CV Drugs 
($2010) 
-1.35 (0.68) 6.07 (2.47) 0.44 (0.80) 0.34 (2.77) 0.97 (0.74) -2.15 (2.58) 1.42 (0.87) -3.40 (2.77) 
Concurrently 
taking:  
2-3 CV Drugs 
-0.05 (0.33) 0.04 (4.15) -0.02 (0.21) -0.91 (3.53) 0.00 (0.15) -0.98 (3.40) 0.04 (0.28) -4.52 (3.51) 
≥4 CV Drugs 0.49 (0.41) -0.03 (1.02) 0.21 (0.39) -0.10 (1.03) 0.06 (0.30) -0.14 (0.89) -0.44 (0.35) -0.81 (0.82) 
Quantiles of 
Ambulatory 
Visits:  
Q 3 (5-7) 
-0.05 (0.30) -0.34 (1.86) -0.11 (0.30) -2.04 (1.62) -0.12 (0.28) -2.78 (1.36) -0.17 (0.34) -3.20 (1.37) 
Q 4 (8-12) 0.83 (0.90) -1.64 (2.33) 0.22 (0.83) -0.25 (2.13) 0.79 (0.71) -2.35 (1.79) 1.01 (0.77) -2.75 (2.05) 
Q 5 (≥13) -0.26 (0.53) 2.39 (1.79) 0.02 (0.59) 0.20 (1.97) -0.14 (0.50) 0.78 (1.70) 0.05 (0.62) 0.43 (2.01) 
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 Table 4-2.      (Continued) 
 
 Characteristics QPDC 10th QPDC 20th QPDC 30th QPDC 40th 
 Estimate (Standard Error) 
 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Had a Usual 
Source of Care 0.24 (0.21) -2.03 (10.38) 0.12 (0.25) 
-10.35 
(14.40) -0.12 (0.24) 4.50 (13.60) -0.03 (0.28) 7.42 (14.52) 
Any Emergency 
Department Visit- 
Baseline Year 
-0.04 (0.24) -0.83 (1.12) 0.21 (0.29) 0.51 (1.23) 0.40 (0.31) 1.09 (0.99) 0.35 (0.28) 1.39 (1.02) 
No. of 
Pharmacies Used -0.19 (1.03) 5.44 (9.33) 0.75 (1.04) -0.14 (8.78) 0.69 (0.94) 2.45 (8.32) 0.73 (1.08) 1.80 (9.18) 
Very Satisfied 
with Received 
Healthcare 
-0.14 (0.40) 0.63 (4.31) -0.70 (0.59) 6.87 (4.38) -0.42 (0.42) 2.88 (4.01) -0.38 (0.39) 2.10 (4.08) 
Provider Always 
Explained  -0.03 (0.32) -3.09 (5.42) -0.06 (0.30) -3.74 (5.10) -0.07 (0.27) -1.95 (4.51) 0.01 (0.24) -0.33 (4.29) 
Provider Always 
Listened  -0.06 (0.22) -1.27 (4.98) -0.10 (0.23) -3.52 (4.79) -0.04 (0.16) -0.53 (4.43) 0.05 (0.23) 3.99 (5.00) 
Provider Always 
Respected -0.04 (0.20) -1.14 (4.42) -0.11 (0.30) -4.21 (4.54) -0.06 (0.22) -3.63 (4.48) -0.09 (0.31) -5.31 (5.47) 
Constant  
(Base QPDC) 
 -10.03 (26.58)  -7.29 (27.29)  
-34.15 
(23.76)  
-36.71 
(28.67) 
Sample Size 3,288 
 
Boldface estimates have P values <0.05. Standard errors were estimated by balanced repeated replications using MEPS-provided 
survey weights and half-sample identifiers.  
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Table 4-3. Oaxaca-Blinder decomposition of black-white differences in adherence across PDC quantiles, 50th-80th, from the 
viewpoint of black seniors 
 
 Outcome QPDC 50th QPDC 60th QPDC 70th QPDC 80th 
 Estimate (Standard Error) 
 Panel A: Fitted Adherence Levels and Differences 
QPDC, Blacks 72.89 (2.42) 81.62 (1.76) 88.90 (1.22) 97.16 (1.06) 
QPDC, Whites 77.78 (1.02) 86.54 (0.94) 93.41 (0.65) 99.36 (0.43) 
Difference -4.89 (2.62) -4.93 (2.03) -4.51 (1.44) -2.20 (1.17) 
 Panel B: Portion of Adherence Difference Due to: 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Aggregate 
Contribution 4.41 (4.50) -9.31 (5.12) 2.19 (3.53) -7.12 (4.25) 0.20 (2.95) -4.70 (3.46) 1.33 (1.93) -3.53 (2.24) 
Age 70-75 0.09 (0.42) 0.81 (1.63) -0.05 (0.34) 0.70 (1.38) -0.20 (0.33) -0.36 (1.19) -0.01 (0.23) 0.17 (0.82) 
Age 75-80 -0.01 (0.19) 0.65 (1.65) -0.02 (0.16) 1.46 (1.39) -0.05 (0.13) 1.68 (1.14) -0.07 (0.11) 1.56 (0.78) 
Age ≥ 80 -0.01 (0.48) 1.84 (2.61) -0.01 (0.41) 2.18 (2.28) 0.03 (0.34) 1.04 (1.86) -0.13 (0.23) 1.10 (1.32) 
Female -0.45 (0.48) -3.82 (3.64) -0.03 (0.33) -0.72 (2.73) -0.27 (0.26) -2.22 (2.22) -0.22 (0.19) -1.61 (1.40) 
Married -0.26 (1.54) 1.35 (3.67) 0.84 (1.28) -1.34 (3.17) 0.85 (0.96) -1.16 (2.39) 0.66 (0.64) -1.06 (1.56) 
Urban Residence 0.04 (0.42) 1.87 (6.62) -0.05 (0.31) -0.40 (4.98) -0.07 (0.25) -2.38 (3.70) -0.00 (0.19) -1.10 (2.84) 
Census Region: 
Midwest -1.53 (0.90) 2.90 (2.20) -0.91 (0.72) 1.91 (1.86) -0.74 (0.52) 1.68 (1.32) -0.30 (0.44) 0.75 (1.12) 
South 1.87 (1.75) 3.39 (2.61) 0.02 (1.24) 0.32 (1.95) 0.06 (0.97) 0.07 (1.56) 0.13 (0.80) 0.17 (1.30) 
West 0.18 (1.48) -0.56 (2.37) 0.62 (1.34) -1.33 (2.18) -0.08 (1.18) -0.07 (1.89) 0.29 (0.75) -0.67 (1.21) 
Health Status: 
Very Good -0.31 (0.72) -0.75 (3.03) -0.39 (0.56) 0.37 (2.38) -0.22 (0.51) -0.04 (2.03) -0.36 (0.39) 1.17 (1.47) 
Good 0.05 (0.30) 0.25 (3.09) 0.07 (0.29) 1.52 (2.57) 0.06 (0.27) 1.62 (2.27) 0.04 (0.18) 0.95 (1.71) 
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 Table 4-3.      (Continued) 
 
 Characteristics QPDC 50th QPDC 60th QPDC 70th QPDC 80th 
 Estimate (Standard Error) 
 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Fair 0.87 (0.92) 0.34 (1.75) 0.86 (0.81) 0.80 (1.46) 0.67 (0.66) 0.74 (1.21) 0.70 (0.52) 0.93 (0.95) 
Poor 0.48 (0.43) 0.92 (0.70) 0.48 (0.38) 0.91 (0.59) 0.39 (0.29) 0.66 (0.47) 0.34 (0.23) 0.51 (0.36) 
Any Physical 
Limitation 0.19 (0.34) 7.32 (3.44) 0.12 (0.23) 5.07 (2.90) 0.02 (0.13) 1.18 (2.37) -0.02 (0.10) 0.09 (1.88) 
Any Cognitive 
Limitation 0.44 (0.65) 0.87 (0.83) 0.03 (0.48) 0.33 (0.63) -0.32 (0.37) -0.14 (0.43) -0.39 (0.27) -0.15 (0.29) 
Depressive 
Symptoms -0.50 (0.58) -0.60 (0.62) -0.12 (0.46) 0.03 (0.52) 0.23 (0.36) 0.40 (0.38) 0.37 (0.29) 0.39 (0.28) 
Hypertension 0.99 (1.10) 5.35 (8.62) 1.54 (0.96) 8.87 (7.26) 0.82 (0.86) 5.39 (6.76) 0.84 (0.61) 6.41 (4.45) 
Hyperlipidemia -0.08 (0.41) -0.57 (3.91) -0.18 (0.36) 0.64 (3.66) -0.14 (0.25) 0.52 (2.56) -0.10 (0.21) 0.85 (1.94) 
Angina/CHD -0.20 (0.26) 0.72 (1.40) -0.13 (0.21) 0.38 (1.08) -0.02 (0.19) -0.34 (0.88) 0.00 (0.14) -0.36 (0.63) 
CHF 0.00 (0.11) -0.20 (0.54) 0.00 (0.09) -0.26 (0.46) -0.01 (0.08) 0.18 (0.32) 0.01 (0.06) -0.17 (0.26) 
AMI 0.14 (0.21) -0.87 (0.87) 0.04 (0.22) -0.26 (0.82) 0.04 (0.21) -0.30 (0.73) 0.06 (0.13) -0.23 (0.45) 
Stroke 0.01 (0.17) 0.44 (0.70) 0.01 (0.13) 0.08 (0.58) -0.01 (0.11) -0.20 (0.47) 0.00 (0.06) 0.03 (0.31) 
Count of 
Comorbid 
Conditions 
0.25 (0.89) 1.83 (5.19) 0.99 (0.89) -2.60 (5.11) 0.67 (0.67) -3.36 (3.67) 0.34 (0.55) -2.49 (2.99) 
Charlson 
Comorbidity 
Score Q3 
0.72 (0.54) 2.95 (1.91) 0.24 (0.42) 1.53 (1.60) -0.05 (0.30) -0.25 (1.16) -0.35 (0.27) -1.43 (0.87) 
Charlson 
Comorbidity 
Score Q4 
0.21 (0.28) 1.31 (1.30) 0.08 (0.20) 0.77 (1.11) 0.11 (0.18) 1.08 (0.86) -0.02 (0.12) 0.09 (0.56) 
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 Table 4-3.      (Continued) 
 
 Characteristics QPDC 50th QPDC 60th QPDC 70th QPDC 80th 
 Estimate (Standard Error) 
 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
More Likely to 
Take Risks 0.06 (0.18) -0.03 (1.31) 0.06 (0.15) -0.15 (1.11) -0.00 (0.12) 0.41 (0.85) 0.03 (0.09) -0.02 (0.59) 
Can overcome 
illness without 
medical care 
0.15 (0.67) -0.45 (1.36) -0.13 (0.60) 0.20 (1.25) -0.17 (0.50) 0.18 (1.04) -0.26 (0.40) 0.49 (0.81) 
Does not need 
health insurance -0.03 (0.15) 0.01 (0.62) -0.01 (0.12) 0.14 (0.51) -0.02 (0.09) -0.06 (0.38) 0.03 (0.08) 0.20 (0.28) 
Current Smoker -0.19 (0.26) -0.49 (0.64) -0.12 (0.21) 0.14 (0.53) -0.02 (0.15) 0.15 (0.39) 0.06 (0.12) 0.19 (0.32) 
Had Moderate / 
Vigorous 
Exercise 
0.10 (0.59) 1.01 (3.09) -0.29 (0.51) 2.63 (2.65) -0.16 (0.40) 1.38 (2.05) -0.16 (0.29) 0.83 (1.41) 
Obese (BMI≥30) 0.38 (0.52) 0.76 (1.69) 0.06 (0.44) -0.39 (1.44) 0.13 (0.37) 0.36 (1.13) 0.29 (0.27) 0.64 (0.91) 
Income: 
Poor/Near-Poor  -1.33 (1.41) -1.16 (1.36) -1.09 (1.20) -1.02 (1.20) -0.58 (1.05) -0.33 (0.99) -0.93 (0.82) -0.77 (0.74) 
Low-Income -0.49 (0.54) -1.58 (1.54) -0.10 (0.42) -0.48 (1.38) -0.10 (0.40) -0.45 (1.14) -0.09 (0.27) -0.13 (0.78) 
Middle-Income  0.01 (0.25) -1.42 (3.11) 0.01 (0.20) -1.13 (2.54) -0.00 (0.18) 0.18 (2.13) 0.00 (0.12) -0.33 (1.38) 
Education:  
Less than High 
School 
-0.65 (2.07) -1.01 (1.58) -1.31 (1.70) -1.29 (1.28) -1.23 (1.58) -0.94 (1.13) 0.01 (1.10) -0.16 (0.82) 
High School 
Diploma 0.51 (1.07) -2.41 (4.76) 0.37 (0.87) -1.47 (3.82) 0.42 (0.76) -0.97 (3.27) -0.07 (0.52) 0.67 (2.19) 
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 Table 4-3.      (Continued) 
 
 Characteristics QPDC 50th QPDC 60th QPDC 70th QPDC 80th 
 Estimate (Standard Error) 
 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Drug Coverage 
Plan:  
Part D: PDPs 
0.19 (0.86) 0.74 (3.05) 0.11 (0.76) 0.16 (2.59) 0.15 (0.65) -0.26 (2.20) -0.25 (0.49) -1.38 (1.69) 
Part D: MA-PD 0.11 (0.61) -0.46 (2.04) -0.21 (0.56) -2.11 (1.89) -0.13 (0.43) -1.44 (1.53) -0.17 (0.34) -1.32 (1.09) 
Employer/Other 
Private -1.11 (0.76) 3.16 (1.84) -0.77 (0.66) 1.86 (1.64) -0.84 (0.56) 1.83 (1.37) -0.71 (0.48) 1.79 (1.12) 
Auto Eligible for 
PD Low-Income 
Subsidy 
0.28 (1.44) 0.19 (0.41) -0.04 (1.15) 0.00 (0.35) -0.03 (0.91) 0.03 (0.26) 0.66 (0.62) 0.26 (0.18) 
Average Copay 
for CV Drugs 
($2010) 
1.78 (0.81) -4.53 (2.39) 1.24 (0.67) -2.79 (1.98) 0.49 (0.52) -0.51 (1.57) 0.29 (0.41) -0.70 (1.25) 
Concurrently 
taking:  
2-3 CV Drugs 
0.06 (0.35) -6.65 (3.24) 0.05 (0.32) -3.45 (3.05) 0.05 (0.30) -3.09 (2.57) 0.04 (0.26) -3.71 (1.64) 
≥4 CV Drugs -0.51 (0.36) -1.01 (0.87) -0.45 (0.31) -0.47 (0.75) -0.34 (0.26) -0.10 (0.59) -0.18 (0.18) 0.16 (0.38) 
Quantiles of 
Ambulatory 
Visits:  
Q 3 (5-7) 
-0.09 (0.24) -1.94 (1.27) 0.02 (0.15) -0.10 (1.18) -0.02 (0.11) -0.32 (0.92) -0.00 (0.08) -0.15 (0.68) 
Q 4 (8-12) 1.36 (0.77) -3.86 (1.85) 0.06 (0.62) -0.44 (1.55) -0.05 (0.49) 0.09 (1.21) -0.07 (0.41) 0.33 (0.99) 
Q 5 (≥13) -0.16 (0.58) 0.77 (1.84) -0.44 (0.50) 1.64 (1.56) -0.27 (0.40) 1.46 (1.27) 0.04 (0.29) 0.04 (0.97) 
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 Table 4-3.      (Continued) 
 
 Characteristics QPDC 50th QPDC 60th QPDC 70th QPDC 80th 
 Estimate (Standard Error) 
 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Had a Usual 
Source of Care 0.04 (0.28) 3.25 (14.38) 0.08 (0.24) -4.22 (13.36) 0.12 (0.21) -9.85 (11.05) 0.14 (0.16) -7.59 (8.08) 
Any Emergency 
Department 
Visit- Baseline 
Year 
0.09 (0.20) 0.19 (0.98) 0.08 (0.19) -0.08 (0.87) 0.08 (0.16) 0.12 (0.69) 0.14 (0.14) 0.47 (0.55) 
No. of 
Pharmacies Used 1.10 (0.86) -2.12 (7.53) 1.05 (0.75) -6.34 (6.56) 1.11 (0.58) -7.86 (5.11) 0.86 (0.43) -6.52 (3.75) 
Very Satisfied 
with Received 
Healthcare 
-0.38 (0.39) 1.75 (3.57) -0.13 (0.27) 0.79 (2.91) -0.20 (0.24) 2.42 (2.46) -0.19 (0.18) 1.79 (1.76) 
Provider Always 
Explained  0.04 (0.28) 0.23 (4.54) -0.00 (0.20) -1.28 (3.88) -0.04 (0.15) -2.57 (2.89) -0.09 (0.17) -3.46 (2.26) 
Provider Always 
Listened  0.00 (0.20) 1.96 (4.30) 0.05 (0.17) 2.85 (3.91) 0.03 (0.11) 1.78 (2.77) 0.03 (0.11) 2.22 (2.18) 
Provider Always 
Respected -0.08 (0.29) -4.23 (5.23) 0.01 (0.22) 0.29 (4.76) 0.06 (0.18) 2.72 (3.30) 0.04 (0.12) 1.38 (2.43) 
Constant  
(Base QPDC) 
 -17.71 (27.77)  
-11.54 
(22.20)  5.49 (18.78)  5.32 (14.23) 
Sample Size 3,288 
 
Boldface estimates have P values <0.05. Standard errors were estimated by balanced repeated replications using MEPS-provided 
survey weights and half-sample identifiers.
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(~150%). As in Appendix Table C-4, having activity limitations was associated with 
better adherence among blacks but not among whites at the 50th PDC percentile. 
Differences in other health-related factors, including having depressive symptoms, were 
not associated with the racial difference in adherence.  
 
 
 Beliefs and Behaviors. Except for obesity among seniors at the 10th and 30th 
percentiles of the PDC distribution, none of the differences related to beliefs about 
healthcare, insurance, risk-taking, exercise, or smoking contributed to the racial 
difference in adherence. Among seniors at the 10th and the 30th percentiles of the PDC 
distribution, had whites and blacks had the same prevalence rates of obesity, or had 
obesity been associated with adherence to the same extent among both groups, the racial 
differences in adherence would have surprisingly increased. This follows from a strong 
positive association between adherence and obesity among black but not among white 
seniors at the 10th and 30th percentiles (see Appendix Table C-2). 
 
 
 Socioeconomic Status and Insurance. Income-related differences were not 
associated with the racial differences in adherence in this sample of Medicare seniors. 
Similarly education, except for the difference in completing high-school diploma among 
those at the 10th percentile. As in Appendix Table C-2, having high-school diploma, 
relative to having education beyond high-school, had a strong negative association with 
adherence among blacks but not among whites. Subsequently, if the rates of having a 
high-school diploma were equal among whites and blacks, the racial difference in 
adherence among seniors at the 10th percentile would have increased by about 30% (see 
Table 4-2). 
 
 The differences related to enrollment in Part D PDPs or MA-PDs did not appear 
to be associated with the racial difference in adherence. The lower likelihood among 
black seniors to have employer-sponsored drug coverage was a significant contributor to 
the racial difference in adherence. Among seniors at the 30th and 40th percentiles of the 
PDC distribution, had the rates of enrollment in employer-sponsored (mostly retiree) drug 
coverage been equal among blacks and whites, the racial difference in adherence would 
have dropped by 1.82 and 2.39 percentage points (about 23% and 27%), respectively. 
Having this type of coverage was associated with large improvements in adherence only 
among black seniors at the 30th and 40th percentiles (see Appendix Table C-2). 
Accordingly, making this coverage works the same way among blacks and whites, e.g. 
changes to benefit design or employee contribution, might increase the racial difference 
in adherence. 
  
 The difference in how being automatically eligible for the LIS is associated with 
adherence appears to play a role in the racial difference in adherence at the 10th and the 
30th percentiles. Appendix Table C-2 shows that auto-eligibility for LIS among black, 
but not white, seniors had a strong negative association with adherence. Had auto-
eligibility for LIS (which also means receiving Medicaid) been associated with adherence 
in the same way across blacks and whites, the racial difference in adherence would have 
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been reduced by 1.05 and 0.83 percentage points (23% and 10%), respectively. Further, 
among seniors at the 10th percentile of the PDC distribution, matching average copay 
amounts for cardiovascular drugs among blacks to those among whites would reduce the 
racial difference in adherence, whereas doing so among seniors at the 50th percentile 
would increase the racial difference in adherence.  
 
 
Use of the Healthcare System. Greater use of physician ambulatory care 
appeared to work disparately among blacks and whites. In Appendix Table C-2, greater 
use of ambulatory care was associated with a reduction in adherence among blacks but 
improvement in adherence among whites at the 30th and 40th percentiles of the PDC 
distribution. Making ambulatory care work equally well for black and white seniors 
would reduce the racial difference in adherence by 2.78 and 3.2 percentage points (about 
35%), respectively (Table 4-2). 
 
 Among seniors at the 50th and 80th percentiles, the concurrent use of multiple (2-
3) cardiovascular medications was associated with worsening adherence more among 
blacks than among whites (see Appendix Table C-4). Eliminating this differential in the 
return to using multiple cardiovascular medications would reduce the racial difference in 
adherence by 6.65 and 3.71 percentage points (more than 100%), respectively as listed in 
Table 4-3. Differences related to satisfaction with healthcare or provider relationship 
were not associated with the racial differences in adherence. 
 
 
 Results from Additional Analyses. In addition to the main analysis from the 
perspective of black seniors, we also calculated detailed OBD estimates using 
coefficients from race-pooled unconditional quantile regressions. These results, listed in 
Appendix Tables C-5 and C-6, suggest the involvement of the same set of factors 
discussed above as potential sources of the racial difference in adherence. In these 
analyses, unexplained components of calculated differences were quite large, negative 
quantities and statistically significant across all modeled quantiles. Some explained 
components were significant only below the median and all had a plus sign. Mean OBD 
analyses based on logit, linear probability, and OLS models only identified differences 
related to employer-sponsored coverage rates and copay levels as potential sources of the 
racial difference in mean adherence. 
 
Discussion 
 
Differences in the distribution of and/or in the behavioral returns to marital status, 
having physical limitation, hyperlipidemia, obesity, enrollment in employer-sponsored 
coverage, being auto-eligible for the LIS, drug copay, use of ambulatory care, and use of 
multiple cardiovascular medications explained some of the racial differences in 
adherence among seniors, especially below the median, where disparities were largest 
and most significant. Such findings would not have been reachable if only differences in 
mean adherence were studied as traditionally carried out. In fact, our OBD analyses of 
the differences in mean adherence were of limited value. 
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The large magnitude and significance of the unexplained component that 
corresponds to the aggregate differential in returns to individual characteristics, 
especially as demonstrated by OBD pooled-coefficient analyses, suggest a 
discrimination-based explanation of adherence disparities. With discrimination, we 
specifically mean how the (causal) process (es) linking individual characteristics to 
adherence have been operating differently for blacks and whites. Although we found this 
differential operation of characteristics on adherence to be a recurrent theme, the validity 
of a discrimination argument further depends on whether relevant covariates were left out 
from the analysis. Although we controlled for a rich set of covariates, data on individuals’ 
self-efficacy, health literacy, degree of social support, neighborhood/household 
environment, and the degree of mistrust of the healthcare system,175,176 all relevant 
covariates, were not available in MEPS. 
 
We have found marriage to have a protective effect against poor adherence among 
blacks, suggesting an element of social support, which seems to particularly help those 
attempting to improve their adherence level (at the 30th percentile, ~ 59% PDC). This 
finding is corroborated by what qualitative studies of adherence among blacks reported of 
the positive association between family/friends’ support with adherence.144,176 Another 
finding that also alludes to social support is the role of having physical limitation. Having 
physical limitation was independently associated with better adherence among black but 
not among white seniors. A potential explanation might be that with physical limitation, 
seniors might be getting more time with their caregivers who maybe further assisting 
them with their medication-taking behavior, which may be tapping as well into the social 
support construct. 
 
Although the lower prevalence of hyperlipidemia among blacks relative to whites 
appeared protective, having hyperlipidemia, which is a largely asymptomatic condition, 
differentially worsened adherence among blacks but not nearly as much among whites at 
the lower end of the distribution (those who were most poorly adherent). This finding is 
suggestive of a higher likelihood of early discontinuation of lipid-lowering therapy 
among hyperlipidemic blacks than whites, leading to much less exposure to statins, a 
finding also reported by several studies.177,178 Table 4-1 and Appendix Table C-1 show 
that blacks were substantially less likely to use statins than whites.  
 
We have found ambulatory care to work differently in determining adherence for 
blacks and whites, where greater use of ambulatory care among blacks was associated 
with lower adherence whereas the opposite was true for whites. The specific reasons for 
why this was the case warrant investigation. A number of factors, however, can be 
hypothesized as potential remedies for this disparate effect. The quality of 
communication and compassion in the patient-provider relationship, especially when 
race-concordance is possible,150,151 has been repeatedly cited as a versatile avenue for 
intervention on medication adherence among blacks.142 Quality provider communication 
can address patients’ beliefs and concerns about how medications work and their side 
effects, and can address issues such as early discontinuation of statins, and the 
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complexity of multi-drug regimens which we found to be associated with 
disproportionately lower adherence among blacks.  
 
Insurance benefit design and cost-sharing schemes may be another set of factors 
amenable for intervention for disparity reduction. We found that employer-sponsored 
coverage was associated with improved adherence among blacks, being auto-eligible for 
the LIS worked worse among blacks, and matching white and black copay levels was 
associated with opposing effects on disparities in two different locations in the 
distribution. Optimizing the design and administration of prescription drug benefits and 
setting copay amounts in Part D plans in a way so as to increase medication use among 
those who would benefit the most out of using those drugs (e.g. by eliminating copays on 
ACE inhibitors, statins, and beta-blockers after acute MI),179,180 in a value-based benefit 
design framework,181 can improve adherence where it matters most and reduce 
disparities, not only in adherence but also in associated clinical and economic 
outcomes.180,182 Combining these reforms in benefit design with medication therapy 
management services52,53 under Part D, can together address multiple dimensions of 
patients’ pharmacotherapy experience, from affordability and access, to appropriateness 
of prescribed medications, education about medications, resolution of medication-related 
problems, and addressing issues that might be particular to individual patients. 
 
In addition to the factors we have found to be significantly associated with the 
racial difference in adherence, other factors that have been reported in the literature, such 
as depression, did not turn out to be significant. Our analysis was limited to the Medicare 
elderly population. Our results are certainly not generalizable to the general adult 
population where depression and other factors that were not significant in our analysis 
(such as SES) might be playing a greater role than in our sample. We’ve also encountered 
the counterintuitive finding that higher rates of obesity among blacks were protective 
against worse adherence especially among seniors at the 10th and 30th percentiles of the 
PDC distribution. This findings is in contrast with research documenting that obesity is 
associated with poor adherence183 and that blacks were more likely to experience weight-
based discrimination which compromised their self-efficacy and consequently their 
adherence behavior.184 Whether this effect is a statistical artifact or can be potentially 
explained by other factors that were not accounted for in the analysis is a matter for 
further investigation. 
 
Limitations 
 
Decomposition analyses are powerful in that they provide a breakdown of how 
the differences in covariates contribute to the overall difference in the outcome. As we 
have reported, these analyses only offer bottom-line estimates of the quantitative 
contributions of covariates to the outcome difference, without providing any information 
on the underlying mechanisms. These mechanisms are left for the analyst to hypothesize 
and test in future research using appropriate methods. The analyses we reported here 
were not meant to be comprehensive. It is very possible that the variables we did not have 
data on may be playing a role in the racial differences in adherence. We also suspect that 
the small sample size we had might have affected the statistical significance for some of 
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our estimates. Although all multivariable analyses had sample sizes above the limit 
recommended by the AHRQ (n>100), our descriptive statistics across PDC quantile 
categories had sample sizes less than 100, which may have rendered those estimates 
unstable. 
 
Our adherence estimation might have suffered a number of limitations. First, our 
derivation of refill days of supply from dispensed quantities was based on the 2010 data 
in our MEPS sample, without validation against an external standard, e.g. Medicare 
claims data. Given that previous research documented the validity of MEPS prescription 
drug data against Medicare claims,87 we believe benchmarking our analysis solely to 
MEPS 2010 is sufficient. While data on dispensed quantities were complete for all refills 
in the study period, a large proportion of 2010 refills had missing days of supply data 
(about 30%). We found the pattern of missing data to be very consistent across drug class 
and respondent characteristics, indicating that a missing-completely-at-random (MCAR) 
assumption is likely plausible. As such, we examined the pattern of refill days of supply 
vis-à-vis dispensed quantities only among individuals with complete days of supply data 
for all of their listed refills. 
 
We also assumed that the patterns of days of supply vis-à-vis dispensed quantities 
in 2010 would hold in earlier years of MEPS. Although we believe this assumption is 
likely true on average, changes in treatment guidelines, generic availability, and coverage 
tier classifications of drugs might have affected the prescribed total daily doses of some 
cardiovascular medications. Since MEPS did not have refill dates, a reasonable choice for 
the index date was the first day of the MEPS round in which the refill occurred. We 
might have thus underestimated adherence for respondents who started late in the round, 
although it is not possible to identify them. If a respondent had too few refills over a 
round (3-4 months), it might also be the case that they skipped refills and not necessarily 
they started taking the medication later in the round. 
 
 
Conclusion 
 
 In this study, we combined the two powerful empirical techniques of Oaxaca-
Blinder decomposition and unconditional quantile regression, to explore the potential 
sources of black-white differences in adherence to cardiovascular medications in a 
nationally representative sample of Medicare seniors. Our findings suggest that 
adherence differences were largely driven by differences in how the determinants of 
adherence operated differently for blacks than whites, including marital status, having 
hyperlipidemia, physical limitations, drug coverage, enrollment in Part D LIS, copay 
amounts, cardiovascular drug regimen, and use of ambulatory care. As such, these 
findings suggest a discrimination-based explanation of the racial differences in 
adherence. Interventions focusing on promoting social support in patients’ environment, 
more collaborative and compassionate patient-provider relationship, and value-based 
drug benefit design along with medication therapy management may be immediate 
avenues for intervention.  
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CHAPTER 5.    CONCLUSION 
 
 
Summary of Findings 
 
 Our difference-in-differences analyses showed that Medicare Part D was 
associated with a 16-percentage-point decrease in the white-Hispanic disparity in overall 
average adherence to cardiovascular medications among the elderly. This decrease was 
most visible in adherence to beta-blockers, where the white-Hispanic disparity decreased 
by 30 percentage points. While there was no significant change in overall and medication 
class-specific black-white disparities, overall adherence among black men 
disproportionately fell by 21 percentage points, relative to white men. Other subgroup 
analyses across gender and Medicaid eligibility lines suggested no statistically significant 
changes in disparities among these subgroups following Part D introduction. Estimates of 
racial disparities in the post-Part D era, 2007-2010, indicate the existence of large and 
significant black-white disparities, overall and in each sub-group. Overall adherence 
levels among both black and Hispanic Medicaid-eligible seniors were 19- and 15-
percentage points lower than whites, which were the largest among all subgroups. Using 
the near-elderly as a control group, with a few caveats, these findings took into account 
the potential level of disparities had Part D not been implemented. These findings also 
remained robust to the levels of empirical adjustment for covariates. 
 
 Among seniors, black-white disparities in adherence were largest (and statistically 
significant) towards the lower end of the distribution, below the 40th percentile and 
peaking around the 30th percentile, namely, among populations with poor adherence 
levels (70 and 60% adherence, respectively). Disparities progressively waned towards the 
upper end of the distribution. This pattern generally recurred among subgroups, with 
some variation in magnitude and statistical significance. Additionally, among men and 
the auto-enrolled LIS population (including Medicaid-eligibles), disparities were most 
concentrated among populations at and below the 30th percentile (adherence levels < 
60%). Although white-Hispanic disparities exhibited a similar pattern, they were smaller 
in magnitude and sporadically significant. 
 
 Distribution-wide Oaxaca-Blinder decompositions analyzed how the racial 
inequality in the determinants of adherence contributed to the adherence differential 
between black and white seniors. These analyses suggested that differences in most 
demographics, income, education, depression and most conditions, type of Part D drug 
coverage plan, or covariates measuring experience with healthcare providers were not 
associated with the adherence differential. Marriage and activity limitations appeared 
protective against poor adherence more among black than among white seniors with 
adherence levels below 60%, tapping into social support as the possibly underlying 
mechanism. Having diagnosed hyperlipidemia, which is mostly an asymptomatic 
condition, was mroe strongly associated with poorer adherence among blacks than among 
whites with very poor adherence (30%), suggestive of higher likelihood of early 
discontinuation of drug therapy (potentially statins) among blacks than among whites in 
this population. 
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The racial differential in enrollment rates in employer-sponsored insurance was 
strongly associated with the adherence differential among seniors with adherence below 
70%. This type of coverage was also independently associated with much higher 
adherence among blacks than among whites. Eliminating the racial differential in 
employer coverage rates was associated with an expected ~ 25% reduction in the 
adherence differential. Being an auto-recipient of the LIS was independently associated 
with worse adherence among blacks than among whites in this population. Matching the 
average copay levels among poorly adherent blacks and whites was associated with an 
increase in the adherence differential, whereas doing do among those with adherence 
close to 80% would reduce the differential. Greater use of ambulatory physician visits 
was associated with better adherence among whites but worse adherence among blacks 
with adherence below 70%. This differential in how visits determined adherence was 
responsible for about 35% of the adherence differential. Among seniors with adherence 
above 77%, taking multiple cardiovascular medications was associated with much worse 
adherence among blacks than among whites. 
 
 
Implications for Research 
 
One key limitation of current research on adherence, including this dissertation, is 
studying adherence as an isolated behavioral phenomenon. Greater appreciation of the 
complexity of adherence is much needed. Adherence should be understood as a series of 
behaviors that start with keeping doctor’s appointments to actual administration of 
medications, involving steps such as regularly filling prescriptions, using reminders, 
exercising, and maintaining healthy diet.111 These contiguous behaviors arise from 
complex interactions among multiple factors, pertinent to the patient and the 
environment. Given this complexity, we need to build a deeper mechanistic 
understanding of how this intricate system works and how/where it engenders disparities. 
Parsing out this intricacy, through complex systems science and simulation approaches, 
enables us to identify novel “leverage points” for effective intervention that were 
potentially otherwise unidentifiable.112 Studying adherence this way can also help us 
answer interesting behavioral and clinical questions, including ones identified in this 
dissertation (for example: how the use of ambulatory care disparately affects adherence 
between blacks and whites; why black LIS recipients fare worse than their white 
counterparts in terms of their adherence behavior; and why disparities in adherence to 
beta-blockers and diuretics are the largest among all cardiovascular drug classes). 
 
Although one could delineate the characteristics of populations where adherence 
disparities were found to be worst, identifying them in routine clinical practice is 
challenging. This is a result of the lack of alignment between the empirical refill-based 
measures of adherence typically employed in research (such as the proportion of days 
covered, PDC, used here), and the measures that can be used to assess patient adherence 
in routine clinical practice.117,152 Further, although using quantile regression enabled us to 
get a more comprehensive picture of the adherence distribution, we still lumped 
adherence into a single number without further parsing out the underlying behavioral 
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details. Instead of summarizing patient adherence over (say) a year into a single number, 
a more informative alternative would be to examine the developmental trajectories of 
adherence over time using group-based trajectory models.153 This would enable us to 
capture more details about regimen execution, i.e. patterns of how the prescribed 
compares to the actual regimen taken, and persistence over time.18,21 Identifiable patterns 
such as brief lapse in therapy due to occasional dose omissions, longer drug holiday but 
then continuation, periodic gaps in therapy, and early discontinuation provide a basis for 
more meaningful classification of adherence behavior with implications for intervention 
and for studying disparities. It is worth noting here that some recently developed 
questionnaire instruments, which can be administered in practice settings, can help 
identify these distinct patterns as well, and can thus offer a closer insight into real-world 
settings.152,154 
 
 
Implications for Policy 
 
While it is important to identify access/quality issues that may disparately 
compromise adherence behavior among minorities, it is at least equally as important to 
envision adherence as a reflection of the structural, physical, and psychosocial 
disadvantage racial minorities typically live in. Poverty, low educational attainment, poor 
social support, disordered physical and social environments, and policies that 
institutionalize racism are systematic, causal antecedents to almost every poor health 
outcome among minorities.108 One example of how social determinants affected 
adherence in this dissertation manifested in the rates of employer-sponsored coverage. 
The black-white differential in employer-sponsored insurance coverage (mostly retiree 
coverage) was responsible for a sizable portion of the adherence differential. Our results 
suggest that if blacks were equally likely to have been employed in a way that provides 
them with generous insurance coverage upon retirement, the adherence differential would 
have been reduced. The nature of employment and type of occupation are direct 
correlates of educational attainment, which is much lower among blacks than whites (in 
our sample, ~50% of black seniors had less than high school education, compared with 
only 20% among whites). Achieving equity in these fundamental determinants of health 
ought to remain a long-term goal for society. 
 
Under Medicare Part D, MTM programs offer a versatile mechanism to address 
the drivers of poor adherence among minorities and to reduce adherence disparities. First, 
however, the utilization-based eligibility criteria for MTM services continue to be an 
impediment to improving the quality of medication use in this population as it deprives 
minorities who would greatly benefit from this service.63,185 Investigating more equitable 
alternatives for these criteria remains an important step. Further, although having an opt-
out, rather than an opt-in, policy for enrollment in MTM is a good step towards greater 
enrollment of seniors for this service, there is still a low turnout rate in keeping up with 
MTM appointments and medication reviews.148 Increasing awareness of the value of 
MTM, particularly among minorities, may prove to be a good step towards improving 
adherence among seniors and particularly minorities. Through comprehensive medication 
reviews, collaboration with patient’s providers (including social workers, and 
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community/home health workers), and establishing an empowering collaborative 
relationship with the patients themselves, pharmacists providing MTM can proactively 
identify and tackle issues compromising medication adherence (and potentially other 
aspects of healthcare). 52,53,109,149 Examples of what MTM and, broadly, what other 
providers can do, include: educating patients about their medications, addressing their 
medication-related problems and concerns (e.g. issues related to discontinuation of statin 
therapy, poor adherence to diuretics and beta-blockers, having to take multiple 
medications), promoting their self-management behavior, improving their health literacy, 
screening for depression, and enhancing their self-efficacy. Current evidence suggest that 
minorities’ adherence to cardiovascular medications significantly improves when there is 
race and language concordance between them and their providers, which should be 
sought whenever possible.150,151 Further research110 is needed on how to optimize MTM 
delivery for minority and low-SES patients.  
 
Insurance benefit design and cost-sharing schemes may be another set of factors 
amenable for intervention for disparity reduction. We found that employer-sponsored 
coverage was associated with improved adherence among blacks, being auto-eligible for 
the LIS worked worse among blacks, and matching white and black copay levels was 
associated with opposing effects on disparities in two different locations in the 
distribution. Optimizing the design and administration of prescription drug benefits and 
setting copay amounts in Part D plans in a way so as to increase medication use among 
those who would benefit the most from using those drugs (e.g. by eliminating copays on 
ACE inhibitors, statins, and beta-blockers after acute MI),179,180 in a value-based benefit 
design framework,181 can improve adherence where it matters most and reduce 
disparities, not only in adherence but also in associated clinical and economic 
outcomes.180,182 Combining these reforms in benefit design with medication therapy 
management services52,53 under Part D, can together address multiple dimensions of 
patients’ pharmacotherapy experience, from affordability and access, to appropriateness 
of prescribed medications, education about medications, resolution of medication-related 
problems, and addressing issues that might be particular to individual patients.  
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APPENDIX A. SUPPLEMENTAL MATERIALS FOR CHAPTER 2 
 
 
Table A-1. Identifying information for included cardiovascular conditions 
 
Condition CCC ICD-9 Codes 
Essential 
Hypertension 
98 4011 4019      
Hypertension with 
complications / 
Secondary 
Hypertension 
99 4010 40200 40201 40210 40211 40290 40291 
4030 40300 40301 4031 40310 40311 4039 
40390 40391 4040 40400 40401 40402 40403 
4041 40410 40411 40412 40413 4049 40490 
40491 40492 40493 40501 40509 40511 40519 
40591 40599 4372     
Hyperlipidemia 53 2720 2721 2722 2723 2724   
Angina and Coronary 
Heart Disease 
(atherosclerosis) 
101 4110 4111 4118 41181 41189 412 4130 
4131 4139 4140 41400 41401 41406 4148 
4149 V4581 V4582     
Congestive Heart 
Failure 
108 39891 4280 4281 42820 42821 42822 42823 
42830 42831 42832 42833 42840 42841 42842 
42843 4289      
Acute Myocardial 
Infarction 
100 4100 41000 41001 41002 4101 41010 41011 
41012 4102 41020 41021 41022 4103 41030 
41031 41032 4104 41040 41041 41042 4105 
41050 41051 41052 4106 41060 41061 41062 
4107 41070 41071 41072 4108 41080 41081 
41082 4109 41090 41091 41092   
Acute 
Cerebrovascular 
Disease 
109 34660 34661 34662 34663 430 431 4320 
4321 4329 43301 43311 43321 43331 43381 
43391 4340 43400 43401 4341 43410 43411 
4349 43490 43491 436    
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Table A-1.     (Continued) 
 
Condition CCC ICD-9 Codes 
Transient Cerebral 
Ischemia 112 4350 4351 4352 4353 4358 4359  
 
CCC: Clinical Classification Codes; ICD-9-CM: International Classification of Diseases, Ninth Revision, Clinical 
Modification. 
 
Source: AHRQ. MEPS HC-137: 2010 Medical Conditions- Appendix 3: Clinical Classification Code to ICD-9-CM Code 
Crosswalk. Rockville, MD 2012.  
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Table A-2. Included cardiovascular medications 
 
Drug Class 
Multum-
Lexicon ® 
Class 
Multum-
Lexicon ® 
Subclass 1 
Specific Agents 
Angiotensin-Converting 
Enzyme (ACE) Inhibitors 
42 None Benazepril, Captopril, Enalapril, Fosinopril, 
Lisinopril, Moexipril, Perindopril, Quinapril, 
Ramipril, Trandolapril  
Angiotensin II Receptor 
Blockers 
56 None Candesartan, Eprosartan, Irbesartan, Losartan, 
Olmesartan, Telmisartan, Valsartan 
HMG-CoA Reductase 
Inhibitors (Statins) 
173 None Atorvastatin, Fluvastatin, Lovastatin, Pitavastatin, 
Pravastatin, Rosuvastatin, Simvastatin 
Beta-Blockers 47 274, 275 Acebutolol, Atenolol, Betaxolol, Bisoprolol, 
Carvedilol, Labetalol, Metoprolol, Nadolol, 
Nebivolol, Penbutolol, Pindolol, Propranolol, 
Sotalol, Timolol 
Calcium Channel 
Blockers 
48 None Amlodipine Besylate, Diltiazem, Felodipine, 
Isradipine, Nicardipine, Nifedipine, Nisoldipine, 
Verapamil 
Diuretics 49 154-158 Acetazolamide, Spironolactone, Amiloride, 
Bumetanide, Chlorothiazide, Chlorthalidone, 
Furosemide, Hydrochlorothiazide, Indapamide, 
Methyclothiazide, Metolazone, Torsemide, 
Triamterene 
Antihypertensive 
Combinations 
55 None Multiple combinations of these drugs with 
diuretics, especially 
 
Source: AHRQ. MEPC HC-135A: 2010 Prescribed Medicines. Rockville, MD 2012.   
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Figure A-1. Sequential adjustment for covariates and the magnitude of the difference-in-differences coefficients 
DID: Difference-in-Differences. All analyses were conducted in the main sample (n=17,677), excluding 2006 data.  
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Table A-3. Multivariable logistic regression results in the main sample and by subgroup 
 
 Covariate Main Analysis 
2006 
Analysis 
Medicare  
65-70 Tx 
Group 
Men Women Non-Dual Dual Eligibles 
 Odds Ratio [95%CI] 
Difference-in-Difference Setup 
Treated Group 
(Medicare Seniors) 
1.11 
[0.90,1.38] 
1.13  
[0.92,1.39] 
0.95 
[0.70,1.28] 
1.12 
[0.83,1.51] 
1.08 
[0.84,1.41] 
1.08 
[0.87,1.36] 
1.86 
[0.87,3.96] 
Post-Part D Period 2.15 [1.71,2.69]ǂ 
1.80 
[1.44,2.24]ǂ 
2.09 
[1.66,2.63]ǂ 
2.70 
[1.93,3.77]ǂ 
1.76 
[1.35,2.29]ǂ 
2.12 
[1.68,2.68]ǂ 
2.53 
[1.05,6.13]† 
Medicare Post Part 
D 
0.89 
[0.70,1.14] 
0.89  
[0.70,1.14] 
1.09 
[0.82,1.46] 
0.89 
[0.62,1.27] 
0.95 
[0.71,1.28] 
0.91 
[0.70,1.18] 
0.71 
[0.27,1.86] 
Black 0.97 [0.18,5.09] 
1.34  
[0.26,6.78] 
1.28 
[0.10,15.87] 
0.60 
[0.05,8.02] 
1.11 
[0.60,2.03] 
3.27 
[0.29,36.74] 
0.62 
[0.06,6.25] 
Black in Medicare 0.94 [0.64,1.39] 
0.93  
[0.63,1.37] 
0.87 
[0.54,1.41] 
1.12 
[0.64,1.97] 
0.85 
[0.50,1.46] 
1.08 
[0.66,1.76] 
0.37 
[0.14,0.99]† 
Black Post-Part D 0.79 [0.50,1.24] 
0.74  
[0.48,1.14] 
0.80 
[0.50,1.27] 
1.04 
[0.46,2.36] 
0.64 
[0.36,1.13] 
0.89 
[0.51,1.53] 
0.35 
[0.10,1.22]* 
Black in Medicare 
Post-Part D 
0.78 
[0.45,1.33] 
0.91  
[0.56,1.49] 
0.78 
[0.41,1.47] 
0.42 
[0.18,0.96]† 
1.17 
[0.60,2.29] 
0.64 
[0.33,1.25] 
2.06 
[0.53,8.03] 
Hispanic 1.35 [0.62,2.95] 
1.69  
[0.77,3.69] 
1.13 
[0.46,2.80] 
0.97 
[0.23,4.13] 
1.20 
[0.42,3.41] 
1.38 
[0.43,4.49] 
2.26 
[0.28,18.40] 
Hispanic in 
Medicare 
0.57 
[0.37,0.88]† 
0.56 
[0.36,0.86]ǂ 
0.76 
[0.46,1.25] 
0.47 
[0.19,1.17] 
0.64 
[0.39,1.05]* 
0.52 
[0.32,0.87]† 
0.45 
[0.15,1.34] 
Hispanic Post-Part 
D 
0.55 
[0.34,0.90]† 
0.54 
[0.33,0.87]† 
0.54 
[0.33,0.89]† 
0.55 
[0.20,1.50] 
0.57 
[0.32,1.01]* 
0.68 
[0.38,1.22] 
0.31 
[0.09,1.10]* 
Hispanic in 
Medicare Post-Part 
D 
2.04 
[1.14,3.63]† 
2.04 
[1.17,3.55]† 
1.34 
[0.66,2.76] 
2.44 
[0.81,7.32] 
1.88 
[0.94,3.75]* 
1.83 
[0.93,3.63]* 
3.03 
[0.75,12.25] 
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Table A-3.     (Continued) 
 
 Covariate Main Analysis 
2006 
Analysis 
Medicare  
65-70 Tx 
Group 
Men Women Non-Dual Dual Eligibles 
Demographics 
Age 0.99 [0.99,1.00]* 
0.99 
[0.98,1.00]ǂ 
1.00 
[0.96,1.05] 
0.99 
[0.98,1.01] 
0.99 
[0.98,1.00] 
0.99 
[0.98,1.00]* 
1.00 
[0.98,1.02] 
Female gender 1.05 [0.96,1.14] 
1.05  
[0.97,1.14] 
1.02 
[0.89,1.16] N/A N/A 
1.06 
[0.97,1.16] 
0.93 
[0.70,1.23] 
Married 0.94 [0.86,1.03] 
0.92 
[0.84,1.00]† 
1.00 
[0.87,1.15] 
1.02 
[0.88,1.18] 
0.90 
[0.81,1.01]* 
0.94 
[0.85,1.04] 
1.01 
[0.71,1.42] 
Urban Residence 1.07 [0.95,1.20] 
1.04  
[0.93,1.16] 
1.18 
[0.99,1.41]* 
1.01 
[0.85,1.19] 
1.11 
[0.96,1.27] 
1.08 
[0.95,1.22] 
0.89 
[0.66,1.21] 
Census Region 
Midwest 1.23 [1.07,1.41]ǂ 
1.20 
[1.05,1.37]ǂ 
1.29 
[1.05,1.57]† 
1.31 
[1.06,1.61]† 
1.20 
[1.02,1.41]† 
1.25 
[1.08,1.44]ǂ 
1.02 
[0.70,1.46] 
South 1.04 [0.91,1.18] 
1.03  
[0.91,1.17] 
1.07 
[0.89,1.30] 
1.13 
[0.93,1.37] 
0.98 
[0.84,1.15] 
1.04 
[0.91,1.20] 
0.91 
[0.64,1.30] 
West 1.02 [0.88,1.18] 
1.01  
[0.87,1.16] 
1.09 
[0.87,1.37] 
1.09 
[0.89,1.34] 
0.97 
[0.80,1.18] 
1.04 
[0.89,1.21] 
0.86 
[0.59,1.27] 
Self-Reported Health 
Very Good 1.01 [0.89,1.15] 
1.02  
[0.90,1.15] 
0.98 
[0.80,1.21] 
1.11 
[0.89,1.37] 
0.97 
[0.82,1.14] 
0.99 
[0.86,1.13] 
2.07 
[1.07,3.97]† 
Good 0.95 [0.83,1.09] 
0.95  
[0.83,1.08] 
0.87 
[0.70,1.07] 
0.90 
[0.74,1.11] 
0.99 
[0.84,1.17] 
0.94 
[0.81,1.08] 
1.40 
[0.75,2.61] 
Fair 1.01 [0.86,1.19] 
1.00  
[0.86,1.16] 
0.96 
[0.74,1.25] 
1.04 
[0.82,1.33] 
1.01 
[0.83,1.22] 
1.01 
[0.85,1.20] 
1.38 
[0.74,2.57] 
Poor  1.06 [0.87,1.29] 
1.05  
[0.88,1.26] 
1.00 
[0.73,1.36] 
1.32 
[0.97,1.80]* 
0.94 
[0.74,1.21] 
1.10 
[0.89,1.37] 
1.19 
[0.59,2.37] 
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Covariate  Main Analysis 
2006 
Analysis 
Medicare  
65-70 Tx 
Group 
Men Women Non-Dual Dual Eligibles 
Any Physical 
Limitation 
1.07 
[0.98,1.17] 
1.06  
[0.98,1.15] 
1.01 
[0.88,1.16] 
1.06 
[0.92,1.22] 
1.07 
[0.95,1.20] 
1.07 
[0.98,1.18] 
1.06 
[0.74,1.52] 
Any Cognitive 
Limitation 
1.14 
[0.99,1.31]* 
1.11  
[0.97,1.26] 
1.14 
[0.85,1.55] 
1.10 
[0.88,1.38] 
1.17 
[0.98,1.39]* 
1.14 
[0.96,1.34] 
1.15 
[0.84,1.57] 
Conditions (over survey year) 
Charlson Score Q3 0.85 [0.77,0.93]ǂ 
0.89 
[0.82,0.97]ǂ 
0.83 
[0.72,0.96]† 
0.82 
[0.71,0.95]ǂ 
0.87 
[0.78,0.98]† 
0.84 
[0.76,0.93]ǂ 
0.90 
[0.68,1.19] 
Charlson Score Q4 0.82 [0.70,0.97]† 
0.89  
[0.76,1.03] 
0.83 
[0.65,1.04] 
0.77 
[0.60,0.98]† 
0.89 
[0.73,1.08] 
0.77 
[0.64,0.91]ǂ 
1.20 
[0.80,1.79] 
Comorbidity Count 0.96 [0.94,0.97]ǂ 
0.96 
[0.95,0.97]ǂ 
0.96 
[0.94,0.99]ǂ 
0.94 
[0.91,0.96]ǂ 
0.97 
[0.95,0.99]ǂ 
0.95 
[0.94,0.97]ǂ 
0.97 
[0.93,1.02] 
Hypertension 1.47 [1.30,1.65]ǂ 
1.48 
[1.32,1.66]ǂ 
1.55 
[1.26,1.90]ǂ 
1.41 
[1.19,1.68]ǂ 
1.51 
[1.27,1.79]ǂ 
1.45 
[1.28,1.65]ǂ 
1.84 
[1.18,2.88]ǂ 
Lipidemia 1.03 [0.94,1.13] 
1.03  
[0.95,1.12] 
1.13 
[0.97,1.31] 
1.02 
[0.88,1.18] 
1.02 
[0.91,1.14] 
1.02 
[0.93,1.13] 
1.08 
[0.80,1.45] 
Angina/CHD 1.05 [0.94,1.17] 
1.16 
[1.05,1.30]ǂ 
1.06 
[0.88,1.29] 
1.14 
[0.97,1.35] 
0.94 
[0.80,1.11] 
1.07 
[0.95,1.20] 
0.94 
[0.66,1.33] 
CHF 1.20 [0.98,1.48]* 
1.15  
[0.95,1.40] 
1.57 
[1.03,2.39]† 
1.22 
[0.89,1.66] 
1.20 
[0.91,1.58] 
1.18 
[0.95,1.47] 
1.39 
[0.85,2.26] 
AMI 0.92 [0.77,1.10] 
0.99  
[0.83,1.17] 
1.15 
[0.84,1.57] 
0.86 
[0.68,1.09] 
0.96 
[0.72,1.28] 
0.93 
[0.76,1.12] 
0.92 
[0.55,1.53] 
Stroke 0.87 [0.72,1.06] 
0.90  
[0.75,1.08] 
0.72 
[0.52,1.00]* 
0.94 
[0.70,1.27] 
0.84 
[0.66,1.07] 
0.89 
[0.72,1.10] 
0.82 
[0.51,1.31] 
Depression 1.04 [0.91,1.19] 
1.06  
[0.93,1.20] 
0.94 
[0.76,1.15] 
1.18 
[0.90,1.53] 
0.98 
[0.84,1.14] 
1.05 
[0.91,1.22] 
0.94 
[0.67,1.31] 
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Covariate  Main Analysis 
2006 
Analysis 
Medicare  
65-70 Tx 
Group 
Men Women Non-Dual Dual Eligibles 
Beliefs & Behaviors 
More Likely to 
Take Risks 
0.94 
[0.85,1.05] 
0.94  
[0.85,1.05] 
0.92 
[0.79,1.07] 
0.94 
[0.80,1.10] 
0.94 
[0.81,1.10] 
0.94 
[0.83,1.06] 
1.01 
[0.72,1.41] 
Do Not Need 
Insurance 
0.96 
[0.78,1.18] 
0.90  
[0.74,1.09] 
0.96 
[0.66,1.39] 
1.03 
[0.74,1.42] 
0.92 
[0.69,1.23] 
1.00 
[0.80,1.25] 
0.67 
[0.39,1.15] 
Can Overcome 
Illness without 
Medical Care 
1.03 
[0.91,1.17] 
1.05  
[0.93,1.18] 
1.09 
[0.91,1.30] 
1.03 
[0.84,1.27] 
1.04 
[0.88,1.23] 
1.03 
[0.90,1.18] 
0.95 
[0.65,1.40] 
Currently Smoking 0.99 [0.87,1.13] 
1.00  
[0.89,1.13] 
1.08 
[0.92,1.28] 
0.98 
[0.80,1.19] 
0.99 
[0.84,1.17] 
0.99 
[0.86,1.14] 
0.95 
[0.68,1.33] 
Moderate/Vigorous 
Exercise 
1.03 
[0.95,1.12] 
1.01  
[0.93,1.10] 
0.99 
[0.87,1.11] 
1.18 
[1.02,1.35]† 
0.94 
[0.84,1.04] 
1.03 
[0.94,1.12] 
0.97 
[0.73,1.29] 
Socioeconomic Status & Insurance 
Income:  
Poor 
1.06 
[0.92,1.22] 
1.06  
[0.93,1.21] 
1.21 
[0.95,1.53] 
1.14 
[0.91,1.45] 
1.04 
[0.87,1.24] 
0.98 
[0.84,1.15] 
1.60 
[0.65,3.92] 
Low-Income 1.06 [0.92,1.23] 
1.04  
[0.91,1.19] 
1.04 
[0.82,1.32] 
1.05 
[0.84,1.32] 
1.04 
[0.87,1.26] 
1.07 
[0.92,1.23] 
1.06 
[0.41,2.75] 
Middle-Income 1.02 [0.93,1.13] 
1.01  
[0.92,1.11] 
1.06 
[0.90,1.25] 
0.98 
[0.84,1.15] 
1.05 
[0.92,1.20] 
1.01 
[0.92,1.12] 
1.57 
[0.60,4.10] 
Education:  
Less than High 
School 
1.14 
[1.00,1.30]* 
1.11 
[0.98,1.26]* 
1.10 
[0.89,1.36] 
1.25 
[1.01,1.54]† 
1.06 
[0.88,1.27] 
1.15 
[1.00,1.33]* 
0.84 
[0.43,1.62] 
High School 
Diploma 
1.05 
[0.95,1.16] 
1.04  
[0.95,1.15] 
1.04 
[0.89,1.21] 
1.04 
[0.89,1.23] 
1.04 
[0.90,1.20] 
1.05 
[0.94,1.16] 
1.01 
[0.48,2.12] 
Language: 
Interview in 
English 
0.78 
[0.46,1.32] 
0.94  
[0.54,1.61] 
0.63 
[0.34,1.18] 
0.35 
[0.14,0.87]† 
1.26 
[0.60,2.64] 
0.76 
[0.30,1.94] 
1.15 
[0.65,2.02] 
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Covariate  Main Analysis 
2006 
Analysis 
Medicare  
65-70 Tx 
Group 
Men Women Non-Dual Dual Eligibles 
Insurance: 
Medicaid 
1.00 
[0.86,1.16] 
0.97  
[0.84,1.11] 
0.95 
[0.76,1.20] 
1.06 
[0.82,1.37] 
0.98 
[0.83,1.15] N/A N/A 
Private, Non-HMO 0.96 [0.87,1.05] 
0.90 
[0.83,0.99]† 
1.00 
[0.86,1.17] 
0.94 
[0.82,1.07] 
0.97 
[0.85,1.10] 
0.97 
[0.88,1.06] 
0.81 
[0.36,1.81] 
Private, HMO 0.98 [0.85,1.13] 
0.94  
[0.82,1.08] 
1.00 
[0.82,1.22] 
0.98 
[0.81,1.20] 
1.00 
[0.83,1.19] 
0.99 
[0.85,1.14] 
0.32 
[0.13,0.78]† 
Healthcare Use (over survey year) 
Concurrently Taken Drugs 
2-3 CV Drugs 0.58 [0.52,0.64]ǂ 
0.58 
[0.53,0.63]ǂ 
0.58 
[0.50,0.68]ǂ 
0.58 
[0.50,0.68]ǂ 
0.57 
[0.50,0.64]ǂ 
0.58 
[0.52,0.64]ǂ 
0.51 
[0.37,0.70]ǂ 
≥4 CV Drugs 0.41 [0.34,0.50]ǂ 
0.40 
[0.34,0.48]ǂ 
0.41 
[0.29,0.58]ǂ 
0.36 
[0.27,0.47]ǂ 
0.46 
[0.36,0.60]ǂ 
0.39 
[0.32,0.48]ǂ 
0.57 
[0.32,1.03]* 
2-4 Other Drugs 1.66 [1.46,1.89]ǂ 
1.63 
[1.44,1.84]ǂ 
1.58 
[1.31,1.91]ǂ 
1.67 
[1.38,2.01]ǂ 
1.66 
[1.39,1.99]ǂ 
1.68 
[1.47,1.92]ǂ 
1.61 
[1.00,2.59]† 
≥5 Other Drugs 2.83 [2.41,3.33]ǂ 
2.65 
[2.28,3.09]ǂ 
2.84 
[2.19,3.68]ǂ 
2.97 
[2.33,3.79]ǂ 
2.75 
[2.22,3.40]ǂ 
2.89 
[2.42,3.45]ǂ 
2.69 
[1.62,4.47]ǂ 
No. of Pharmacies 
Used 
0.78 
[0.72,0.84]ǂ 
0.77 
[0.71,0.83]ǂ 
0.81 
[0.72,0.90]ǂ 
0.76 
[0.67,0.85]ǂ 
0.79 
[0.72,0.88]ǂ 
0.76 
[0.70,0.83]ǂ 
1.01 
[0.77,1.33] 
Had a Usual Source 
of Care 
1.18 
[0.93,1.51] 
1.12  
[0.89,1.41] 
1.10 
[0.77,1.56] 
1.25 
[0.91,1.73] 
1.15 
[0.82,1.60] 
1.15 
[0.89,1.50] 
1.41 
[0.79,2.53] 
Quintiles of Ambulatory Physician Visits 
Q 2 (3-4 Visits) 1.03 [0.92,1.16] 
1.00  
[0.89,1.12] 
1.03 
[0.87,1.23] 
1.02 
[0.85,1.22] 
1.05 
[0.91,1.23] 
1.06 
[0.94,1.20] 
0.78 
[0.54,1.14] 
Q 3 (5-7 Visits) 0.92 [0.80,1.05] 
0.88 
[0.77,1.00]† 
0.92 
[0.76,1.12] 
0.95 
[0.77,1.17] 
0.91 
[0.78,1.07] 
0.94 
[0.81,1.09] 
0.79 
[0.54,1.14] 
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Covariate  Main Analysis 
2006 
Analysis 
Medicare  
65-70 Tx 
Group 
Men Women Non-Dual Dual Eligibles 
Q 4 (8-12 Visits) 0.91 [0.79,1.04] 
0.86 
[0.76,0.98]† 
0.97 
[0.80,1.18] 
1.00 
[0.81,1.24] 
0.86 
[0.72,1.02]* 
0.93 
[0.80,1.08] 
0.75 
[0.49,1.16] 
Q 5 (≥13 Visits) 0.93 [0.80,1.07] 
0.86 
[0.75,0.99]† 
1.06 
[0.86,1.32] 
0.94 
[0.74,1.19] 
0.93 
[0.78,1.11] 
0.97 
[0.83,1.14] 
0.72 
[0.46,1.13] 
Experience with Providers 
Always Listens 1.08 [0.86,1.34] 
1.06  
[0.87,1.29] 
1.21 
[0.85,1.72] 
1.09 
[0.77,1.54] 
1.08 
[0.81,1.43] 
1.14 
[0.89,1.45] 
0.81 
[0.45,1.46] 
Always Explains 1.00 [0.83,1.19] 
1.02  
[0.86,1.21] 
0.77 
[0.57,1.05] 
0.98 
[0.73,1.33] 
1.03 
[0.80,1.34] 
0.97 
[0.79,1.18] 
1.21 
[0.73,2.00] 
Always Respects 1.01 [0.81,1.25] 
1.05  
[0.86,1.27] 
1.26 
[0.92,1.73] 
0.95 
[0.67,1.35] 
1.04 
[0.78,1.39] 
1.00 
[0.79,1.28] 
0.98 
[0.56,1.73] 
Satisfied with 
Healthcare  
1.08 
[0.92,1.26] 
1.09  
[0.94,1.26] 
1.02 
[0.81,1.28] 
1.03 
[0.79,1.34] 
1.08 
[0.90,1.30] 
1.06 
[0.90,1.26] 
1.13 
[0.76,1.69] 
Very Satisfied with 
Healthcare 
1.02 
[0.87,1.19] 
1.03  
[0.88,1.20] 
1.01 
[0.79,1.29] 
0.95 
[0.72,1.25] 
1.04 
[0.87,1.25] 
1.02 
[0.86,1.22] 
0.91 
[0.62,1.34] 
H-L GOF P Value 0.7 0.93 0.97 0.83 0.39 0.79 0.88 
Sample Size 17,677 19,919 7,447 7,180 10,495 15,012 2,665 
Weighted 
Population 24,915,354 24,801,597 10,757,736 10,688,687 14,225,567 22,746,778 2,168,576 
 
*P <0.1 † P<0.05 ǂ P<0.01 
Estimates were also adjusted for interactions terms of black and Hispanic indicators with income and education levels. CV: 
Cardiovascular; Q: Quartile; CHD: Coronary Heart Disease; CHF: Congestive Heart Failure; AMI: Acute Myocardial 
Infarction; HMO: Health Maintenance Organization; H-L GOF: Hosmer-Lemeshow Goodness-of-Fit test (modified for survey 
data).  
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 Covariate ACEIs/ARBs Statins Beta Blockers Ca Channel Blockers Diuretics 
  Odds Ratio[95%CI] 
Difference-in-Difference Setup 
Treated Group 
(Medicare Senior) 
1.11 
[0.87,1.43] 
0.94 
[0.69,1.29] 
1.12 
[0.77,1.62] 
1.15 
[0.75,1.78] 
1.06 
[0.78,1.46] 
Post-Part D Period 1.99 [1.51,2.62]*** 
2.29 
[1.68,3.13]*** 
1.37 
[0.95,1.98]* 
1.71 
[1.06,2.76]** 
1.56 
[1.08,2.24]** 
Medicare Post Part 
D 
0.84 
[0.62,1.15] 
1.06 
[0.75,1.50] 
1.02 
[0.68,1.53] 
0.83 
[0.49,1.40] 
0.85 
[0.57,1.26] 
Black 1.64 [0.17,15.64] 
0.68 
[0.04,10.48] 
0.56 
[0.27,1.14] 
1.33 
[0.62,2.88] 
1.53 
[0.11,21.47] 
Black in Medicare 0.83 [0.51,1.35] 
1.79 
[1.00,3.20]** 
1.14 
[0.57,2.28] 
0.71 
[0.34,1.51] 
1.36 
[0.78,2.40] 
Black Post-Part D  0.77 [0.42,1.43] 
1.21 
[0.64,2.27] 
1.49 
[0.67,3.32] 
1.06 
[0.43,2.62] 
1.22 
[0.62,2.40] 
Black in Medicare 
Post-Part D 
0.98 
[0.51,1.86] 
0.50 
[0.23,1.08]* 
0.49 
[0.19,1.23] 
0.99 
[0.35,2.80] 
0.56 
[0.27,1.18] 
Hispanic 1.80 [0.63,5.16] 
2.00 
[0.19,20.82] 
1.18 
[0.32,4.33] 
2.85 
[0.55,14.88] 
0.95 
[0.19,4.88] 
Hispanic in 
Medicare 
0.66 
[0.37,1.18] 
0.50 
[0.21,1.19] 
0.59 
[0.27,1.33] 
0.43 
[0.18,0.99]** 
0.45 
[0.21,0.99]** 
Hispanic Post-Part D  0.67 [0.34,1.35] 
0.61 
[0.26,1.44] 
0.40 
[0.16,1.00]* 
0.90 
[0.33,2.46] 
0.68 
[0.28,1.67] 
Hispanic in 
Medicare Post-Part 
D 
1.59 
[0.74,3.43] 
2.30 
[0.83,6.32] 
3.35 
[1.21,9.28]** 
1.06 
[0.35,3.23] 
1.76 
[0.65,4.81] 
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 Covariate ACEIs/ARBs Statins Beta Blockers Ca Channel Blockers Diuretics 
Demographics      
Age 1.00 [0.99,1.01] 
1.00 
[0.99,1.01] 
0.99 
[0.98,1.00]* 
0.99 
[0.98,1.01] 
0.99 
[0.98,1.00] 
Female gender 1.02 [0.91,1.13] 
1.02 
[0.90,1.15] 
1.11 
[0.98,1.26] 
1.13 
[0.95,1.35] 
0.95 
[0.83,1.09] 
Married 0.93 [0.83,1.04] 
0.97 
[0.85,1.10] 
0.98 
[0.85,1.14] 
0.87 
[0.74,1.03] 
0.92 
[0.80,1.05] 
MSA residence 0.98 [0.86,1.12] 
1.07 
[0.92,1.25] 
0.94 
[0.81,1.09] 
0.97 
[0.79,1.20] 
1.11 
[0.95,1.29] 
Census Region      
Midwest 1.18 [1.01,1.39]** 
1.16 
[0.95,1.42] 
1.13 
[0.94,1.36] 
1.26 
[0.98,1.62]* 
1.30 
[1.08,1.57]*** 
South 0.93 [0.80,1.09] 
0.96 
[0.81,1.15] 
1.10 
[0.92,1.32] 
1.17 
[0.93,1.47] 
1.04 
[0.89,1.23] 
West 1.01 [0.84,1.22] 
0.94 
[0.79,1.12] 
1.02 
[0.84,1.25] 
1.03 
[0.80,1.33] 
1.03 
[0.85,1.25] 
Self-Reported Health 
Very Good 1.09 [0.90,1.32] 
1.11 
[0.92,1.35] 
1.10 
[0.89,1.35] 
1.03 
[0.76,1.39] 
0.96 
[0.78,1.17] 
Good 1.10 [0.92,1.31] 
0.97 
[0.80,1.16] 
1.02 
[0.81,1.28] 
0.98 
[0.73,1.32] 
1.01 
[0.83,1.24] 
Fair 1.18 [0.96,1.44] 
1.08 
[0.88,1.33] 
1.03 
[0.81,1.32] 
0.96 
[0.69,1.33] 
0.98 
[0.78,1.23] 
Poor 1.19 [0.93,1.52] 
1.03 
[0.75,1.41] 
1.00 
[0.75,1.33] 
1.14 
[0.75,1.74] 
0.93 
[0.68,1.27] 
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Table A-4.     (Continued) 
 
 Covariate ACEIs/ARBs Statins Beta Blockers Ca Channel Blockers Diuretics 
Any Physical 
Limitation 
0.97 
[0.87,1.09] 
1.11 
[0.98,1.26]* 
1.12 
[0.97,1.28] 
1.21 
[1.02,1.44]** 
1.01 
[0.88,1.16] 
Any Cognitive 
Limitation 
1.08 
[0.90,1.29] 
1.09 
[0.88,1.34] 
1.14 
[0.92,1.42] 
1.07 
[0.83,1.39] 
1.15 
[0.93,1.42] 
Conditions (over survey year) 
Condition Count 0.96 [0.94,0.98]*** 
0.97 
[0.94,0.99]*** 
0.98 
[0.96,1.01] 
0.98 
[0.95,1.01] 
0.96 
[0.94,0.99]*** 
Charlson 
Comorbidity Score 
Q3 
0.90 
[0.79,1.02]* 
0.84 
[0.73,0.96]*** 
0.83 
[0.72,0.95]*** 
0.81 
[0.69,0.96]** 
0.79 
[0.69,0.91]*** 
Charlson 
Comorbidity Score 
Q4 
0.94 
[0.77,1.14] 
0.82 
[0.66,1.01]* 
0.82 
[0.64,1.04]* 
0.66 
[0.49,0.89]*** 
0.99 
[0.79,1.24] 
Hypertension 1.49 [1.12,1.97]*** 
1.19 
[0.99,1.44]* 
1.54 
[1.20,1.96]*** 
1.22 
[0.79,1.90] 
1.29 
[0.94,1.77] 
Lipidemia 1.02 [0.92,1.13] 
1.79 
[1.31,2.44]*** 
1.05 
[0.91,1.20] 
0.96 
[0.81,1.14] 
1.01 
[0.88,1.15] 
Angina/CHD 1.05 [0.90,1.22] 
1.08 
[0.94,1.25] 
1.18 
[1.00,1.40]* 
1.35 
[1.05,1.73]** 
1.09 
[0.91,1.31] 
CHF 1.17 [0.92,1.48] 
1.04 
[0.75,1.44] 
1.38 
[1.04,1.83]** 
0.86 
[0.56,1.32] 
1.12 
[0.89,1.42] 
AMI 0.78 [0.63,0.96]** 
0.97 
[0.77,1.21] 
0.91 
[0.74,1.10] 
1.09 
[0.76,1.55] 
0.98 
[0.75,1.27] 
Stroke 0.87 [0.68,1.12] 
0.98 
[0.76,1.27] 
1.00 
[0.75,1.35] 
0.96 
[0.68,1.36] 
0.82 
[0.61,1.11] 
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Table A-4.     (Continued) 
 
 Covariate ACEIs/ARBs Statins Beta Blockers Ca Channel Blockers Diuretics 
Depression 0.93 [0.78,1.10] 
1.24 
[1.04,1.48]** 
0.94 
[0.77,1.15] 
0.97 
[0.72,1.29] 
1.01 
[0.81,1.27] 
Beliefs & Behaviors      
More Likely to Take 
Risks 
0.91 
[0.79,1.06] 
1.03 
[0.88,1.21] 
1.04 
[0.86,1.24] 
0.92 
[0.74,1.16] 
0.91 
[0.77,1.07] 
Do Not Need 
Insurance 
1.04 
[0.80,1.36] 
0.85 
[0.62,1.17] 
0.83 
[0.60,1.15] 
0.82 
[0.52,1.30] 
1.15 
[0.84,1.57] 
Can Overcome 
Illness without 
Medical Care 
1.05 
[0.89,1.24] 
0.97 
[0.80,1.17] 
1.14 
[0.93,1.40] 
1.27 
[0.94,1.70] 
0.93 
[0.76,1.13] 
Currently Smoking 1.13 [0.95,1.34] 
1.03 
[0.86,1.23] 
1.03 
[0.84,1.26] 
1.12 
[0.85,1.47] 
0.97 
[0.79,1.18] 
Moderate/Vigorous 
Physical Activity 
0.96 
[0.86,1.07] 
1.10 
[0.98,1.23]* 
0.99 
[0.85,1.15] 
1.01 
[0.86,1.19] 
1.08 
[0.96,1.21] 
Socioeconomic Status & Insurance 
Income: 
Poor 
1.09 
[0.90,1.32] 
1.09 
[0.91,1.32] 
1.05 
[0.83,1.33] 
1.01 
[0.74,1.38] 
0.98 
[0.78,1.22] 
Low-Income 0.95 [0.80,1.14] 
1.03 
[0.85,1.24] 
1.08 
[0.87,1.34] 
1.04 
[0.79,1.36] 
1.15 
[0.91,1.46] 
Middle-Income 1.00 [0.87,1.16] 
1.02 
[0.88,1.19] 
1.12 
[0.94,1.33] 
1.02 
[0.82,1.27] 
1.07 
[0.91,1.26] 
Education: 
Less than High 
School 
1.12 
[0.93,1.34] 
1.23 
[1.02,1.48]** 
1.06 
[0.84,1.33] 
1.26 
[0.95,1.67] 
1.07 
[0.87,1.31] 
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 Covariate ACEIs/ARBs Statins Beta Blockers Ca Channel Blockers Diuretics 
High School 
Diploma 
1.11 
[0.97,1.28] 
1.05 
[0.91,1.21] 
1.04 
[0.86,1.25] 
1.06 
[0.85,1.32] 
0.98 
[0.82,1.16] 
Language: Interview 
in English 
0.84 
[0.40,1.79] 
0.86 
[0.11,6.60] 
0.72 
[0.31,1.68] 
0.85 
[0.28,2.57] 
1.30 
[0.42,4.00] 
Insurance: Received 
Medicaid 
1.01 
[0.84,1.21] 
1.08 
[0.87,1.36] 
0.97 
[0.78,1.22] 
1.07 
[0.81,1.42] 
1.03 
[0.83,1.28] 
Had Private Non-
HMO Coverage 
1.03 
[0.91,1.16] 
1.04 
[0.92,1.18] 
0.92 
[0.79,1.07] 
1.02 
[0.84,1.24] 
0.95 
[0.82,1.11] 
Had Private HMO 
Coverage 
1.00 
[0.84,1.20] 
1.12 
[0.94,1.35] 
1.06 
[0.85,1.33] 
1.12 
[0.86,1.47] 
0.90 
[0.74,1.10] 
Use of Healthcare (over survey year) 
Concurrently Taken Drugs 
2-3 CV Drugs 0.90 [0.78,1.04] 
0.90 
[0.74,1.09] 
1.01 
[0.86,1.20] 
0.70 
[0.57,0.86]*** 
0.77 
[0.65,0.92]*** 
≥4 CV Drugs 0.79 [0.64,0.98]** 
0.81 
[0.63,1.04] 
0.96 
[0.74,1.23] 
0.50 
[0.37,0.68]*** 
0.69 
[0.55,0.87]*** 
2-4 Other Drugs 1.65 [1.35,2.01]*** 
1.82 
[1.46,2.27]*** 
1.02 
[0.80,1.31] 
1.92 
[1.44,2.57]*** 
1.60 
[1.29,1.99]*** 
≥5 Other Drugs 2.87 [2.25,3.66]*** 
2.96 
[2.29,3.81]*** 
1.47 
[1.10,1.98]** 
2.94 
[2.10,4.13]*** 
2.56 
[2.01,3.27]*** 
Number of 
Pharmacies Used 
0.75 
[0.68,0.83]*** 
0.84 
[0.76,0.93]*** 
0.73 
[0.64,0.82]*** 
0.69 
[0.59,0.81]*** 
0.76 
[0.68,0.86]*** 
Had a Usual Source 
of Care 
1.09 
[0.79,1.50] 
0.99 
[0.72,1.36] 
1.30 
[0.90,1.87] 
1.07 
[0.64,1.81] 
1.04 
[0.73,1.48] 
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 Covariate ACEIs/ARBs Statins Beta Blockers Ca Channel Blockers Diuretics 
Quintiles of Ambulatory Physician Visits 
Q 2 (3-4 Visits) 0.87 [0.74,1.02]* 
1.09 
[0.92,1.30] 
0.91 
[0.74,1.12] 
1.03 
[0.80,1.32] 
1.04 
[0.86,1.26] 
Q 3 (5-7 Visits) 0.93 [0.78,1.11] 
1.03 
[0.87,1.23] 
0.85 
[0.69,1.05] 
0.91 
[0.71,1.18] 
0.96 
[0.80,1.16] 
Q 4 (8-12 Visits) 0.92 [0.77,1.10] 
1.07 
[0.89,1.29] 
0.94 
[0.75,1.17] 
1.03 
[0.78,1.37] 
0.86 
[0.71,1.05] 
Q 5 (≥13 Visits) 0.86 [0.71,1.04] 
0.99 
[0.80,1.24] 
0.85 
[0.67,1.08] 
0.84 
[0.63,1.11] 
0.96 
[0.77,1.20] 
Experience with Providers 
Always Listens 0.98 [0.73,1.31] 
1.06 
[0.78,1.45] 
1.15 
[0.80,1.65] 
1.13 
[0.73,1.75] 
0.80 
[0.56,1.15] 
Always Explains 
Care 
1.29 
[1.00,1.67]** 
1.08 
[0.82,1.42] 
1.00 
[0.75,1.34] 
0.82 
[0.57,1.17] 
0.93 
[0.67,1.28] 
Always Respects:  0.90 [0.68,1.18] 
1.12 
[0.82,1.54] 
0.97 
[0.69,1.37] 
1.24 
[0.82,1.88] 
1.07 
[0.76,1.52] 
Satisfied with 
Healthcare Received 
1.00 
[0.80,1.24] 
0.98 
[0.78,1.23] 
0.96 
[0.76,1.23] 
1.14 
[0.84,1.56] 
1.27 
[1.02,1.58]** 
Very Satisfied with 
Healthcare 
0.97 
[0.79,1.21] 
0.91 
[0.72,1.15] 
0.98 
[0.77,1.25] 
1.18 
[0.88,1.60] 
1.22 
[0.96,1.55] 
H-L GOF P Value 0.95 1.00 0.88 0.89 0.44 
Sample Size 9,917 8,851 6,535 4,649 7,228 
Weighted Population 13,802,972 13,139,144 9,253,278 6,123,863 10,084,654 
 
*P <0.1 † P<0.05 ǂ P<0.01 
Estimates were also adjusted for interactions terms of black and Hispanic indicators with income and education levels. CV: 
Cardiovascular; Q: Quartile; CHD: Coronary Heart Disease; CHF: Congestive Heart Failure; AMI: Acute Myocardial 
Infarction; HMO: Health Maintenance Organization.  
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Table A-5. Effect of Part D on adherence disparities, and estimates of disparities among seniors in 2007-2010 by 
subgroup 
 
Analysis Sample Size 
 (1)  
Difference-in-Differences Effect 
 (2)  
Current Racial Disparities in Medicare 
(2007-10) 
White-Black 
Disparities 
White-Hispanic 
Disparities 
 White-Black 
Disparities 
White-Hispanic 
Disparities 
Main Analysis 17,677 0.06 [-0.06,0.18] -0.16 [-0.29,-0.03]†  0.08 [0.04,0.12]‡ 0.01 [-0.04,0.05] 
Main 
Analysis, 
including 2006 
19,919 0.03 [-0.08,0.14] -0.16 [-0.28,-0.03]† 
 
0.06 [0.03,0.10]‡ 0.02 [-0.03,0.06] 
Medicare 65-
70 Tx Group 7,447 0.06 [-0.08,0.20] -0.09 [-0.25,0.08] 
 0.10 [0.05,0.16]‡ 0.05 [-0.03,0.14] 
Men 7,180 0.21 [0.03,0.38]† -0.20 [-0.44,0.04]  0.11 [0.06,0.16]‡ -0.02 [-0.08,0.04] 
Women 10,495 -0.04 [-0.19,0.12] -0.14 [-0.29,0.01]*  0.07 [0.02,0.12]‡ 0.03 [-0.03,0.09] 
Non-Dual 15,012 0.10 [-0.05,0.25] -0.13 [-0.29,0.03]  0.08 [0.03,0.12]‡ -0.02 [-0.08,0.04] 
Dual Eligibles 2,665 -0.16 [-0.45,0.13] -0.25 [-0.54,0.03]*  0.19 [0.09,0.28]‡ 0.15 [0.04,0.26]‡ 
ACEIs/ARBS 9,917 0.01 [-0.14,0.16] -0.09 [-0.27,0.09]  0.06 [0.01,0.11]† -0.01 [-0.06,0.04] 
Statins 8,851 0.15 [-0.02,0.33]* -0.21 [-0.45,0.02]*  0.04 [-0.02,0.10] -0.01 [-0.07,0.05] 
Beta-Blockers 6,535 0.17 [-0.04,0.39] -0.30 [-0.55,-0.06]†  0.08 [0.03,0.14]‡ -0.03 [-0.11,0.04] 
Ca Channel 
Blockers 4,649 0.01 [-0.22,0.24] 0.00 [-0.25,0.26] 
 
0.01 [-0.07,0.08] 0.05 [-0.05,0.15] 
Diuretics 7,228 0.12 [-0.06,0.30] -0.15 [-0.38,0.09]  0.08 [0.02,0.13]‡ 0.02 [-0.05,0.10] 
 
* P <0.1; † P<0.05; ǂ P<0.01 
CI: confidence interval. ACEIs/ARBs: Angiotensin-Converting Enzyme Inhibitors/Angiotensin II Receptor Blockers.  
Estimates in Column (1) are the double differences between race-specific adherence margins, across time and treatment/control 
groups. Column (2) estimates are the differences between race-specific adherence margins among Medicare seniors in the 
post-Part D period only. All estimates are probability-scale predictions, and all were adjusted for health status and clinical need 
using the rank-and–replace procedure. Standard errors underlying confidence intervals were estimated via Taylor series 
linearization and combined across 5 multiply imputed datasets.   
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Table A-6. Sensitivity of results to various definitions of adherence disparities 
 
Disparity Definition 
(1)  
Difference-in-Differences Effect 
 (2)  
Current Racial Disparities in 
Medicare (2007-10) 
White-Black 
Disparities 
White-Hispanic 
Disparities 
 White-Black 
Disparities 
White-Hispanic 
Disparities 
 Estimate [95% CI] 
Unadjusted  0.05 [-0.07,0.17] -0.18 [-0.31,-0.05]‡  0.08 [0.04,0.12]‡ 0.01 [-0.04,0.05] 
A
dj
us
te
d 
Demographics 0.06 [-0.06,0.18] -0.16 [-0.29,-0.02]†  0.08 [0.04,0.12]‡ 0.01 [-0.04,0.05] 
Demo+Health 0.06 [-0.06,0.18] -0.16 [-0.29,-0.03]†  0.08 [0.04,0.12]‡ 0.01 [-0.04,0.05] 
Demo+Health+Rx 0.06 [-0.06,0.18] -0.16 [-0.29,-0.02]†  0.08 [0.04,0.12]‡ 0.01 [-0.04,0.05] 
Demo+Geography+Health+Rx 0.06 [-0.06,0.18] -0.15 [-0.28,-0.02]†  0.08 [0.04,0.12]‡ 0.01 [-0.04,0.05] 
Main Analysis: 
Demo+Geo+Health+Rx+Beliefs 0.06 [-0.06,0.18] -0.16 [-0.29,-0.03]† 
 0.08 [0.04,0.12]‡ 0.01 [-0.04,0.05] 
Full Adjustment, RDE 0.06 [-0.06,0.18] -0.15 [-0.28,-0.02]†  0.10 [0.06,0.15]‡ 0.02 [-0.05,0.08] 
 
* P <0.1; † P<0.05; ǂ P<0.01.  
CI: confidence interval; RDE: residual direct effect (of race).  
All analyses were conducted on the main sample (n=17,677, representing 24,915,354 treated and control individuals).  
As in Table 2, demographics included age, gender, marital status, and urban residence. Health included self-reported health as 
well as diagnosed conditions. “Rx” included the number of other prescription drugs concurrently taken. Geography was 
represented by the Census Region. Unadjusted disparities (and difference-in-differences) were calculated as differences across 
race-specific adherence proportions. RDE disparities, were estimated directly from the main analysis using predictive margins. 
All other stages of adjustment were conducted using the rank-and-replace procedure prior to estimating race-specific, 
probability-scale predictions. Disparities were then the differences between these predictions (margins) Standard errors 
underlying confidence intervals were estimated via Taylor series linearization and combined across 5 multiply imputed 
datasets.  
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APPENDIX B. SUPPLEMENTAL MATERIALS FOR CHAPTER 3 
 
 
Table B-1. Main unconditional quantile regression analyses of overall adherence 
 
Characteristics 
(at baseline) 10
th QPDC 20th QPDC 30th QPDC 40th QPDC 50th QPDC 60th QPDC 70th QPDC 
 Coefficient [95% Confidence Interval] 
Black -7.26 [-17.80,3.28] 
-7.73 
[-15.67,0.21] 
-9.05 
[-14.32,-3.77] 
-7.28 
[-8.97,-5.59] 
-5.55 
[-7.60,-3.50] 
-5.08 
[-7.49,-2.67] 
-3.28 
[-4.29,-2.27] 
Hispanic -2.09 [-5.44,1.26] 
-4.07 
[-8.04,-0.10] 
-1.71 
[-6.18,2.76] 
-1.40 
[-2.48,-0.32] 
-1.98 
[-5.42,1.47] 
-1.12 
[-3.48,1.24] 
0.48 
[-0.70,1.67] 
Age 70-75 -2.62 [-6.52,1.29] 
-3.80 
[-6.39,-1.22] 
-4.91 
[-7.99,-1.83] 
-3.56 
[-7.65,0.53] 
-3.23 
[-6.18,-0.29] 
-4.24 
[-5.74,-2.74] 
-1.37 
[-4.41,1.67] 
Age 75-80 -10.47 [-17.37,-3.57] 
-8.44 
[-11.55,-5.34] 
-4.77 
[-7.00,-2.53] 
-3.43 
[-7.22,0.35] 
-2.82 
[-7.15,1.51] 
-5.75 
[-9.78,-1.72] 
-3.42 
[-5.24,-1.59] 
Age ≥ 80 -5.61 [-19.70,8.49] 
-4.99 
[-14.44,4.46] 
-4.75 
[-12.21,2.71] 
-5.40 
[-14.12,3.32] 
-6.44 
[-14.92,2.05] 
-6.62 
[-12.67,-0.57] 
-3.63 
[-7.92,0.67] 
Female 1.82 [-2.88,6.51] 
1.05 
[-7.90,9.99] 
-0.07 
[-4.50,4.36] 
-0.39 
[-2.14,1.35] 
1.72 
[-1.42,4.85] 
1.27 
[-0.17,2.70] 
0.41 
[-0.67,1.49] 
Married -0.55 [-8.18,7.08] 
-5.30 
[-13.63,3.02] 
-6.66 
[-13.32,0.00] 
-4.47 
[-11.86,2.91] 
-3.77 
[-9.35,1.80] 
-2.46 
[-4.33,-0.59] 
-1.99 
[-2.59,-1.38] 
Urban Residence -2.54 [-16.51,11.44] 
-0.50 
[-8.20,7.20] 
-0.80 
[-10.41,8.81] 
-1.55 
[-16.55,13.44] 
-0.79 
[-18.09,16.50] 
-0.74 
[-21.57,20.09] 
0.73 
[-15.17,16.63] 
Census Region: 
Midwest 
2.25 
[-6.62,11.12] 
2.21 
[-5.54,9.96] 
3.82 
[-1.47,9.11] 
2.26 
[0.26,4.27] 
4.02 
[1.53,6.52] 
1.62 
[-0.36,3.60] 
0.94 
[-2.22,4.09] 
South -4.69 [-12.32,2.94] 
-2.22 
[-8.00,3.57] 
-2.80 
[-7.75,2.15] 
-2.41 
[-4.30,-0.52] 
-2.15 
[-3.30,-1.00] 
-2.00 
[-5.23,1.23] 
-0.18 
[-2.43,2.06] 
West -4.09 [-7.76,-0.42] 
-1.23 
[-4.11,1.64] 
0.79 
[-1.65,3.22] 
0.75 
[-2.33,3.84] 
1.47 
[-0.11,3.05] 
1.57 
[-2.73,5.87] 
1.06 
[-3.26,5.37] 
Health Status: 
Very Good 
6.18 
[1.60,10.75] 
6.16 
[2.88,9.44] 
4.87 
[1.79,7.94] 
5.76 
[1.37,10.15] 
6.18 
[2.49,9.86] 
4.69 
[-0.92,10.30] 
2.65 
[-0.07,5.36] 
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Characteristics 
 (at baseline) 10
th QPDC 20th QPDC 30th QPDC 40th QPDC 50th QPDC 60th QPDC 70th QPDC 
Good 2.47 [-7.01,11.96] 
6.38 
[1.06,11.71] 
4.51 
[-1.93,10.94] 
5.55 
[-1.54,12.65] 
4.09 
[-3.42,11.61] 
2.34 
[-6.61,11.30] 
0.85 
[-3.33,5.03] 
Fair 6.47 [0.27,12.66] 
9.40 
[6.61,12.18] 
7.47 
[3.07,11.87] 
7.25 
[1.35,13.16] 
5.89 
[-0.63,12.40] 
5.17 
[-3.68,14.02] 
2.34 
[-3.09,7.77] 
Poor 3.45 [-1.35,8.25] 
2.26 
[-2.58,7.09] 
0.85 
[-5.89,7.59] 
-0.62 
[-9.46,8.21] 
-1.96 
[-12.98,9.06] 
-1.03 
[-10.51,8.44] 
-2.40 
[-9.55,4.75] 
Any Physical 
Limitation 
1.32 
[-5.75,8.39] 
-1.46 
[-6.24,3.32] 
-0.25 
[-1.68,1.18] 
0.11 
[-3.63,3.85] 
0.50 
[-3.61,4.62] 
-0.00 
[-4.17,4.16] 
-0.14 
[-2.49,2.20] 
Any Cognitive 
Limitation 
-6.10 
[-17.12,4.93] 
-1.48 
[-13.39,10.42] 
-1.86 
[-10.93,7.21] 
-0.68 
[-9.27,7.92] 
0.90 
[-5.63,7.43] 
-0.13 
[-6.68,6.42] 
-1.13 
[-4.91,2.64] 
Charlson 
Comorbidity 
Score Q3 
-2.32 
[-5.29,0.66] 
-2.33 
[-4.17,-0.50] 
-0.44 
[-4.96,4.09] 
-0.40 
[-4.67,3.87] 
-1.24 
[-6.67,4.20] 
-1.92 
[-7.05,3.21] 
-0.51 
[-3.12,2.11] 
Charlson 
Comorbidity 
Score Q4 
-1.23 
[-7.94,5.48] 
-2.07 
[-13.74,9.61] 
0.81 
[-3.99,5.61] 
1.35 
[-0.20,2.90] 
0.91 
[-0.25,2.07] 
-0.08 
[-1.78,1.62] 
-2.02 
[-4.40,0.35] 
Count of 
Comorbid 
Conditions 
-0.93 
[-2.10,0.25] 
-0.85 
[-2.13,0.43] 
-0.99 
[-2.07,0.09] 
-0.99 
[-1.65,-0.33] 
-1.12 
[-1.92,-0.31] 
-0.73 
[-1.26,-0.21] 
-0.30 
[-0.65,0.05] 
Hypertension 6.06 [-1.52,13.64] 
3.61 
[-2.04,9.26] 
4.55 
[-2.28,11.38] 
3.00 
[-5.52,11.52] 
2.47 
[-5.86,10.80] 
0.39 
[-8.51,9.29] 
-1.67 
[-8.22,4.88] 
Hyperlipidemia 2.01 [-3.18,7.21] 
0.86 
[-1.43,3.15] 
0.61 
[-0.76,1.98] 
-0.27 
[-3.95,3.40] 
0.94 
[-0.44,2.31] 
-0.77 
[-1.78,0.24] 
-1.27 
[-2.44,-0.10] 
Angina/CHD 1.54 [-4.93,8.01] 
2.54 
[-0.69,5.77] 
5.21 
[-2.86,13.27] 
3.21 
[-3.30,9.73] 
3.49 
[-2.23,9.20] 
2.17 
[-1.39,5.72] 
1.32 
[-0.47,3.10] 
CHF 3.15 [-5.30,11.59] 
5.23 
[-3.18,13.63] 
1.04 
[-12.90,14.98] 
-0.84 
[-9.83,8.14] 
1.59 
[-1.28,4.46] 
2.62 
[-1.16,6.41] 
0.56 
[-0.75,1.88] 
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 Table B-1.      (Continued) 
 
Characteristics 
 (at baseline) 10
th QPDC 20th QPDC 30th QPDC 40th QPDC 50th QPDC 60th QPDC 70th QPDC 
AMI 2.29 [-7.30,11.88] 
0.61 
[-8.62,9.83] 
-2.67 
[-26.58,21.25] 
0.14 
[-13.40,13.67] 
-1.72 
[-10.71,7.27] 
-2.37 
[-9.10,4.37] 
-0.07 
[-3.56,3.43] 
Stroke 0.23 [-8.91,9.37] 
0.02 
[-14.07,14.10] 
-2.51 
[-5.00,-0.01] 
-1.53 
[-4.01,0.95] 
-2.64 
[-6.71,1.43] 
0.95 
[-6.51,8.40] 
-0.64 
[-5.64,4.36] 
Depressive 
Symptoms 
-6.25 
[-17.08,4.58] 
-4.77 
[-10.55,1.00] 
-3.11 
[-9.44,3.23] 
-3.44 
[-8.53,1.64] 
0.95 
[-4.47,6.37] 
-0.02 
[-7.84,7.81] 
-2.17 
[-5.18,0.85] 
More Likely to 
Take Risks 
0.83 
[-10.83,12.48] 
1.51 
[-4.88,7.89] 
-1.08 
[-9.03,6.87] 
-2.44 
[-4.87,-0.01] 
-2.98 
[-6.53,0.57] 
-2.60 
[-4.02,-1.18] 
-2.57 
[-3.83,-1.30] 
Can overcome 
illness without 
medical care 
0.09 
[-5.69,5.88] 
-0.36 
[-4.54,3.81] 
-1.08 
[-9.98,7.81] 
-1.98 
[-8.60,4.63] 
-0.80 
[-6.33,4.74] 
-0.19 
[-6.01,5.62] 
1.20 
[-2.06,4.45] 
Does not need 
health insurance 
-3.93 
[-12.50,4.64] 
-8.31 
[-18.45,1.83] 
-7.05 
[-15.39,1.29] 
-9.59 
[-15.02,-4.16] 
-3.50 
[-7.86,0.85] 
-4.71 
[-8.52,-0.89] 
-2.30 
[-4.36,-0.25] 
Took 2-4 Drugs 
Concurrently 
4.25 
[-1.22,9.72] 
4.56 
[-2.16,11.27] 
-0.32 
[-3.17,2.54] 
0.22 
[-1.46,1.90] 
-2.73 
[-6.22,0.76] 
-2.38 
[-6.33,1.56] 
-2.67 
[-4.62,-0.72] 
Took  ≥5 Drug 
Concurrently 
11.51 
[4.49,18.53] 
10.90 
[1.13,20.67] 
4.54 
[-2.95,12.03] 
5.53 
[1.88,9.17] 
2.03 
[-0.03,4.09] 
0.09 
[-2.45,2.64] 
-0.79 
[-2.43,0.85] 
Constant  
(Base QPDC) 
30.35 
[10.83,49.88] 
48.45 
[26.33,70.58] 
63.22 
[50.57,75.86] 
73.95 
[61.13,86.78] 
82.15 
[70.01,94.28] 
94.53 
[76.16,112.91] 
100.17 
[84.08,116.27] 
Sample Size 3,743 
 
Boldface estimates have P values <0.05. Q: Quantile, PDC: proportion of days covered, CHD: Coronary Heart Disease, CHF: 
Congestive Heart Failure, AMI: Acute Myocardial Infarction. Main models adjust race coefficient estimates for demographics and 
health status only, following the Institute of Medicine’s framework on disparities. Standard errors underlying confidence intervals 
were estimated using 5,000 replications of a block bootstrap procedure.  
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Table B-2. Racial disparities in adherence across the PDC distribution by subgroup 
 
 Subgroup 10th QPDC 20th QPDC 30th QPDC 40th QPDC 50th QPDC 60th QPDC 70th QPDC 
 Race Coefficient [95% Confidence Interval] 
Black-White Disparity in PDC among: 
Entire Sample 
(n=3,749) 
-7.26  
[-17.80,3.28] 
-7.73  
[-15.67,0.21] 
-9.05  
[-14.32,-3.77] 
-7.28  
[-8.97,-5.59] 
-5.55  
[-7.60,-3.50] 
-5.08  
[-7.49,-2.67] 
-3.28  
[-4.29,-2.27] 
Men (n=1,569) -10.07 [-11.78,-8.36] 
-11.31 
[-14.55,-8.06] 
-10.16  
[-14.99,-5.33] 
-4.83  
[-9.47,-0.19] 
-5.06 
[-7.56,-2.56] 
-3.78 
[-6.90,-0.66] 
-2.53 
[-3.99,-1.07] 
Women 
(n=2,180) 
-6.24 
[-22.72,10.24] 
-5.47 
[-19.09,8.15] 
-9.24 
[-16.76,-1.71] 
-7.79 
[-11.05,-4.53] 
-3.75 
[-6.62,-0.87] 
-7.27 
[-12.31,-2.24] 
-3.89 
[-6.35,-1.44] 
Auto Recipients 
of LIS (n=617) 
-15.70 
[-22.18,-9.22] 
-14.81 
[-19.47,-10.16] 
-8.35 
[-12.33,-4.37] 
-3.86 
[-6.84,-0.88] 
0.94 
[-4.55,6.42] 
-5.45 
[-7.69,-3.21] 
-2.22 
[-6.62,2.18] 
Non-Auto. LIS 
Recipients 
(n=3,132) 
-6.37 
[-18.27,5.53] 
-5.04 
[-13.65,3.57] 
-9.23 
[-15.38,-3.07] 
-8.67 
[-11.40,-5.93] 
-7.25 
[-10.41,-4.09] 
-5.22 
[-8.54,-1.89] 
-4.10  
[-5.31,-2.89] 
ACE Inhibitor 
/ARB Users 
(n=2,250) 
-7.13 
[-13.43,-0.84] 
-11.40 
[-20.54,-2.27] 
-10.75 
[-31.77,10.28] 
-13.21 
[-29.44,3.01] 
-8.41 
[-18.07,1.25] 
-4.34 
[-8.94,0.26] 
-3.30 
[-6.08,-0.53] 
Statin Users 
(n=2,138) 
-4.31 
[-11.89,3.27] 
-2.68 
[-10.99,5.62] 
-3.80 
[-9.39,1.79] 
-4.55 
[-7.92,-1.18] 
-5.97 
[-8.22,-3.72] 
-2.70 
[-3.97,-1.44] 
-2.80 
[-4.87,-0.74] 
β-Blocker Users 
(n=1,536) 
-6.13 
[-8.18,-4.08] 
-10.39 
[-15.86,-4.92] 
-10.18 
[-14.21,-6.16] 
-8.58 
[-10.58,-6.58] 
-8.84 
[-10.11,-7.57] 
-3.25 
[-3.70,-2.80] 
-2.23 
[-2.82,-1.65] 
Ca Channel 
Blocker Users 
(n=872) 
-6.17 
[-12.54,0.20] 
-5.25 
[-13.45,2.95] 
-2.99 
[-13.73,7.75] 
-3.96 
[-8.76,0.85] 
-3.46 
[-9.87,2.95] 
4.46 
[-1.25,10.18] 
0.90 
[-2.33,4.13] 
Diuretic Users 
(n=1,650) 
-4.48 
[-8.83,-0.12] 
-12.71 
[-29.40,3.99] 
-7.33 
[-17.95,3.28] 
-18.60 
[-23.50,-13.69] 
-15.55 
[-21.52,-9.58] 
-5.93 
[-8.69,-3.16] 
-4.91 
[-5.98,-3.83] 
 
        
 131 
 Table B-2.      (Continued) 
 
 Subgroup 10th QPDC 20th QPDC 30th QPDC 40th QPDC 50th QPDC 60th QPDC 70th QPDC 
Hispanic-White Disparity in PDC among: 
Entire Sample 
(n=3,749) 
-2.09 
[-5.44,1.26] 
-4.07 
[-8.04,-0.10] 
-1.71 
[-6.18,2.76] 
-1.40 
[-2.48,-0.32] 
-1.98 
[-5.42,1.47] 
-1.12 
[-3.48,1.24] 
0.48 
[-0.70,1.67] 
Men (n=1,569) -9.25 [-24.73,6.24] 
-10.56 
[-23.80,2.68] 
-5.70 
[-14.50,3.10] 
-3.04 
[-12.11,6.02] 
-2.79 
[-7.93,2.36] 
-3.30 
[-7.85,1.26] 
-0.32 
[-4.67,4.02] 
Women 
(n=2,180) 
4.01 
[-4.09,12.11] 
0.70 
[-10.20,11.61] 
0.64 
[-8.99,10.28] 
0.63 
[-4.98,6.24] 
0.33 
[-5.16,5.82] 
0.66 
[-5.48,6.80] 
0.71 
[-1.61,3.04] 
Auto Recipients 
of LIS (n=617) 
-7.65 
[-16.38,1.07] 
-8.03 
[-12.42,-3.64] 
-4.36  
[-7.68,-1.05] 
0.44  
[-4.39,5.27] 
5.97 
[-1.57,13.51] 
1.49 
[-2.88,5.85] 
1.77  
[-1.07,4.61] 
Non-Auto LIS 
Recipients 
(n=3,132) 
0.85 
[-9.88,11.58] 
-0.22 
[-1.96,1.53] 
0.72 
[-2.15,3.60] 
0.38 
[-6.85,7.61] 
-3.37 
[-8.77,2.02] 
-1.29 
[-8.36,5.78] 
-0.26 
[-3.61,3.09] 
ACE Inhibitor 
/ARB Users 
(n=2,250) 
-5.84 
[-14.18,2.51] 
-3.37 
[-5.37,-1.38] 
-3.38 
[-5.38,-1.37] 
-6.36 
[-13.84,1.12] 
-2.46 
[-12.59,7.67] 
-0.28 
[-5.49,4.93] 
-2.69 
[-8.80,3.41] 
Statin Users 
(n=2,138) 
-0.90 
[-9.64,7.84] 
-0.13 
[-16.45,16.20] 
0.87 
[-9.02,10.75] 
1.62 
[-7.22,10.46] 
1.99 
[-11.21,15.19] 
0.85 
[-1.92,3.63] 
1.80 
[0.56,3.04] 
β-Blocker Users 
(n=1,536) 
3.58 
[-4.31,11.48] 
7.23 
[-3.01,17.47] 
5.78 
[3.36,8.21] 
6.06 
[-4.56,16.68] 
0.02 
[-14.55,14.59] 
-0.46 
[-5.01,4.09] 
-0.33 
[-3.02,2.36] 
Ca Channel 
Blocker Users 
(n=872) 
-8.18 
[-17.35,0.98] 
-4.00 
[-17.07,9.07] 
-1.56 
[-9.65,6.54] 
-3.89 
[-10.19,2.41] 
-6.69 
[-12.92,-0.46] 
-2.15 
[-7.09,2.78] 
0.84 
[-1.70,3.39] 
Diuretic Users 
(n=1,650) 
-12.63 
[-18.35,-6.91] 
-13.58 
[-23.32,-3.84] 
-10.48 
[-18.83,-2.14] 
-15.42 
[-24.39,-6.46] 
-7.86 
[-14.92,-0.80] 
-4.55 
[-6.76,-2.34] 
-2.49 
[-4.26,-0.71] 
 
Boldface estimates have P values <0.05. Q: Quantile, PDC: proportion of days covered, LIS: Low-income subsidy, ACE: 
Angiotensin-converting enzyme, ARB: Angiotensin II receptor blocker. Disparity estimates correspond to race coefficients estimated 
in the primary models adjusted for demographics and health status only, following the IOM framework on disparities. Standard errors 
underlying confidence intervals were estimated using 5,000 replications of a block bootstrap procedure.   
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Table B-3. Sensitivity of disparity estimates to various adjustments/definitions of racial disparity 
 
QPDC Demo Demo+Health Demo+Health +Rx 
Demo+Geo 
+Health+Rx 
Demo+Geo 
+Health 
+Rx +Beliefs 
“Main Analysis” 
Fully 
Adjusted 
 Race Coefficient [95% Confidence Interval] 
Black-White Disparity at QPDC: 
Q10 -8.33 [-16.99,0.34] 
-8.46 
[-18.30,1.37] 
-8.18 
[-17.93,1.57] 
-7.26 
[-17.96,3.44] 
-7.26 
[-17.80,3.28] 
-7.37 
[-17.85,3.11] 
Q20 -7.80 [-13.60,-2.00] 
-8.60 
[-16.62,-0.58] 
-8.33 
[-16.19,-0.46] 
-7.70 
[-16.00,0.60] 
-7.73 
[-15.67,0.21] 
-9.57 
[-16.99,-2.14] 
Q30 -8.98 [-12.67,-5.29] 
-10.18 
[-14.55,-5.82] 
-10.07 
[-14.38,-5.77] 
-8.92 
[-14.23,-3.62] 
-9.05 
[-14.32,-3.77] 
-11.36 
[-16.00,-6.71] 
Q40 -7.02 [-9.60,-4.44] 
-8.12 
[-9.13,-7.10] 
-7.98 
[-9.06,-6.90] 
-7.06 
[-8.13,-6.00] 
-7.28 
[-8.97,-5.59] 
-8.97 
[-12.00,-5.93] 
Q50 -5.15 [-8.48,-1.83] 
-6.53 
[-8.01,-5.04] 
-6.49 
[-7.93,-5.06] 
-5.42 
[-7.18,-3.65] 
-5.55 
[-7.60,-3.50] 
-7.04 
[-9.86,-4.22] 
Q60 -4.98 [-8.69,-1.27] 
-5.82 
[-7.82,-3.82] 
-5.82 
[-7.78,-3.87] 
-4.97 
[-7.32,-2.63] 
-5.08 
[-7.49,-2.67] 
-6.40 
[-9.59,-3.20] 
Q70 -3.58 [-5.03,-2.13] 
-3.49 
[-4.38,-2.60] 
-3.52 
[-4.38,-2.67] 
-3.26 
[-4.25,-2.28] 
-3.28 
[-4.29,-2.27] 
-4.07 
[-5.46,-2.69] 
Hispanic-White Disparity at QPDC: 
Q10 -4.32 [-6.98,-1.66] 
-4.25 
[-8.71,0.21] 
-3.68 
[-7.77,0.40] 
-2.15 
[-5.60,1.30] 
-2.09 
[-5.44,1.26] 
2.47 
[-17.28,22.22] 
Q20 -4.89 [-7.44,-2.33] 
-5.47 
[-10.68,-0.27] 
-4.96 
[-9.63,-0.29] 
-4.16 
[-8.40,0.09] 
-4.07 
[-8.04,-0.10] 
-2.63 
[-9.64,4.37] 
Q30 -1.64 [-5.77,2.49] 
-2.78 
[-7.72,2.17] 
-2.44 
[-7.15,2.26] 
-1.67 
[-6.11,2.77] 
-1.71 
[-6.18,2.76] 
-0.55 
[-13.89,12.80] 
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Table B-3.      (Continued) 
 
QPDC Demo Demo+Health Demo+Health +Rx 
Demo+Geo 
+Health+Rx 
Demo+Geo 
+Health 
+Rx +Beliefs 
“Main Analysis” 
Fully 
Adjusted 
Q40 -1.23 [-2.54,0.08] 
-2.16 
[-2.91,-1.41] 
-1.78 
[-2.56,-1.00] 
-1.28 
[-2.23,-0.34] 
-1.40 
[-2.48,-0.32] 
-3.37 
[-13.31,6.58] 
Q50 -1.66 [-4.81,1.49] 
-2.77 
[-6.57,1.03] 
-2.48 
[-5.95,0.98] 
-1.86 
[-5.22,1.51] 
-1.98 
[-5.42,1.47] 
-3.46 
[-15.31,8.39] 
Q60 -0.74 [-3.59,2.11] 
-1.38 
[-3.76,1.01] 
-1.24 
[-3.40,0.92] 
-1.05 
[-3.36,1.26] 
-1.12 
[-3.48,1.24] 
-1.88 
[-9.08,5.31] 
Q70 0.15 [-1.25,1.56] 
0.42 
[-0.32,1.16] 
0.51 
[-0.36,1.38] 
0.51 
[-0.73,1.74] 
0.48 
[-0.70,1.67] 
-2.72 
[-4.04,-1.39] 
 
Boldface estimates have P values <0.05. Q: Quantile, PDC: proportion of days covered. All analyses were conducted on the entire 
sample (n=3,749). As in Table 2-1 in the text, demographics included age, gender, marital status, and urban residence. Health 
included self-reported health as well as diagnosed conditions. “Rx” included the number of other prescription drugs concurrently 
taken. Geography was represented by the Census Region. “Fully adjusted” estimates were adjusted for all covariates in Table 2-1 as 
appropriate. Standard errors underlying confidence intervals were estimated using 5,000 replications of a block bootstrap procedure.  
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Figure B-1. Sensitivity of disparity estimates to various adjustments/definition of disparity 
PDC: proportion of days covered. All analyses were conducted on the entire sample (n=3,749). As in Table 2-1 in the text, 
demographics included age, gender, marital status, and urban residence. Health included self-reported health as well as diagnosed 
conditions. “Rx” included the number of other prescription drugs concurrently taken. Geography was represented by the Census 
Region. “Fully adjusted” estimates were adjusted for all covariates in Table 2-1 as appropriate. Standard errors for confidence 
intervals were estimated using 5,000 replications in a block bootstrap procedure.  
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APPENDIX C. SUPPLEMENTAL MATERIALS FOR CHAPTER 4 
 
 
Table C-1. Characteristics of sampled Medicare seniors by race across PDC quantile categories, Q10th-Q40th 
 
Characteristics 
QPDC 10th  QPDC 20th  QPDC 30th  QPDC 40th 
White Black   White Black   White Black   White Black 
 %, unless otherwise noted 
Demographics            
Female 56.70 57.13  54.12 63.48  57.44 67.61  57.64 74.69 
Married 58.07 28.60  63.84 26.86  59.84 37.36  50.40 31.69 
Urban/MSA 80.29 87.14  77.71 85.93  79.48 82.45  82.03 85.22 
Census Region            
Northeast 16.82 23.86  22.04 15.90  23.19 14.00  20.45 28.90 
Midwest 20.05 9.60  25.48 19.12  22.26 11.34  27.70 10.31 
South 40.24 53.54  35.82 59.45  37.97 69.64  35.12 53.91 
West 22.89 13.00  16.65 5.52  16.58 5.01  16.74 6.88 
Self-Reported Health Status          
Excellent 18.91 10.21  15.51 9.83  11.38 3.89  15.58 10.67 
Very Good 29.21 24.03  33.71 24.76  29.24 22.13  29.17 24.97 
Good 33.81 32.02  28.27 43.85  34.52 40.13  31.35 37.08 
Fair 12.36 26.63  15.71 17.57  18.64 26.86  17.24 20.69 
Poor 5.71 7.12  6.80 3.99  6.22 7.00  6.66 6.59 
Any Physical 
Limitation 59.60 63.68  64.03 60.45  64.84 51.00  63.15 51.97 
Any Cognitive 
Limitation 11.89 24.20  9.83 8.31  10.80 13.71  9.82 15.86 
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Table C-1.     (Continued) 
 
Characteristics 
QPDC 10th  QPDC 20th  QPDC 30th  QPDC 40th 
White Black  White Black  White Black  White Black 
 %, unless otherwise noted 
Depressive 
Symptoms 8.43 21.23  7.96 11.18  8.14 8.37  8.35 14.20 
Cardiovascular Conditions & Comorbidity        
Hypertension 74.61 89.29  81.42 94.58  83.99 96.40  83.47 96.95 
Lipidemia 63.12 53.77  66.63 55.93  67.45 62.69  67.39 52.28 
Angina/CHD 19.17 14.18  20.80 12.78  18.59 17.21  24.51 19.26 
CHF 3.28 2.57  2.69 3.24  6.62 1.19  4.51 5.03 
AMI 5.69 8.33  9.63 5.92  10.50 9.32  7.39 5.99 
Stroke 6.21 2.78  7.71 4.24  6.03 6.96  6.26 3.42 
Count of 
Comorbid 
Conditions, 
Mean±SD 
5.88 
±3.89 
3.85 
±2.61  
5.63 
±3.74 
4.44 
±2.96  
6.08 
±3.77 
4.73 
±3.31  
5.69 
±3.21 
4.74 
±3.50 
Charlson 
Comorbidity 
Score Q1-2 
54.56 58.50  54.34 50.38  57.41 50.77  55.97 44.43 
Charlson 
Comorbidity 
Score Q3 
33.01 30.99  31.40 39.62  29.94 41.76  31.18 41.95 
Charlson 
Comorbidity 
Score Q4 
12.43 10.51  14.26 10.00  12.64 7.47  12.84 13.62 
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Table C-1.     (Continued) 
 
Characteristics 
QPDC 10th  QPDC 20th  QPDC 30th  QPDC 40th 
White Black  White Black  White Black  White Black 
 %, unless otherwise noted 
Beliefs            
More Likely to 
Take Risk 16.15 10.35  17.90 18.38  17.74 22.79  21.10 10.90 
Can Overcome 
Illness without 
Medical Care 
12.02 9.11  11.67 6.84  11.91 14.22  13.93 5.40 
No Need for 
Health Insurance 6.41 5.80  5.67 3.31  4.86 7.85  7.89 3.67 
Behaviors            
Current Smoker 8.06 10.69  10.18 12.29  9.81 6.52  5.56 16.06 
Moderate / 
Vigorous 
Exercise 
50.71 39.70  53.42 44.42  48.66 43.95  46.70 36.11 
Obese  26.71 22.52  24.37 37.46  28.40 33.72  24.62 49.83 
Socioeconomic Status          
Income:  
Poor/Near Poor 14.72 38.59  14.32 27.78  13.90 26.51  14.87 33.08 
Low-Income 15.95 18.30  14.24 25.49  17.08 23.99  14.69 21.20 
Mid-Income 26.49 35.13  29.39 27.76  31.77 35.21  35.17 23.17 
High-Income 
(Ref) 42.84 7.98  42.05 18.97  37.26 14.29  35.28 22.56 
Education:  
Less than High 
School 
18.81 52.11  15.97 44.57  20.94 37.12  18.49 51.09 
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Table C-1.     (Continued) 
 
Characteristics 
QPDC 10th  QPDC 20th  QPDC 30th  QPDC 40th 
White Black  White Black  White Black  White Black 
 %, unless otherwise noted 
High School 
Diploma 52.65 41.24  58.78 34.63  49.25 51.50  52.83 40.56 
Above High 
School (Ref) 28.54 6.65  25.25 20.80  29.81 11.37  28.68 8.35 
Primary Drug Coverage at Baseline          
No Known Rx 
Coverage (Ref) 21.35 21.04  21.78 12.98  20.92 14.39  18.38 9.47 
Part D: PDPs 31.71 39.89  34.43 52.89  34.26 42.69  38.67 41.44 
Part D: MA-PD 22.78 33.00  20.42 22.80  21.43 32.70  20.09 34.60 
Employer/Other 
Private 24.16 6.07  23.37 11.34  23.38 10.22  22.87 14.49 
Auto Eligible for 
PD Low-Income 
Subsidy 
3.46 31.42  5.29 31.54  5.47 9.51  7.00 18.49 
Use of CV Drugs in Year 2          
ACEI/ARBs 49.45 53.82  57.32 67.08  60.55 70.84  58.00 59.69 
Statins 52.69 34.07  62.16 63.59  62.03 54.38  64.55 42.82 
Beta-Blockers 29.41 26.10  42.23 38.91  39.87 41.75  51.46 37.11 
CCBs 13.92 33.93  24.46 26.38  24.68 38.96  23.69 40.48 
Diuretics 33.57 49.62  41.60 59.15  48.47 59.08  47.08 67.56 
Healthcare Use at Baseline          
No. of Concurrent CV Medications         
0-1 51.14 39.94  34.84 30.50  27.20 15.01  28.47 24.30 
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Table C-1.     (Continued) 
 
Characteristics 
QPDC 10th  QPDC 20th  QPDC 30th  QPDC 40th 
White Black  White Black  White Black  White Black 
 %, unless otherwise noted 
2-3 42.90 53.21  56.44 60.61  63.28 64.19  59.08 59.54 
≥4 5.96 6.85  8.72 8.89  9.52 20.81  12.45 16.16 
No. of concurrent medications overall         
0-1 13.63 19.08  10.77 15.36  6.25 11.14  10.51 17.82 
2-4 49.47 54.56  47.19 43.13  43.56 40.24  47.05 40.81 
≥5 36.90 26.36  42.04 41.51  50.19 48.62  42.44 41.37 
No. of 
Pharmacies Used 
1.38 
±0.54 
1.14 
±0.45  1.4 ±0.60 
1.22 
±0.45  
1.37 
±0.57 
1.16 
±0.37  
1.38 
±0.54 
1.15 
±0.48 
Average Copay 
for CV Drugs 
($2010)  
29.92 
±40.09 
16.01 
±32.39  
27.23 
±35.2 
20.24 
±24.27  
23.69 
±30.25 
25.18 
±31.67  
24.98 
±34.45 
21.66 
±24.57 
Had a Usual 
Source of Care 98.61 98.08  94.91 89.61  97.12 99.65  99.17 97.30 
Had any Inpatient 
Stay? 16.91 22.15  19.52 12.73  20.82 14.87  16.27 14.16 
Had any ER 
visit? 15.95 15.85  16.03 13.10  16.48 22.43  21.42 26.02 
Quintiles of ambulatory physician visits (range)        
Q 1 (0-2) 17.85 34.28  16.56 26.28  18.74 30.66  18.67 25.31 
Q 2 (3-4) 14.18 18.98  21.30 17.80  19.19 20.21  16.37 25.01 
Q 3 (5-7) 21.12 24.68  16.62 28.41  17.20 21.00  18.98 17.39 
Q 4 (8-12) 20.43 11.92  25.56 14.86  17.52 11.05  23.18 19.77 
Q 5 (≥13) 26.42 10.14  19.97 12.64  27.36 17.08  22.79 12.52 
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Table C-1.     (Continued) 
 
Characteristics 
QPDC 10th  QPDC 20th  QPDC 30th  QPDC 40th 
White Black  White Black  White Black  White Black 
 %, unless otherwise noted 
Experience with the Healthcare System        
Very Satisfied 
with Health Care 57.32 58.23  54.25 48.44  58.81 49.42  57.70 51.37 
Provider Always 
Explained 53.37 67.46  53.23 58.59  60.55 52.42  57.12 55.27 
Provider Always 
Listened 60.96 70.60  59.00 63.41  62.00 51.44  62.27 58.08 
Provider Always 
Respected 63.66 72.88  62.28 66.80  58.46 54.91  64.99 64.09 
Sample Size 259 95   269 90   225 63   256 72 
Weighted 
Population 1,746,012 276,837   1,780,105 221,492   1,592,621 190,496   1,754,713 181,076 
 
Boldface estimates have P<0.05 for pairwise comparisons relative to whites.  
PDC: Proportion of Days Covered; MSA: Metropolitan Statistical Area; CHD: Coronary Heart Disease; CHF: Congestive Heart 
Failure; AMI: Acute Myocardial Infarction; SD: Standard Deviation; Q: Quantile; BMI: Body Mass Index; PD: Part D; PDP: stand-
alone prescription drug plan; MA-PD: Medicare Advantage Prescription Drug plan; ACE: Angiotensin-Converting Enzyme; ARB: 
Angiotensin II Receptor Blocker   
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Table C-2. Characteristics of sampled Medicare seniors by race across PDC quantile categories, Q50th-Q80th 
 
Characteristics  
QPDC 50th  QPDC 60th  QPDC 70th  QPDC 80th 
White Black   White Black   White Black   White Black 
 %, unless otherwise noted 
Demographics            
Female 52.77 46.53  57.54 74.43  57.38 66.11  57.81 61.14 
Married 53.57 41.01  52.30 31.83  57.30 32.26  55.25 28.40 
Urban/MSA 78.71 84.13  78.71 83.27  74.50 84.95  80.62 81.48 
Census Region            
Northeast 23.57 16.47  20.41 12.93  24.53 13.67  20.53 18.30 
Midwest 22.10 7.47  32.31 20.33  28.15 20.66  26.26 19.26 
South 35.88 69.96  31.09 64.59  28.42 57.60  33.50 57.63 
West 18.45 6.10  16.19 2.15  18.90 8.08  19.71 4.81 
Self-Reported Health Status        
Excellent 12.98 5.66  9.51 8.84  10.18 5.20  13.24 6.69 
Very Good 26.28 21.77  32.42 20.55  28.53 21.55  34.79 26.14 
Good 39.05 23.72  36.86 36.84  35.26 36.95  32.39 33.28 
Fair 16.61 41.91  17.22 24.28  19.33 27.16  16.30 24.55 
Poor 5.07 6.94  3.99 9.49  6.71 9.14  3.28 9.35 
Any Physical 
Limitation 63.56 65.55  64.07 72.77  63.81 78.57  60.05 63.39 
Any Cognitive 
Limitation 9.53 17.41  9.48 24.63  11.88 29.50  8.26 15.04 
Depressive 
Symptoms 4.30 8.82  8.81 16.05  12.52 15.68  5.30 16.33 
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Table C-2.     (Continued) 
 
Characteristics 
QPDC 50th  QPDC 60th  QPDC 70th  QPDC 80th 
White Black  White Black  White Black  White Black 
 %, unless otherwise noted 
Cardiovascular Conditions & Comorbidity        
Hypertension 85.28 84.63  85.88 95.86  88.22 97.50  81.01 93.99 
Lipidemia 64.31 67.10  70.88 61.76  67.25 59.41  65.22 52.18 
Angina/CHD 22.44 20.05  25.14 16.44  21.90 22.37  21.69 18.17 
CHF 2.98 4.94  3.34 2.43  5.50 5.45  3.87 3.80 
AMI 10.81 9.10  11.04 7.24  7.64 7.09  8.77 6.15 
Stroke 6.67 7.00  2.94 16.94  8.95 1.82  5.08 6.73 
Count of 
Comorbid 
Conditions, 
Mean±SD 
5.99 
±3.56 
5.00 
±2.87  
5.47 
±3.34 
4.81 
±2.95  
5.48 
±3.53 
5.09 
±3.01  
5.31 
±3.40 
4.45 
±3.44 
CCI Q1-2 53.00 35.10  54.22 31.84  56.54 33.40  59.17 52.00 
CCI Q3 34.56 44.64  34.03 48.81  25.97 51.27  31.66 32.00 
CCI Q4 12.44 20.26  11.75 19.35  17.49 15.33  9.17 16.00 
Beliefs            
More Likely to 
Take Risk 16.73 10.69  15.76 12.58  16.58 15.21  14.23 13.49 
Can Overcome 
Illness without 
Medical Care 
8.95 1.98  11.11 5.13  8.24 3.74  11.76 7.62 
No Need for 
Health 
Insurance 
0.52 4.66  4.62 8.36  2.98 0.00  3.90 5.51 
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Table C-2.     (Continued) 
 
Characteristics 
QPDC 50th  QPDC 60th  QPDC 70th  QPDC 80th 
White Black  White Black  White Black  White Black 
 %, unless otherwise noted 
Behaviors            
Current Smoker 7.18 9.64  13.39 16.64  7.09 6.19  7.34 10.40 
Moderate / 
Vigorous 
Exercise 
46.35 37.00  43.66 27.91  42.26 27.79  47.48 38.79 
Obese  28.45 35.80  29.09 44.10  34.10 33.12  29.87 39.59 
Socioeconomic Status        
Income: 
Poor/Near Poor 18.07 39.24  15.67 32.32  19.25 37.97  14.30 29.00 
Low-Income 16.69 14.98  13.96 20.41  17.20 22.06  16.59 19.90 
Mid-Income 29.04 33.87  35.88 32.43  30.52 24.72  32.09 33.07 
High-Income 
(Ref) 36.20 11.91  34.50 14.85  33.03 15.25  37.02 18.02 
Education: Less 
than High 
School 
19.48 55.80  21.59 53.24  20.78 50.91  20.47 41.82 
High School 
Diploma 49.33 29.97  54.84 38.88  58.03 34.62  51.26 39.16 
Above High 
School (Ref) 31.18 14.23  23.57 7.88  21.19 14.47  28.27 19.02 
Primary Drug Coverage at Baseline        
No Known Rx 
Coverage (Ref) 18.58 8.19  24.01 9.20  23.71 13.48  16.70 12.08 
Part D: PDPs 38.46 36.10  37.88 42.71  32.64 50.97  37.10 42.74 
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Table C-2.     (Continued) 
 
Characteristics 
QPDC 50th  QPDC 60th  QPDC 70th  QPDC 80th 
White Black  White Black  White Black  White Black 
 %, unless otherwise noted 
Part D: MA-PD 20.01 34.51  19.51 38.43  25.49 25.50  26.67 27.03 
Employer/Other 
Private 22.96 21.20  18.60 9.66  18.16 10.05  19.53 18.14 
Auto Eligible 
for PD Low-
Income Subsidy 
7.38 21.40  5.09 36.62  6.85 21.24  5.55 28.63 
Use of CV Drugs in Year 2        
ACEI/ARBs 66.78 58.45  63.08 59.07  64.96 77.96  53.96 48.06 
Statins 60.42 55.63  68.42 61.36  64.28 47.11  55.66 46.69 
Beta-Blockers 44.74 35.06  51.34 39.19  44.46 47.80  37.75 36.12 
CCBs 21.63 37.58  20.65 40.28  20.77 48.08  15.96 33.61 
Diuretics 44.77 54.73  54.69 53.48  50.65 58.09  39.48 47.69 
Healthcare Use at Baseline        
No. of Concurrent CV Medications        
0-1 33.33 40.74  23.59 27.67  25.46 22.15  41.62 43.71 
2-3 58.09 48.01  65.34 60.44  63.06 67.24  51.65 43.36 
≥4 8.58 11.25  11.07 11.89  11.48 10.60  6.74 12.93 
No. of concurrent medications overall        
0-1 5.80 3.27  8.43 17.03  7.10 9.40  12.24 14.96 
2-4 44.24 55.42  39.53 37.14  46.81 34.91  42.39 45.70 
≥5 49.95 41.30  52.04 45.83  46.09 55.69  45.37 39.34 
No. of 
Pharmacies  
1.28 
±0.48 
1.26 
±0.5  
1.26 
±0.52 
1.12 
±0.32  
1.29 
±0.53 
1.22 
±0.49  
1.30 
±0.52 
1.17 
±0.44 
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Table C-2.     (Continued) 
 
Characteristics 
QPDC 50th  QPDC 60th  QPDC 70th  QPDC 80th 
White Black  White Black  White Black  White Black 
 %, unless otherwise noted 
Average Copay 
for CV Drugs 
($2010)  
25.84 
±29.08 
17.45 
±19.39  
24.62 
±29.3 
12.68 
±15.64  
25.99 
±32.54 
14.09 
±15.74  
23.28 
±26.56 
15.04 
±24.05 
Had a Usual 
Source of Care 98.06 94.76  96.58 97.21  96.11 99.20  97.90 92.80 
Had any 
Inpatient Stay? 16.84 17.66  17.74 20.90  18.69 18.07  15.31 19.18 
Had any ER 
visit? 18.36 26.87  14.46 20.58  19.89 19.21  16.88 24.40 
Quintiles of ambulatory physician visits (range)       
Q 1 (0-2) 14.37 16.43  17.94 40.42  15.78 27.35  20.03 27.50 
Q 2 (3-4) 19.48 33.01  16.31 11.99  19.16 22.94  18.41 22.09 
Q 3 (5-7) 21.41 19.63  23.75 21.44  20.80 23.94  21.52 18.77 
Q 4 (8-12) 22.39 21.76  23.55 5.91  20.79 7.89  22.63 13.56 
Q 5 (≥13) 22.35 9.17  18.45 20.24  23.47 17.88  17.41 18.08 
Experience with the Healthcare System       
Very Satisfied 
with Health 
Care 
55.06 50.55  64.39 47.15  59.09 59.10  60.08 58.46 
Provider Always 
Explained 52.53 53.43  55.81 57.76  55.71 53.96  59.96 59.98 
Provider Always 
Listened 58.50 60.41  60.64 55.46  60.16 61.63  62.96 67.01 
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Table C-2.     (Continued) 
 
Characteristics 
QPDC 50th  QPDC 60th  QPDC 70th  QPDC 80th 
White Black  White Black  White Black  White Black 
 %, unless otherwise noted 
Provider Always 
Respected 59.33 58.31  63.26 51.04  61.90 68.09  65.59 68.78 
Sample Size 274 59   264 74   264 72   774 178 
Weighted 
Population 1,784,639 163,306   1,722,877 196,246   1,737,023 196,465   5,329,553 465,402 
 
Boldface estimates have P<0.05 for pairwise comparisons relative to whites.  
PDC: Proportion of Days Covered; MSA: Metropolitan Statistical Area; CHD: Coronary Heart Disease; CHF: Congestive Heart 
Failure; AMI: Acute Myocardial Infarction; SD: Standard Deviation; Q: Quantile; BMI: Body Mass Index; PD: Part D; PDP: stand-
alone prescription drug plan; MA-PD: Medicare Advantage Prescription Drug plan; ACE: Angiotensin-Converting Enzyme; ARB: 
Angiotensin II Receptor Blocker   
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Table C-3. RIF unconditional quantile regressions for by race, Q10th-Q40th 
 
 Covariate  QPDC 10
th  QPDC 20th  QPDC 30th  QPDC 40th 
Whites Blacks  Whites Blacks  Whites Blacks  Whites Blacks 
 Coefficient Estimate (Standard Error) 
Age 70-75 -2.78 (3.36) 
-10.67 
(2.89)  
-5.28 
(1.71) 
-0.86 
(4.69)  
-4.11 
(4.16) 
1.61 
(3.35)  
-2.18 
(3.24) 
0.34 
(2.15) 
Age 75-80 -7.04 (2.08) 
-14.19 
(3.30)  
-6.15 
(1.43) 
-3.65 
(2.79)  
-2.68 
(3.67) 
0.48 
(4.57)  
-1.88 
(2.80) 
0.79 
(3.10) 
Age ≥ 80 -6.95 (6.60) 
-8.29 
(3.79)  
-5.80 
(5.43) 
-2.81 
(3.24)  
-5.21 
(7.26) 
3.40 
(2.69)  
-4.58 
(6.31) 
3.22 
(5.08) 
Female -1.55 (1.87) 
-0.88 
(3.84)  
-1.39 
(3.33) 
7.18 
(3.01)  
-2.52 
(1.77) 
2.61 
(2.68)  
-2.68 
(1.47) 
-3.55 
(3.40) 
Married -1.74 (3.09) 
-2.39 
(7.74)  
-4.46 
(3.70) 
3.12 
(3.08)  
-6.05 
(4.37) 
7.34 
(2.34)  
-3.28 
(3.54) 
3.77 
(4.39) 
Urban Residence -0.13 (7.20) 
4.79 
(2.28)  
0.49 
(8.92) 
-2.95 
(2.73)  
-0.56 
(10.30) 
-3.59 
(2.94)  
-1.82 
(5.67) 
-0.98 
(2.06) 
Census Region:  
Midwest 
1.96 
(3.96) 
6.19 
(6.65)  
3.62 
(5.47) 
15.01 
(4.18)  
6.20 
(2.54) 
2.04 
(3.07)  
1.53 
(1.25) 
8.28 
(3.03) 
South -6.14 (1.28) 
4.10 
(9.17)  
-1.83 
(3.20) 
7.78 
(7.28)  
-1.13 
(2.07) 
0.80 
(4.25)  
-3.53 
(0.86) 
3.58 
(2.66) 
West -5.93 (1.81) 
-16.81 
(10.94)  
0.69 
(3.85) 
-7.59 
(14.78)  
2.02 
(1.89) 
-5.98 
(9.84)  
0.58 
(1.52) 
-6.00 
(6.49) 
Health Status:  
Very Good 
7.06 
(3.67) 
-0.32 
(8.03)  
6.03 
(3.84) 
2.12 
(3.43)  
4.52 
(2.41) 
5.27 
(4.30)  
5.76 
(1.95) 
-0.96 
(5.05) 
Good 5.89 (6.19) 
1.07 
(7.71)  
7.59 
(5.80) 
2.07 
(7.51)  
4.27 
(5.18) 
-1.42 
(9.12)  
5.79 
(4.05) 
-2.98 
(7.89) 
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Table C-3.      (Continued) 
 
Covariate 
QPDC 10th  QPDC 20th  QPDC 30th  QPDC 40th 
Whites Blacks  Whites Blacks  Whites Blacks  Whites Blacks 
 Coefficient Estimate (Standard Error) 
Fair 13.36 (6.18) 
-0.95 
(10.68)  
12.14 
(5.54) 
7.84 
(6.68)  
6.85 
(4.29) 
9.89 
(6.54)  
7.54 
(3.27) 
3.76 
(3.54) 
Poor 5.85 (8.26) 
0.72 
(21.52)  
4.06 
(6.16) 
12.05 
(10.88)  
-0.99 
(10.46) 
10.36 
(10.59)  
-3.59 
(5.88) 
8.13 
(7.64) 
Any Physical Limitation 0.76 (4.51) 
3.99 
(3.79)  
-3.51 
(3.48) 
1.65 
(2.68)  
-3.91 
(3.29) 
-4.46 
(5.24)  
-1.94 
(2.60) 
4.43 
(5.84) 
Any Cognitive Limitation -5.59 (8.72) 
-10.51 
(6.02)  
-4.71 
(9.66) 
0.62 
(5.72)  
-4.88 
(8.85) 
6.51 
(3.88)  
-2.55 
(7.16) 
6.99 
(2.13) 
Depressive Symptoms -6.41 (8.14) 
-10.10 
(7.59)  
-3.43 
(7.87) 
-15.53 
(7.35)  
-2.52 
(11.54) 
-7.71 
(6.77)  
-3.77 
(5.42) 
-5.53 
(8.00) 
Hypertension 4.49 (2.59) 
-7.29 
(3.68)  
3.39 
(3.55) 
-5.58 
(6.71)  
6.19 
(2.25) 
8.31 
(2.49)  
5.06 
(3.22) 
6.61 
(2.46) 
Hyperlipidemia 1.87 (4.07) 
-12.56 
(5.94)  
1.24 
(2.51) 
-4.10 
(6.15)  
1.65 
(1.59) 
0.85 
(6.87)  
1.06 
(1.49) 
5.54 
(6.64) 
Angina/CHD -1.95 (2.59) 
5.44 
(3.39)  
-1.30 
(0.92) 
7.44 
(5.40)  
2.35 
(2.51) 
4.65 
(6.23)  
1.29 
(2.63) 
4.32 
(9.91) 
CHF 2.57 (4.37) 
-1.46 
(15.31)  
4.82 
(4.01) 
-7.70 
(4.70)  
-0.53 
(5.51) 
0.96 
(4.14)  
-0.66 
(4.46) 
6.12 
(10.02) 
AMI 4.58 (9.70) 
1.65 
(5.59)  
1.76 
(5.61) 
-12.12 
(3.41)  
0.21 
(13.32) 
-11.21 
(2.10)†  
2.59 
(9.29) 
-6.52 
(6.86) 
Stroke 0.88 (4.62) 
9.99 
(9.19)  
-4.31 
(8.88) 
5.73 
(6.47)  
-4.67 
(1.94) 
2.23 
(12.39)  
-4.16 
(0.84) 
-1.53 
(16.26) 
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Table C-3.      (Continued) 
 
Covariate 
QPDC 10th  QPDC 20th  QPDC 30th  QPDC 40th 
Whites Blacks  Whites Blacks  Whites Blacks  Whites Blacks 
 Coefficient Estimate (Standard Error) 
Count of Comorbid 
Conditions 
0.05 
(0.61) 
1.60 
(0.54)  
0.11 
(0.79) 
1.04 
(0.61)  
-0.31 
(0.71) 
0.30 
(0.36)  
-0.18 
(0.41) 
0.14 
(0.24) 
Charlson Comorbidity 
Score Q3 
-2.13 
(1.26) 
1.61 
(4.15)  
-2.74 
(1.33) 
4.59 
(1.89)  
-0.70 
(1.88) 
6.72 
(1.56)  
-0.59 
(2.03) 
6.46 
(3.15) 
Charlson Comorbidity 
Score Q4 
-3.04 
(5.97) 
-0.03 
(5.14)  
-2.63 
(6.36) 
5.10 
(1.45)  
0.37 
(3.29) 
9.59 
(3.32)  
-0.63 
(1.73) 
12.38 
(3.86) 
More Likely to Take 
Risks 
1.76 
(5.19) 
4.33 
(4.08)  
-1.18 
(4.45) 
8.14 
(4.86)  
-0.43 
(4.45) 
-1.45 
(4.22)  
-2.03 
(1.49) 
-6.52 
(2.78) 
Can overcome illness 
without medical care 
0.60 
(1.22) 
-1.73 
(12.84)  
2.40 
(1.44) 
-3.29 
(18.23)  
-0.30 
(1.54) 
-12.41 
(9.17)  
-0.76 
(1.11) 
-11.41 
(10.92) 
Does not need health 
insurance 
-9.41 
(1.50) 
-8.47 
(19.76)  
-9.79 
(3.53) 
-9.66 
(22.38)  
-7.97 
(2.08) 
1.76 
(16.68)  
-12.93 
(1.81) 
7.17 
(15.42) 
Current Smoker -2.94 (1.56) 
5.42 
(2.18)  
-4.02 
(2.02) 
0.60 
(2.63)  
-3.77 
(7.31) 
-1.08 
(3.46)  
0.34 
(4.31) 
1.91 
(2.95) 
Had Moderate / 
Vigorous Exercise 
-0.93 
(1.58) 
0.60 
(5.57)  
-3.88 
(1.32) 
-4.60 
(5.61)  
-4.66 
(0.93) 
-1.55 
(6.81)  
-3.21 
(1.93) 
-1.31 
(5.57) 
Obese (BMI≥30) -0.88 (1.02) 
14.91 
(3.58)  
1.46 
(1.12) 
11.96 
(2.41)  
0.63 
(0.88) 
12.83 
(3.92)  
1.67 
(0.65)† 
9.26 
(2.22) 
Income:  
Poor/Near-Poor  
-1.73 
(4.45) 
-5.58 
(3.44)  
-0.17 
(1.32) 
-13.74 
(6.00)  
0.75 
(5.01) 
-2.32 
(5.54)  
1.86 
(2.80) 
-6.90 
(2.25) 
 150 
Table C-3.      (Continued) 
 
Covariate 
QPDC 10th  QPDC 20th  QPDC 30th  QPDC 40th 
Whites Blacks  Whites Blacks  Whites Blacks  Whites Blacks 
 Coefficient Estimate (Standard Error) 
Low-Income -0.21 (1.85) 
-5.21 
(3.51)  
4.06 
(1.44) 
-11.83 
(2.73)  
-0.50 
(1.10) 
-4.90 
(3.37)  
1.31 
(0.84) 
-10.77 
(5.19) 
Middle-Income  4.16 (2.68) 
-4.11 
(5.38)  
4.71 
(1.70) 
-7.55 
(7.61)  
2.26 
(2.68) 
-3.24 
(5.08)  
1.42 
(2.41) 
-7.59 
(3.21) 
Education:  
Less than High School 
-2.23 
(2.71) 
-7.49 
(8.38)  
-2.14 
(2.17) 
3.68 
(7.64)  
-0.25 
(2.87) 
0.62 
(5.86)  
1.83 
(2.79) 
1.87 
(4.31) 
High School Diploma -0.68 (2.67) 
-14.44 
(7.16)  
-4.16 
(2.55) 
-0.87 
(7.61)  
-1.80 
(2.30) 
-2.80 
(3.15)  
0.68 
(2.78) 
-2.12 
(6.33) 
Drug Coverage Plan:  
Part D: PDPs 
1.49 
(2.45) 
26.03 
(7.05)  
2.47 
(0.93) 
15.07 
(1.22)  
2.07 
(2.65) 
8.27 
(3.82)  
-0.55 
(1.58) 
10.94 
(4.48) 
Part D: MA-PD 1.95 (4.27) 
22.97 
(6.57)  
3.61 
(1.42) 
14.02 
(3.80)  
3.64 
(1.88) 
13.38 
(5.46)  
2.93 
(2.00) 
14.43 
(7.73) 
Employer/Other Private -1.61 (1.97) 
19.00 
(4.33)  
1.09 
(0.98) 
18.36 
(3.02)  
0.68 
(1.50) 
21.03 
(7.83)  
-1.83 
(1.02) 
27.54 
(9.05) 
Auto Eligible for PD 
Low-Income Subsidy 
6.80 
(4.96) 
-12.98 
(7.23)  
1.42 
(2.39) 
-12.87 
(5.46)  
3.29 
(3.87) 
-12.29 
(3.17)  
-0.21 
(2.63) 
-4.34 
(3.27) 
Average Copay for CV 
Drugs ($2010) 
-0.07 
(0.04) 
0.17 
(0.04)  
-0.07 
(0.04) 
-0.06 
(0.07)  
-0.04 
(0.04) 
-0.12 
(0.08)  
-0.05 
(0.02) 
-0.18 
(0.09) 
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Table C-3.      (Continued) 
 
Covariate 
QPDC 10th  QPDC 20th  QPDC 30th  QPDC 40th 
Whites Blacks  Whites Blacks  Whites Blacks  Whites Blacks 
 Coefficient Estimate (Standard Error) 
Concurrently taking:  
2-3 CV Drugs 
10.44 
(5.65) 
10.51 
(3.41)  
6.51 
(5.25) 
4.91 
(1.12)  
0.67 
(3.01) 
-1.05 
(2.33)  
-1.54 
(1.94) 
-9.49 
(1.33) 
≥4 CV Drugs 12.98 (15.12) 
12.70 
(2.93)  
6.61 
(9.14) 
5.49 
(3.68)  
3.21 
(9.93) 
1.60 
(3.18)  
-2.40 
(5.88) 
-11.46 
(4.31) 
Quantiles of Ambulatory 
Visits:  
Q 3 (5-7) 
-1.47 
(1.59) 
-3.11 
(9.26)  
3.16 
(1.53) 
-6.55 
(5.78)  
6.18 
(2.44) 
-7.05 
(6.03)  
5.00 
(2.36) 
-10.24 
(2.69) 
Q 4 (8-12) -2.22 (2.11) 
-9.52 
(11.90)  
-1.39 
(4.61) 
-2.50 
(7.37)  
1.26 
(2.78) 
-9.17 
(7.16)  
0.58 
(1.88) 
-11.63 
(4.00) 
Q 5 (≥13) -6.96 (5.36) 
3.99 
(7.44)  
-1.31 
(6.31) 
-0.37 
(3.62)  
-1.40 
(5.87) 
2.18 
(3.13)  
-2.76 
(4.56) 
-0.78 
(3.84) 
Had a Usual Source of 
Care 
-11.41 
(10.66) 
-13.49 
(9.96)  
3.64 
(4.89) 
-6.96 
(12.11)  
2.01 
(6.08) 
6.62 
(4.59)  
-6.02 
(4.40) 
1.59 
(7.35) 
Any Emergency 
Department Visit- 
Baseline Year 
3.78 
(3.82) 
-1.03 
(3.89)  
3.23 
(4.04) 
6.22 
(2.78)  
5.31 
(2.58) 
11.67 
(5.08)  
1.98 
(1.12) 
10.09 
(5.46) 
No. of Pharmacies Used -2.92 (3.04) 
1.17 
(5.15)  
-4.52 
(1.67) 
-4.62 
(6.06)  
-6.07 
(2.71) 
-4.23 
(4.03)  
-5.86 
(2.69) 
-4.51 
(4.93) 
Very Satisfied with 
Received Healthcare 
1.89 
(2.07) 
2.91 
(6.35)  
3.11 
(1.74) 
14.35 
(5.47)  
3.95 
(0.77) 
8.66 
(6.26)  
4.32 
(1.50) 
7.77 
(4.04) 
 152 
Table C-3.      (Continued) 
 
Covariate 
QPDC 10th  QPDC 20th  QPDC 30th  QPDC 40th 
Whites Blacks  Whites Blacks  Whites Blacks  Whites Blacks 
 Coefficient Estimate (Standard Error) 
Provider Always 
Explained  
3.41 
(2.69) 
-1.83 
(5.73)  
3.13 
(3.94) 
-3.21 
(7.80)  
-0.41 
(0.89) 
-3.71 
(6.86)  
1.16 
(0.52)† 
0.60 
(5.93) 
Provider Always 
Listened  
-1.84 
(3.42) 
-3.84 
(3.72)  
-0.64 
(1.72) 
-6.17 
(3.93)  
-1.40 
(3.30) 
-2.23 
(7.12)  
-3.16 
(0.76)† 
3.11 
(6.11) 
Provider Always 
Respected 
-1.42 
(1.18) 
-3.16 
(7.00)  
-2.46 
(2.76) 
-8.88 
(7.79)  
0.56 
(3.32) 
-4.97 
(10.28)  
0.96 
(1.82) 
-7.12 
(9.19) 
Constant (Base QPDC) 41.86 (13.73) 
31.83 
(31.56)  
48.09 
(11.90) 
40.80 
(12.60)  
65.63 
(9.32) 
31.49 
(12.29)  
84.83 
(8.00) 
48.12 
(11.74) 
Sample Size 2,585 703   2,585 703   2,585 703   2,585 703 
 
Boldface estimates have P values <0.05. Standard errors were estimated by balanced repeated replications using MEPS-provided 
survey weights and half-sample identifiers. 
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Table C-4. RIF unconditional quantile regressions for by race, Q50th-Q80th 
 
 Covariate  QPDC 50
th  QPDC 60th  QPDC 70th  QPDC 80th 
Whites Blacks  Whites Blacks  Whites Blacks  Whites Blacks 
 Coefficient Estimate (Standard Error) 
Age 70-75 -2.06 (1.10) 
1.29 
(7.79)  
-3.67 
(0.85) 
-0.79 
(5.63)  
-1.49 
(1.73) 
-2.96 
(6.48)  
-0.89 
(1.17) 
-0.18 
(3.92) 
Age 75-80 -2.54 (2.25) 
0.57 
(6.27)  
-5.74 
(2.41) 
1.23 
(4.12)  
-4.45 
(1.54) 
3.59 
(5.69)  
-2.53 
(0.65) 
4.92 
(3.46) 
Age ≥ 80 -5.80 (4.64) 
0.09 
(9.02)  
-6.86 
(2.71) 
0.15 
(5.76)  
-3.83 
(3.03) 
-0.49 
(4.28)  
-1.50 
(1.59) 
2.04 
(3.60) 
Female 0.68 (1.98) 
-6.02 
(4.13)  
0.83 
(1.15) 
-0.42 
(1.51)  
0.21 
(0.96) 
-3.67 
(2.42)  
-0.08 
(0.84) 
-2.91 
(2.85) 
Married -1.40 (3.19) 
1.01 
(3.50)  
-0.89 
(1.65) 
-3.29 
(3.11)  
-1.26 
(0.83) 
-3.33 
(2.67)  
-0.71 
(0.29) 
-2.60 
(2.33) 
Urban Residence -1.57 (6.49) 
0.79 
(3.86)  
-0.61 
(5.42) 
-1.12 
(3.24)  
1.59 
(4.61) 
-1.41 
(3.46)  
1.32 
(4.31) 
-0.07 
(4.34) 
Census Region:  
Midwest 
4.07 
(2.03) 
15.25 
(6.92)  
1.78 
(1.64) 
9.13 
(8.20)  
0.91 
(1.85) 
7.39 
(4.73)  
0.09 
(1.07) 
2.96 
(1.59) 
South -2.00 (0.62) 
7.76 
(7.15)  
-0.84 
(1.49) 
0.08 
(7.53)  
0.03 
(0.94) 
0.24 
(3.88)  
0.02 
(1.38) 
0.52 
(1.40) 
West 1.53 (1.29) 
-1.55 
(7.69)  
1.94 
(1.11) 
-5.45 
(5.94)  
1.05 
(1.03) 
0.67 
(3.90)  
1.16 
(0.44) 
-2.55 
(2.52) 
Health Status:  
Very Good 
6.61 
(1.90) 
4.24 
(1.85)  
4.19 
(2.12) 
5.37 
(4.56)  
3.11 
(0.55) 
2.99 
(2.59)  
1.23 
(0.28) 
4.94 
(2.94) 
Good 4.16 (3.94) 
4.89 
(3.27)  
1.96 
(2.86) 
6.49 
(5.34)  
1.16 
(1.89) 
6.01 
(1.30)  
0.67 
(1.38) 
3.52 
(2.18) 
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Table C-4.      (Continued) 
 
Covariate 
QPDC 50th  QPDC 60th  QPDC 70th  QPDC 80th 
Whites Blacks  Whites Blacks  Whites Blacks  Whites Blacks 
 Coefficient Estimate (Standard Error) 
Fair 7.27 (3.73) 
9.30 
(7.28)  
4.41 
(2.46) 
9.23 
(6.89)  
2.70 
(1.47) 
7.18 
(6.02)  
1.83 
(0.70) 
7.45 
(5.46) 
Poor -2.18 (5.10) 
17.13 
(4.83)  
-1.80 
(4.38) 
17.20 
(4.07)  
0.29 
(3.14) 
14.05 
(2.89)  
1.43 
(0.88) 
12.10 
(3.78) 
Any Physical 
Limitation 
-1.21 
(1.43) 
10.62 
(2.91)  
-1.19 
(2.10) 
6.99 
(3.29)  
-0.55 
(2.14) 
1.37 
(3.02)  
-1.10 
(1.40) 
-0.95 
(1.66) 
Any Cognitive 
Limitation 
-4.16 
(4.10) 
5.25 
(1.85)  
-3.18 
(6.20) 
0.41 
(3.21)  
-2.32 
(2.21) 
-3.85 
(1.42)  
-3.03 
(1.76) 
-4.67 
(2.11) 
Depressive 
Symptoms 
1.93 
(5.15) 
-6.19 
(3.78)  
-1.98 
(3.38) 
-1.53 
(3.69)  
-2.57 
(1.86) 
2.88 
(1.33)  
-0.64 
(0.97) 
4.60 
(0.80) 
Hypertension 3.08 (3.18) 
9.44 
(4.48)  
4.07 
(3.58) 
14.64 
(3.47)  
1.39 
(3.03) 
7.81 
(4.12)  
0.39 
(1.89) 
8.02 
(1.48) 
Hyperlipidemia 1.90 (1.43) 
1.05 
(7.95)  
1.53 
(0.92) 
2.49 
(5.63)  
1.13 
(0.93) 
1.90 
(2.40)  
0.12 
(0.79) 
1.38 
(1.44) 
Angina/CHD 1.22 (2.63) 
4.49 
(7.53)  
1.22 
(1.53) 
2.91 
(4.95)  
1.90 
(1.47) 
0.36 
(2.31)  
1.64 
(1.47) 
-0.00 
(1.95) 
CHF 3.60 (2.55) 
-1.17 
(7.12)  
5.25 
(3.20) 
-1.02 
(6.66)  
-0.17 
(2.63) 
4.11 
(2.53)  
1.51 
(4.55) 
-2.53 
(5.51) 
AMI 2.10 (6.66) 
-7.88 
(3.53)  
0.58 
(5.05) 
-2.44 
(4.05)  
1.41 
(4.41) 
-2.02 
(7.00)  
-1.00 
(3.65) 
-3.61 
(2.05) 
Stroke -3.57 (2.20) 
3.72 
(17.65)  
0.95 
(1.24) 
2.21 
(12.54)  
-0.94 
(1.89) 
-4.20 
(3.35)  
0.74 
(1.03) 
1.24 
(2.44) 
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Covariate 
QPDC 50th  QPDC 60th  QPDC 70th  QPDC 80th 
Whites Blacks  Whites Blacks  Whites Blacks  Whites Blacks 
 Coefficient Estimate (Standard Error) 
Count of Comorbid 
Conditions 
-0.57 
(0.29) 
-0.24 
(0.31)  
-0.53 
(0.40) 
-0.99 
(0.55)  
-0.08 
(0.18) 
-0.67 
(0.43)  
0.10 
(0.20) 
-0.34 
(0.45) 
Charlson 
Comorbidity Score 
Q3 
-1.15 
(2.50) 
8.15 
(2.73)  
-2.16 
(1.78) 
2.67 
(3.60)  
0.24 
(0.74) 
-0.56 
(3.94)  
0.56 
(0.55) 
-3.95 
(0.88) 
Charlson 
Comorbidity Score 
Q4 
0.19 
(0.88) 
10.86 
(2.38)  
-2.21 
(1.69) 
4.06 
(1.49)  
-3.22 
(1.64) 
5.58 
(4.10)  
-1.89 
(2.66) 
-1.12 
(1.58) 
More Likely to Take 
Risks 
-2.50 
(2.51) 
-2.67 
(1.61)  
-2.07 
(1.57) 
-2.97 
(2.83)  
-2.28 
(0.98) 
0.12 
(2.31)  
-1.54 
(1.58) 
-1.63 
(2.91) 
Can overcome illness 
without medical care 
0.87 
(1.31) 
-2.98 
(12.17)  
0.98 
(1.02) 
2.65 
(8.98)  
1.71 
(2.13) 
3.26 
(8.17)  
0.87 
(1.89) 
5.04 
(7.53) 
Does not need health 
insurance 
-3.76 
(4.09) 
-3.57 
(15.92)  
-4.85 
(2.86) 
-1.72 
(10.83)  
-1.07 
(2.45) 
-2.34 
(5.81)  
-0.28 
(2.58) 
4.10 
(4.64) 
Current Smoker 0.12 (1.88) 
-5.97 
(5.46)  
-5.56 
(1.92) 
-3.79 
(3.35)  
-2.56 
(2.02) 
-0.73 
(3.48)  
-0.43 
(2.36) 
1.92 
(1.80) 
Had Moderate / 
Vigorous Exercise 
-3.21 
(2.00) 
-1.08 
(2.86)  
-2.33 
(2.16) 
3.20 
(2.88)  
-1.09 
(1.76) 
1.81 
(4.37)  
0.00 
(0.84) 
1.74 
(2.51) 
Obese (BMI≥30) 1.49 (2.01) 
4.10 
(0.57)  
2.00 
(1.76) 
0.66 
(0.96)  
0.12 
(0.82) 
1.38 
(1.03)  
0.89 
(0.97) 
3.12 
(0.64) 
Income:  
Poor/Near-Poor  
-0.07 
(1.97) 
-7.81 
(3.08)  
0.32 
(1.68) 
-6.44 
(4.44)  
-1.22 
(1.37) 
-3.41 
(6.90)  
-0.39 
(0.82) 
-5.48 
(4.55) 
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Covariate 
QPDC 50th  QPDC 60th  QPDC 70th  QPDC 80th 
Whites Blacks  Whites Blacks  Whites Blacks  Whites Blacks 
 Coefficient Estimate (Standard Error) 
Low-Income 0.63 (1.62) 
-9.15 
(4.36)  
1.09 
(2.48) 
-1.89 
(6.98)  
0.96 
(1.37) 
-1.85 
(8.75)  
-0.85 
(0.85) 
-1.64 
(4.85) 
Middle-Income  1.24 (0.61) 
-3.25 
(3.70)  
0.29 
(1.01) 
-3.30 
(6.58)  
0.02 
(0.99) 
0.58 
(8.34)  
-0.32 
(0.84) 
-1.36 
(4.74) 
Education:  
Less than High 
School 
2.81 
(1.40) 
-2.38 
(4.45)  
1.85 
(1.30) 
-4.77 
(4.08)  
0.33 
(0.69) 
-4.49 
(2.01)  
0.84 
(0.42) 
0.05 
(1.75) 
High School 
Diploma 
0.77 
(1.55) 
-3.79 
(3.60)  
-0.03 
(0.47) 
-2.80 
(3.20)  
-1.29 
(0.24) 
-3.12 
(2.17)  
-0.76 
(0.37) 
0.50 
(3.50) 
Drug Coverage 
Plan:  
Part D: PDPs 
-0.01 
(1.23) 
2.06 
(4.59)  
0.79 
(1.61) 
1.23 
(4.28)  
2.34 
(0.93) 
1.60 
(8.76)  
1.10 
(0.97) 
-2.76 
(6.28) 
Part D: MA-PD 3.78 (3.53) 
1.80 
(8.80)  
5.75 
(1.08) 
-3.36 
(4.74)  
4.12 
(0.81) 
-2.11 
(6.43)  
2.97 
(0.70) 
-2.76 
(3.42) 
Employer/Other 
Private 
-1.94 
(2.01) 
12.79 
(3.33)  
0.21 
(1.76) 
8.87 
(2.97)  
1.18 
(1.07) 
9.70 
(2.43)  
-0.18 
(0.95) 
8.15 
(2.34) 
Auto Eligible for PD 
Low-Income 
Subsidy 
-2.22 
(3.76) 
1.29 
(3.31)  
-0.23 
(2.24) 
-0.18 
(4.49)  
-0.68 
(0.93) 
-0.12 
(3.23)  
-1.71 
(0.99) 
3.09 
(2.49) 
Average Copay for 
CV Drugs ($2010) 
-0.05 
(0.01) 
-0.23 
(0.05)  
-0.05 
(0.02) 
-0.16 
(0.05)  
-0.04 
(0.02) 
-0.06 
(0.06)  
-0.01 
(0.01) 
-0.04 
(0.05) 
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Table C-4.      (Continued) 
 
Covariate 
QPDC 50th  QPDC 60th  QPDC 70th  QPDC 80th 
Whites Blacks  Whites Blacks  Whites Blacks  Whites Blacks 
 Coefficient Estimate (Standard Error) 
Concurrently taking:  
2-3 CV Drugs 
-1.13 
(1.30) 
-12.82 
(3.63)  
-5.27 
(1.14) 
-11.34 
(3.45)  
-4.97 
(1.86) 
-10.41 
(1.66)  
-3.09 
(0.58) 
-9.61 
(1.87) 
≥4 CV Drugs -2.00 (2.72) 
-13.34 
(2.76)  
-6.36 
(2.29) 
-11.61 
(4.09)  
-7.77 
(3.18) 
-8.89 
(3.23)  
-6.59 
(1.51) 
-4.75 
(2.13) 
Quantiles of 
Ambulatory Visits:  
Q 3 (5-7) 
3.89 
(2.13) 
-5.33 
(2.49)  
1.46 
(2.42) 
0.98 
(4.24)  
0.46 
(1.49) 
-1.08 
(5.67)  
0.47 
(0.70) 
-0.24 
(2.66) 
Q 4 (8-12) 1.47 (0.98) 
-15.69 
(5.07)  
1.19 
(1.54) 
-0.74 
(2.96)  
0.18 
(1.00) 
0.60 
(1.37)  
-0.67 
(0.64) 
0.77 
(0.84) 
Q 5 (≥13) -1.08 (2.29) 
2.45 
(3.95)  
-0.92 
(2.45) 
6.62 
(4.28)  
-2.60 
(1.67) 
4.12 
(4.96)  
-0.88 
(1.23) 
-0.68 
(3.34) 
Had a Usual Source 
of Care 
-5.55 
(3.43) 
-2.21 
(10.25)  
-0.10 
(2.92) 
-4.42 
(10.52)  
3.20 
(3.53) 
-6.90 
(7.89)  
-0.08 
(3.99) 
-7.85 
(2.52) 
Any Emergency 
Department Visit- 
Baseline Year 
1.45 
(0.81) 
2.57 
(4.29)  
2.76 
(1.20) 
2.27 
(3.88)  
1.73 
(1.55) 
2.43 
(3.23)  
1.42 
(1.12) 
4.18 
(2.47) 
No. of Pharmacies 
Used 
-5.17 
(1.46) 
-6.76 
(3.40)  
-1.66 
(2.07) 
-6.44 
(6.26)  
-0.90 
(1.02) 
-6.81 
(4.40)  
-0.40 
(0.80) 
-5.30 
(2.45) 
Very Satisfied with 
Received Healthcare 
4.99 
(2.69) 
7.85 
(1.40  
1.40 
(2.44) 
2.68 
(2.58)  
0.20 
(1.10) 
4.17 
(0.96)  
1.03 
(0.50) 
3.96 
(2.30) 
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Table C-4.      (Continued) 
 
Covariate 
QPDC 50th  QPDC 60th  QPDC 70th  QPDC 80th 
Whites Blacks  Whites Blacks  Whites Blacks  Whites Blacks 
 Coefficient Estimate (Standard Error) 
Provider Always 
Explained  
1.95 
(2.37) 
2.33 
(3.96)  
2.01 
(1.92) 
-0.16 
(1.79)  
2.02 
(1.09) 
-2.34 
(3.32)  
0.94 
(0.98) 
-4.92 
(1.79) 
Provider Always 
Listened  
-2.89 
(1.27) 
0.19 
(4.97)  
-1.60 
(0.48) 
2.86 
(3.47)  
-0.95 
(0.57) 
1.84 
(2.41)  
-1.57 
(1.13) 
1.91 
(1.78) 
Provider Always 
Respected 
0.33 
(1.21) 
-6.10 
(7.32)  
0.55 
(1.25) 
1.00 
(7.13)  
0.61 
(1.01) 
4.75 
(3.70)  
0.83 
(0.54) 
2.93 
(2.41) 
Constant (Base QPDC) 87.74 (8.13) 
70.03 
(27.98)  
92.18 
(6.40) 
80.64 
(14.34)  
93.28 
(7.27) 
98.77 
(15.40)  
100.45 
(9.46) 
105.77 
(6.75) 
Sample Size 2,585 703   2,585 703   2,585 703   2,585 703 
 
Boldface estimates have P values <0.05. Standard errors were estimated by balanced repeated replications using MEPS-provided 
survey weights and half-sample identifiers.  
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Table C-5. Oaxaca-Blinder decomposition using coefficients from pooled RIF models, Q10th-Q40th 
 
 Outcome QPDC 10th QPDC 20th QPDC 30th QPDC 40th 
 Estimate (Standard Error) 
 Panel A: Fitted Adherence Levels and Differences 
QPDC, Blacks 26.63 (3.33) 43.99 (2.52) 50.65 (2.68) 64.39 (2.37) 
QPDC, Whites 34.28 (1.22) 51.50 (1.11) 60.10 (1.28) 70.45 (1.14) 
Difference -7.65 (3.77) -7.51 (2.86) -9.45 (3.06) -6.05 (2.69) 
 Panel B: Portion of Adherence Difference Due to: 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Aggregate 
Contribution 1.68 (2.00) -9.33 (3.80) 2.23 (1.74) -9.73 (2.98) 3.77 (1.68) -13.22 (3.20) 3.21 (1.37) -9.26 (2.70) 
Age 70-75 -0.27 (0.30) -2.60 (2.47) -0.30 (0.28) 0.39 (2.44) -0.26 (0.25) 2.38 (2.08) -0.16 (0.22) 0.90 (1.99) 
Age 75-80 0.13 (0.17) -1.83 (1.95) 0.10 (0.14) 0.87 (1.46) 0.03 (0.07) 0.27 (1.41) 0.02 (0.07) 0.47 (1.35) 
Age ≥ 80 0.47 (0.35) 0.84 (2.54) 0.33 (0.23) 1.46 (2.10) 0.29 (0.23) 1.69 (2.12) 0.29 (0.21) 1.01 (1.98) 
Female -0.02 (0.19) 2.67 (5.61) -0.05 (0.17) 4.47 (4.39) -0.16 (0.18) 0.73 (4.24) -0.21 (0.18) -2.55 (3.85) 
Married 0.05 (0.71) 0.36 (2.97) 1.05 (0.57) 3.82 (2.35) 1.35 (0.66) 3.14 (2.35) 0.90 (0.59) 1.98 (2.13) 
Urban 
Residence -0.01 (0.21) 0.64 (7.88) 0.00 (0.17) -3.40 (7.03) -0.03 (0.17) -0.52 (7.13) -0.10 (0.15) 2.44 (6.72) 
Census Region: 
Midwest -0.39 (0.34) 1.88 (1.84) -0.37 (0.27) 1.02 (1.53) -0.57 (0.37) 0.08 (1.76) -0.32 (0.33) 1.66 (1.56) 
South -0.89 (0.72) 7.25 (6.42) -0.25 (0.60) 4.11 (4.59) -0.45 (0.72) 2.13 (5.16) -0.55 (0.72) 5.90 (4.52) 
West 0.76 (0.50) -0.43 (1.73) 0.12 (0.42) -0.11 (1.07) -0.09 (0.45) -0.85 (1.03) -0.11 (0.38) -0.41 (0.88) 
Health Status: 
Very Good -0.48 (0.33) -0.60 (4.54) -0.45 (0.26) -1.48 (3.02) -0.34 (0.28) -0.41 (3.34) -0.45 (0.29) -0.88 (2.67) 
Good 0.04 (0.14) 1.18 (6.25) 0.07 (0.17) -3.18 (3.95) 0.04 (0.13) -1.70 (4.49) 0.07 (0.18) -1.98 (3.49) 
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  Table C-5.      (Continued) 
 
Characteristics QPDC 10th QPDC 20th QPDC 30th QPDC 40th 
 Estimate (Standard Error) 
 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Fair 0.94 (0.50) -1.25 (5.21) 1.02 (0.48) -1.53 (3.35) 0.70 (0.50) -0.17 (3.84) 0.87 (0.46) -0.01 (2.94) 
Poor 0.14 (0.21) 0.83 (1.62) 0.12 (0.18) 0.55 (1.24) 0.05 (0.17) 0.90 (1.42) 0.01 (0.16) 1.23 (1.11) 
Any Physical 
Limitation 0.01 (0.10) -0.54 (5.41) -0.05 (0.11) 1.87 (4.35) -0.04 (0.09) 5.66 (4.25) -0.03 (0.08) 7.70 (3.72) 
Any Cognitive 
Limitation -0.47 (0.38) -0.30 (1.83) -0.20 (0.30) 0.77 (1.57) -0.31 (0.33) 2.03 (1.46) -0.15 (0.26) 1.15 (1.39) 
Depressive 
Symptoms -0.73 (0.41) -1.88 (1.88) -0.42 (0.33) -0.77 (1.38) -0.24 (0.31) -0.43 (1.29) -0.32 (0.26) -0.68 (1.13) 
Hypertension 0.26 (0.35) -11.53 (14.21) 0.01 (0.31) 
-2.36 
(11.44) 0.59 (0.36) 0.29 (10.50) 0.61 (0.32) -0.26 (9.42) 
Hyperlipidemia -0.10 (0.20) -5.26 (4.49) -0.00 (0.16) 0.13 (3.96) -0.14 (0.19) 1.29 (3.77) -0.12 (0.19) 2.43 (3.55) 
Angina/CHD 0.06 (0.15) 0.48 (1.70) 0.00 (0.12) 1.42 (1.37) -0.13 (0.12) 0.33 (1.22) -0.07 (0.10) 0.43 (1.30) 
CHF -0.01 (0.04) -0.03 (0.47) -0.01 (0.04) -0.26 (0.46) 0.00 (0.05) 0.22 (0.47) 0.00 (0.04) 0.05 (0.45) 
AMI -0.06 (0.10) -0.53 (1.15) -0.02 (0.09) -0.72 (0.89) 0.01 (0.09) -0.56 (0.89) -0.04 (0.09) -0.75 (0.75) 
Stroke 0.00 (0.07) 0.86 (0.86) -0.00 (0.06) 0.39 (0.66) -0.01 (0.07) 0.11 (0.81) -0.01 (0.07) 0.30 (0.80) 
Count of 
Comorbid 
Conditions 
-0.17 (0.57) 8.16 (6.58) -0.11 (0.42) 3.04 (5.13) 0.41 (0.47) 1.31 (5.05) 0.23 (0.38) -0.62 (4.32) 
Charlson 
Comorbidity 
Score Q3 
-0.01 (0.28) 3.48 (3.36) -0.13 (0.24) 3.25 (2.54) 0.01 (0.23) 2.97 (2.30) 0.05 (0.22) 2.99 (2.25) 
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  Table C-5.      (Continued) 
 
Characteristics QPDC 10th QPDC 20th QPDC 30th QPDC 40th 
 Estimate (Standard Error) 
 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Charlson 
Comorbidity 
Score Q4 
-0.04 (0.15) 0.92 (1.89) -0.04 (0.13) 1.14 (1.58) 0.03 (0.11) 1.82 (1.62) 0.01 (0.10) 1.63 (1.41) 
More Likely to 
Take Risks -0.04 (0.10) 0.97 (1.22) -0.04 (0.08) 0.43 (1.20) 0.02 (0.08) -0.91 (1.42) 0.05 (0.09) -0.48 (1.20) 
Can overcome 
illness without 
medical care 
0.04 (0.22) -1.01 (1.07) -0.00 (0.19) -0.50 (0.80) 0.00 (0.24) -0.87 (0.82) 0.07 (0.18) -0.23 (0.71) 
Does not need 
health 
insurance 
-0.04 (0.10) 0.29 (0.77) -0.06 (0.12) 0.51 (0.77) -0.05 (0.11) 0.60 (0.82) -0.10 (0.14) 0.87 (0.69) 
Current 
Smoker -0.00 (0.12) 0.70 (1.11) -0.10 (0.13) 0.61 (0.87) -0.10 (0.15) 0.84 (0.87) -0.01 (0.12) -0.53 (0.82) 
Had Moderate / 
Vigorous 
Exercise 
0.23 (0.25) 0.32 (3.29) 0.26 (0.21) 0.06 (2.39) 0.41 (0.25) 1.17 (2.82) 0.28 (0.22) 0.86 (2.40) 
Obese 
(BMI≥30) -0.00 (0.24) 7.09 (2.91) 0.16 (0.21) 4.05 (2.29) 0.14 (0.23) 3.83 (2.50) 0.15 (0.20) 1.14 (2.11) 
Income: 
Poor/Near-Poor  -0.47 (0.64) -4.53 (3.44) -0.02 (0.59) -3.39 (2.86) 0.11 (0.58) -2.39 (3.21) 0.18 (0.55) -1.41 (2.61) 
Low-Income -0.07 (0.22) -2.63 (2.12) 0.18 (0.19) -3.15 (1.77) 0.02 (0.23) -2.44 (2.05) 0.03 (0.19) -1.26 (1.91) 
Middle-Income  -0.01 (0.13) -4.04 (3.70) -0.01 (0.14) -3.07 (3.28) -0.00 (0.10) -3.69 (3.50) -0.00 (0.08) -0.42 (2.97) 
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  Table C-5.      (Continued) 
 
Characteristics QPDC 10th QPDC 20th QPDC 30th QPDC 40th 
 Estimate (Standard Error) 
 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Education: 
Less than High 
School 
-0.98 (0.89) -1.18 (3.78) -0.42 (0.78) 3.58 (3.85) -0.03 (0.86) 1.43 (3.86) 0.17 (0.76) -1.67 (3.60) 
High School 
Diploma 0.24 (0.39) -4.94 (3.79) 0.32 (0.34) 1.99 (3.84) 0.26 (0.40) -0.21 (4.07) 0.10 (0.34) -1.21 (3.68) 
Drug Coverage 
Plan: Part D: 
PDPs 
0.40 (0.36) 12.30 (6.27) 0.24 (0.25) 2.80 (4.86) 0.33 (0.29) 3.23 (4.58) 0.00 (0.24) 1.92 (3.62) 
Part D: MA-PD 0.16 (0.28) 5.80 (4.36) 0.26 (0.23) 2.16 (3.08) 0.31 (0.27) 3.05 (3.08) 0.18 (0.22) 0.94 (2.48) 
Employer/Othe
r Private 0.06 (0.34) 3.68 (2.23) -0.21 (0.27) 2.15 (1.60) -0.25 (0.30) 3.52 (1.43) 0.06 (0.26) 2.67 (1.19) 
Auto Eligible 
for PD Low-
Income 
Subsidy 
0.59 (0.96) -4.90 (2.31) -0.23 (0.85) -4.08 (1.81) 0.42 (0.94) -2.42 (1.88) 0.16 (0.80) 0.09 (1.65) 
Average Copay 
for CV Drugs 
($2010) 
0.54 (0.35) 2.16 (2.77) 0.35 (0.28) -0.18 (2.13) 0.42 (0.29) -2.41 (2.11) 0.41 (0.24) -2.50 (1.85) 
Concurrently 
taking:  
2-3 CV Drugs 
-0.04 (0.23) -0.28 (5.29) -0.03 (0.15) -4.06 (3.63) -0.00 (0.07) -6.22 (3.70) 0.01 (0.10) -5.76 (3.28) 
≥4 CV Drugs 0.44 (0.30) -0.01 (1.75) 0.31 (0.19) -0.62 (1.35) 0.09 (0.16) -1.62 (1.19) -0.13 (0.16) -1.49 (1.08) 
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  Table C-5.      (Continued) 
 
Characteristics QPDC 10th QPDC 20th QPDC 30th QPDC 40th 
 Estimate (Standard Error) 
 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Ambulatory Visit Quantiles:        
Q 3 (5-7) -0.05 (0.15) 0.28 (2.27) 0.02 (0.09) -2.60 (1.77) 0.07 (0.14) -2.94 (1.58) 0.07 (0.14) -2.10 (1.26) 
Q 4 (8-12) 0.21 (0.29) -0.13 (1.77) 0.21 (0.24) -0.71 (1.36) -0.12 (0.25) -1.44 (1.35) -0.03 (0.21) -1.25 (1.24) 
Q 5 (≥13) 0.46 (0.34) 2.04 (1.76) 0.18 (0.27) 1.00 (1.31) 0.12 (0.28) 0.36 (1.47) 0.18 (0.25) 0.37 (1.32) 
Had a Usual 
Source of Care 0.18 (0.15) 
-7.53 
(13.74) -0.07 (0.13) 2.72 (15.34) -0.05 (0.13) -2.38 (14.92) 0.09 (0.13) 2.13 (13.42) 
Any ED Visit- 
Baseline Year 0.13 (0.15) 0.13 (1.57) 0.09 (0.12) 1.92 (1.43) 0.19 (0.15) 1.01 (1.29) 0.06 (0.10) 0.70 (1.03) 
No. of 
Pharmacies  0.48 (0.37) 
-1.10 
(10.02) 0.62 (0.34) -5.26 (7.86) 0.89 (0.38) 0.31 (8.33) 1.07 (0.32) 2.34 (7.17) 
Very Satisfied 
with Healthcare -0.01 (0.14) 3.79 (4.92) -0.17 (0.17) 5.21 (4.20) -0.18 (0.18) 4.15 (3.88) -0.24 (0.19) 1.38 (3.56) 
Provider 
Explained  0.06 (0.14) -3.63 (6.47) 0.07 (0.14) -5.14 (4.70) -0.01 (0.10) -1.62 (4.92) 0.00 (0.09) -0.74 (4.40) 
Provider 
Listened  -0.03 (0.10) -3.77 (6.07) -0.04 (0.11) -1.61 (4.73) -0.02 (0.10) 3.48 (5.69) -0.04 (0.10) 5.32 (4.32) 
Provider 
Respected -0.01 (0.09) -3.15 (5.55) -0.05 (0.11) -1.83 (5.18) 0.01 (0.09) -5.65 (5.74) 0.00 (0.08) -6.44 (5.20) 
Constant  
(Base QPDC)  
-8.80 
(32.31)  
-17.62 
(25.77)  
-25.75 
(30.57)  
-26.61 
(26.37) 
Sample Size 3,288 
 
Boldface estimates have P values <0.05. Standard errors were estimated by balanced repeated replications using MEPS-provided 
survey weights and half-sample identifiers.  
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Table C-6. Oaxaca-Blinder decomposition using coefficients from pooled RIF models, Q50th-Q80th 
 
 Outcome QPDC 50th QPDC 60th QPDC 70th QPDC 80th 
 Estimate (Standard Error) 
 Panel A: Fitted Adherence Levels and Differences 
QPDC, Blacks 73.83 (1.89)† 81.38 (1.60)† 89.54 (1.07)† 96.98 (0.60)† 
QPDC, Whites 77.86 (1.02)† 86.19 (0.95)† 93.22 (0.71)† 99.42 (0.41)†  
Difference -4.03 (2.15) -4.80 (1.88)† -3.68 (1.37)† -2.44 (0.76)† 
 Panel B: Portion of Adherence Difference Due to: 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Aggregate 
Contribution 2.52 (1.30) -6.55 (2.29) 1.64 (1.27) -6.45 (2.16) 0.91 (0.88) -4.59 (1.53) 0.20 (0.54) -2.64 (0.87) 
Age 70-75 -0.18 (0.19) 0.82 (1.73) -0.26 (0.21) 0.38 (1.74) -0.10 (0.14) 0.02 (1.14) -0.06 (0.08) 0.13 (0.61) 
Age 75-80 0.04 (0.07) 0.86 (1.22) 0.07 (0.10) 1.80 (1.20) 0.05 (0.08) 1.88 (0.82) 0.03 (0.04) 1.12 (0.49) 
Age ≥ 80 0.37 (0.22) 1.42 (1.83) 0.39 (0.24) 2.01 (1.80) 0.25 (0.16) 1.42 (1.20) 0.08 (0.07) 0.88 (0.72) 
Female 0.06 (0.14) -0.32 (3.19) 0.03 (0.12) -3.01 (2.93) 0.00 (0.11) -1.76 (1.86) -0.02 (0.06) -0.46 (1.06) 
Married 0.37 (0.52) 0.80 (1.85) 0.25 (0.48) -0.79 (1.73) 0.41 (0.34) -0.67 (1.10) 0.11 (0.20) 0.26 (0.61) 
Urban 
Residence -0.07 (0.15) -0.65 (5.81) -0.05 (0.15) -0.13 (5.07) 0.05 (0.10) -1.54 (3.66) 0.06 (0.07) 0.65 (1.99) 
Census Region: 
Midwest -0.48 (0.33) 1.79 (1.21) -0.19 (0.26) 1.20 (1.11) -0.11 (0.20) 0.34 (0.78) 0.01 (0.10) 0.46 (0.48) 
South -0.32 (0.57) 3.85 (3.57) -0.31 (0.54) 0.51 (3.10) -0.00 (0.41) -0.35 (2.41) -0.10 (0.25) 0.55 (1.34) 
West -0.14 (0.32) -0.41 (0.79) -0.22 (0.31) -0.26 (0.81) -0.14 (0.24) -0.38 (0.51) -0.07 (0.13) 0.03 (0.27) 
Health Status: 
Very Good -0.48 (0.27) -1.06 (1.98) -0.33 (0.24) -0.10 (1.75) -0.24 (0.18) 0.40 (1.27) -0.11 (0.10) -0.17 (0.75) 
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 Table C-6.      (Continued) 
 
Characteristics QPDC 50th QPDC 60th QPDC 70th QPDC 80th 
 Estimate (Standard Error) 
 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Good 0.04 (0.13) -0.96 (2.81) 0.03 (0.10) 1.35 (2.69) 0.02 (0.07) 1.00 (1.94) 0.01 (0.04) -0.64 (1.14) 
Fair 0.63 (0.38) -1.31 (2.30) 0.55 (0.38) 0.86 (2.17) 0.29 (0.28) 1.00 (1.58) 0.15 (0.16) -0.36 (0.91) 
Poor -0.02 (0.15) 1.03 (0.90) 0.02 (0.13) 1.30 (0.87) 0.05 (0.08) 1.03 (0.62) 0.05 (0.05) 0.06 (0.33) 
Any Physical 
Limitation -0.00 (0.06) 5.47 (3.11) -0.02 (0.06) 2.48 (2.90) -0.01 (0.05) -0.10 (1.98) -0.02 (0.04) 0.88 (1.22) 
Any Cognitive 
Limitation -0.13 (0.27) 0.99 (1.15) -0.25 (0.26) 0.94 (1.07) -0.24 (0.16) -0.16 (0.65) -0.19 (0.10) 0.21 (0.35) 
Depressive 
Symptoms 0.10 (0.25) -0.50 (1.01) -0.04 (0.22) 0.04 (0.98) -0.20 (0.16) 0.68 (0.57) -0.07 (0.09) 0.14 (0.30) 
Hypertension 0.41 (0.27) 8.84 (8.11) 0.41 (0.27) 7.33 (8.34) 0.20 (0.18) 4.43 (6.25) 0.09 (0.12) 4.67 (2.71) 
Hyperlipidemia -0.17 (0.16) -0.42 (3.24) -0.11 (0.14) -0.23 (2.82) -0.09 (0.10) 0.31 (1.97) -0.03 (0.06) 0.11 (1.12) 
Angina/CHD -0.08 (0.09) 0.13 (1.00) -0.08 (0.10) -0.14 (0.88) -0.10 (0.08) -0.16 (0.58) -0.08 (0.05) -0.04 (0.39) 
CHF -0.01 (0.04) -0.23 (0.42) -0.02 (0.05) -0.11 (0.35) -0.01 (0.03) -0.18 (0.27) -0.00 (0.02) -0.08 (0.16) 
AMI -0.02 (0.07) -0.43 (0.62) 0.01 (0.07) -0.13 (0.66) -0.02 (0.05) -0.20 (0.44) 0.02 (0.03) -0.05 (0.24) 
Stroke -0.01 (0.07) 0.52 (0.59) 0.00 (0.05) -0.73 (0.59) -0.00 (0.03) 0.06 (0.35) 0.00 (0.02) -0.02 (0.20) 
Count of 
Comorbid 
Conditions 
0.64 (0.31) 0.10 (4.10) 0.42 (0.31) -0.00 (4.36) 0.11 (0.23) -2.87 (2.56) -0.08 (0.15) -0.59 (1.49) 
Charlson 
Comorbidity 
Score Q3 
-0.05 (0.20) 2.24 (2.01) -0.18 (0.18) 0.53 (1.97) -0.04 (0.12) -1.25 (1.16) 0.06 (0.07) -0.61 (0.66) 
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 Table C-6.      (Continued) 
 
Characteristics QPDC 50th QPDC 60th QPDC 70th QPDC 80th 
 Estimate (Standard Error) 
 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Charlson 
Comorbidity 
Score Q4 
0.00 (0.08) 0.78 (1.31) -0.03 (0.08) 0.75 (1.28) -0.07 (0.08) 0.61 (0.66) -0.03 (0.04) 0.33 (0.37) 
More Likely to 
Take Risks 0.04 (0.08) -0.05 (1.08) 0.04 (0.08) 0.46 (0.93) 0.06 (0.07) 0.42 (0.59) 0.03 (0.04) 0.20 (0.34) 
Can overcome 
illness without 
medical care 
-0.03 (0.15) -0.02 (0.64) -0.04 (0.13) 0.01 (0.68) -0.11 (0.11) -0.01 (0.47) -0.06 (0.07) -0.11 (0.24) 
Does not need 
health 
insurance 
-0.02 (0.06) 0.17 (0.61) -0.04 (0.07) -0.03 (0.53) -0.01 (0.04) 0.19 (0.35) -0.00 (0.02) 0.16 (0.22) 
Current 
Smoker 0.01 (0.11) -0.29 (0.71) -0.17 (0.14) 0.08 (0.66) -0.08 (0.08) 0.27 (0.46) -0.00 (0.04) 0.27 (0.30) 
Had Moderate / 
Vigorous 
Exercise 
0.25 (0.20) 1.17 (2.19) 0.18 (0.19) 1.03 (2.07) 0.06 (0.13) 1.35 (1.26) 0.02 (0.07) -0.17 (0.70) 
Obese 
(BMI≥30) 0.18 (0.19) 0.29 (1.91) 0.19 (0.19) -0.18 (1.76) 0.06 (0.12) 0.87 (1.19) 0.09 (0.08) 0.08 (0.73) 
Income: 
Poor/Near-Poor  -0.09 (0.44) -3.02 (2.39) -0.01 (0.42) -1.49 (2.48) -0.27 (0.28) -0.54 (1.71) -0.12 (0.17) -0.78 (0.92) 
Low-Income 0.01 (0.17) -1.75 (1.73) 0.07 (0.16) -0.81 (1.80) 0.07 (0.11) -0.43 (1.15) -0.05 (0.06) 0.24 (0.64) 
Middle-Income  -0.00 (0.07) -2.06 (2.68) -0.00 (0.06) -0.45 (2.51) -0.00 (0.04) 0.44 (1.53) 0.00 (0.03) -0.54 (0.89) 
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 Table C-6.      (Continued) 
 
Characteristics QPDC 50th QPDC 60th QPDC 70th QPDC 80th 
 Estimate (Standard Error) 
 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Education: 
Less than High 
School 
0.56 (0.67) -1.73 (2.91) 0.39 (0.72) -3.68 (2.71) -0.01 (0.52) -1.42 (2.02) 0.09 (0.32) -1.24 (1.14) 
High School 
Diploma -0.05 (0.27) -0.65 (2.88) -0.02 (0.25) -2.68 (2.87) 0.18 (0.18) -0.47 (1.77) 0.11 (0.12) 0.07 (0.96) 
Drug Coverage 
Plan: 
Part D: PDPs 
0.03 (0.21) 0.28 (3.37) 0.13 (0.19) 0.34 (3.20) 0.24 (0.15) -1.27 (2.29) 0.10 (0.09) -0.32 (0.95) 
Part D: MA-PD 0.22 (0.20) -1.14 (2.37) 0.33 (0.21) -2.49 (2.15) 0.25 (0.17) -1.56 (1.53) 0.17 (0.11) -0.59 (0.77) 
Employer/Othe
r Private 0.13 (0.22) 1.43 (1.04) -0.07 (0.23) 1.32 (1.02) -0.14 (0.18) 1.10 (0.72) -0.00 (0.11) 0.70 (0.41) 
Auto Eligible 
for PD Low-
Income 
Subsidy 
-0.11 (0.73) 1.06 (1.41) -0.08 (0.63) -0.33 (1.40) 0.11 (0.42) 0.89 (0.89) -0.06 (0.23) 0.89 (0.52) 
Average Copay 
for CV Drugs 
($2010) 
0.43 (0.22) -2.25 (1.41) 0.39 (0.20) -1.20 (1.31) 0.35 (0.13) 0.15 (0.87) 0.08 (0.08) 0.17 (0.53) 
Concurrently 
taking:  
2-3 CV Drugs 
0.01 (0.07) -3.14 (2.91) 0.02 (0.14) -2.74 (3.13) 0.03 (0.16) -2.58 (1.96) 0.02 (0.09) -2.15 (1.20) 
≥4 CV Drugs -0.10 (0.16) -0.64 (0.98) -0.24 (0.18) -0.27 (1.07) -0.30 (0.15) 0.26 (0.65) -0.24 (0.11) 0.42 (0.39) 
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 Table C-6.      (Continued) 
 
Characteristics QPDC 50th QPDC 60th QPDC 70th QPDC 80th 
 Estimate (Standard Error) 
 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Ambulatory Visits Quantiles        
Q 3 (5-7) 0.06 (0.12) -1.15 (1.27) 0.02 (0.08) -0.20 (1.18) 0.00 (0.05) -0.08 (0.80) 0.00 (0.03) -0.30 (0.46) 
Q 4 (8-12) -0.13 (0.21) -1.23 (1.01) -0.03 (0.21) -0.33 (0.95) 0.02 (0.14) 0.31 (0.61) 0.03 (0.09) 0.26 (0.42) 
Q 5 (≥13) 0.01 (0.19) 1.19 (1.10) 0.10 (0.20) 0.81 (1.06) 0.16 (0.15) 0.76 (0.76) 0.07 (0.09) -0.19 (0.42) 
Had a Usual 
Source of Care 0.08 (0.11) 2.51 (12.50) 0.02 (0.09) 
-4.97 
(13.03) -0.03 (0.06) 
-12.36 
(8.94) 0.01 (0.04) -6.35 (5.24) 
Any ED Visit- 
Baseline Year 0.05 (0.09) 0.08 (1.07) 0.08 (0.09) 0.13 (1.01) 0.05 (0.06) 0.27 (0.63) 0.05 (0.05) 0.15 (0.41) 
No. of 
Pharmacies  0.74 (0.28) -2.52 (5.76) 0.39 (0.26) -4.20 (5.60) 0.16 (0.17) -5.65 (3.64) 0.07 (0.12) -1.80 (2.36) 
Very Satisfied 
with Healthcare -0.24 (0.19) 0.02 (2.91) -0.10 (0.14) 1.69 (2.78) -0.04 (0.09) 1.25 (1.79) -0.04 (0.06) 0.26 (1.02) 
Provider 
Explained  0.02 (0.08) -0.69 (3.95) 0.02 (0.08) -3.24 (3.85) 0.03 (0.06) -3.33 (2.48) 0.01 (0.03) -0.71 (1.33) 
Provider 
Listened  -0.04 (0.09) 3.21 (3.90) -0.02 (0.08) 2.58 (3.82) -0.01 (0.06) 2.24 (2.35) -0.03 (0.04) 2.09 (1.66) 
Provider 
Respected  0.01 (0.06) -3.42 (5.63) 0.01 (0.07) 1.82 (4.01) 0.01 (0.05) 2.13 (2.88) 0.02 (0.04) -0.27 (1.54) 
Constant  
(Base QPDC)  
-15.53 
(22.44)  
-3.28 
(21.40)  8.68 (14.98)  -0.53 (8.67) 
Sample Size 3,288 
 
Boldface estimates have P values <0.05. Standard errors were estimated by balanced repeated replications using MEPS-provided 
survey weights and half-sample identifiers.  
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Table C-7. Oaxaca-Blinder decomposition of mean differences in continuous PDC and in the probability of having 
PDC≥80% 
 
Outcome Linear Probability Model (PDC≥80%) 
Logistic Model 
(PDC≥80%) 
Ordinary Least Squares 
(Continuous PDC) 
 Estimate (Standard Error) 
 Panel A: Fitted Adherence Levels and Difference 
 Average Probability of Adherence (PDC≥80%) Mean PDC 
Blacks 0.41 (0.02) 0.41 (0.02) 68.05 (1.42) 
Whites 0.47 (0.01) 0.47 (0.01) 73.09 (0.67) 
Difference -0.06 (0.03) -0.06 (0.03) -5.04 (1.62) 
 Panel B: Portion of adherence difference due to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Aggregate 
Contribution 0.03 (0.03) -0.09 (0.04) 0.03 (0.03) -0.09 (0.04) 0.95 (2.58) -5.99 (3.09) 
Age 70-75 -0.00 (0.00) 0.00 (0.02) -0.00 (0.00) 0.00 (0.02) -0.08 (0.21) 0.30 (0.93) 
Age 75-80 -0.00 (0.00) 0.01 (0.02) -0.00 (0.00) 0.01 (0.01) 0.01 (0.11) 0.56 (0.89) 
Age ≥ 80 -0.00 (0.00) 0.03 (0.03) -0.00 (0.00) 0.03 (0.03) 0.02 (0.25) 1.21 (1.38) 
Female -0.00 (0.00) -0.01 (0.03) -0.00 (0.00) -0.01 (0.03) -0.05 (0.26) -0.19 (2.06) 
Married 0.01 (0.01) -0.01 (0.04) 0.01 (0.01) -0.01 (0.03) 0.03 (1.01) 1.07 (2.37) 
Urban Residence 0.00 (0.00) 0.01 (0.06) 0.00 (0.00) 0.01 (0.06) -0.02 (0.23) 0.09 (3.57) 
Census Region: 
Midwest -0.01 (0.01) 0.03 (0.02) -0.01 (0.01) 0.03 (0.02) -0.68 (0.50) 1.23 (1.29) 
South 0.01 (0.02) 0.02 (0.03) 0.01 (0.01) 0.02 (0.03) 0.60 (0.99) 1.45 (1.53) 
West 0.01 (0.01) -0.02 (0.02) 0.01 (0.01) -0.01 (0.02) 0.52 (1.02) -0.90 (1.64) 
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Table C-7.      (Continued) 
 
Characteristics Linear Probability Model (PDC≥80%) 
Logistic Model 
(PDC≥80%) 
Ordinary Least Squares 
(Continuous PDC) 
 Estimate (Standard Error) 
 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Health Status: 
Very Good -0.00 (0.01) -0.00 (0.03) -0.00 (0.01) 0.00 (0.03) -0.29 (0.50) 0.05 (2.04) 
Good 0.00 (0.00) 0.01 (0.03) 0.00 (0.00) 0.01 (0.03) 0.03 (0.20) -0.11 (2.13) 
Fair 0.01 (0.01) 0.00 (0.02) 0.01 (0.01) 0.00 (0.02) 0.57 (0.65) 0.11 (1.22) 
Poor 0.01 (0.00) 0.01 (0.01) 0.01 (0.00) 0.01 (0.01) 0.31 (0.26) 0.53 (0.44) 
Any Physical 
Limitation 0.00 (0.00) 0.07 (0.04) 0.00 (0.00) 0.06 (0.03) 0.03 (0.12) 1.77 (2.21) 
Any Cognitive 
Limitation 0.00 (0.01) 0.01 (0.01) 0.00 (0.00) 0.01 (0.01) -0.02 (0.33) 0.29 (0.46) 
Depressive 
Symptoms -0.00 (0.01) -0.01 (0.01) -0.00 (0.01) -0.01 (0.01) -0.34 (0.37) -0.15 (0.39) 
Hypertension 0.02 (0.01) 0.12 (0.09) 0.02 (0.01) 0.12 (0.09) 0.46 (0.63) 1.57 (5.02) 
Hyperlipidemia -0.00 (0.00) 0.00 (0.04) -0.00 (0.00) 0.00 (0.04) 0.04 (0.21) -1.01 (2.20) 
Angina/CHD -0.00 (0.00) -0.00 (0.01) -0.00 (0.00) 0.00 (0.01) -0.12 (0.15) 0.50 (0.80) 
CHF 0.00 (0.00) -0.00 (0.01) 0.00 (0.00) -0.00 (0.00) 0.00 (0.06) -0.09 (0.29) 
AMI 0.00 (0.00) -0.01 (0.01) 0.00 (0.00) -0.00 (0.01) 0.08 (0.16) -0.49 (0.57) 
Stroke 0.00 (0.00) 0.00 (0.01) 0.00 (0.00) 0.00 (0.01) 0.00 (0.09) 0.19 (0.40) 
Comorbid 
Conditions Count 0.01 (0.01) -0.03 (0.07) 0.01 (0.01) -0.03 (0.06) -0.06 (0.53) 1.18 (3.29) 
Charlson 
Comorbidity Score 
Q3 
0.00 (0.01) 0.02 (0.02) 0.00 (0.00) 0.02 (0.02) 0.24 (0.28) 1.13 (1.04) 
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Table C-7.      (Continued) 
 
Characteristics Linear Probability Model (PDC≥80%) 
Logistic Model 
(PDC≥80%) 
Ordinary Least Squares 
(Continuous PDC) 
 Estimate (Standard Error) 
 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Charlson 
Comorbidity Score 
Q3 
0.00 (0.01) 0.02 (0.02) 0.00 (0.00) 0.02 (0.02) 0.24 (0.28) 1.13 (1.04) 
Charlson 
Comorbidity Score 
Q4 
0.00 (0.00) 0.01 (0.01) 0.00 (0.00) 0.01 (0.01) 0.10 (0.15) 0.76 (0.78) 
More Likely to 
Take Risks 0.00 (0.00) -0.00 (0.01) 0.00 (0.00) -0.00 (0.01) 0.01 (0.10) 0.12 (0.74) 
Can overcome 
illness without 
medical care 
-0.00 (0.01) -0.00 (0.01) -0.00 (0.00) -0.00 (0.01) 0.10 (0.40) -0.32 (0.79) 
Does not need 
health insurance -0.00 (0.00) 0.00 (0.01) -0.00 (0.00) 0.00 (0.01) -0.01 (0.09) 0.17 (0.37) 
Current Smoker -0.00 (0.00) -0.00 (0.01) -0.00 (0.00) -0.00 (0.01) -0.02 (0.13) 0.13 (0.34) 
Had Moderate / 
Vigorous Exercise -0.00 (0.01) 0.04 (0.03) -0.00 (0.00) 0.03 (0.03) 0.05 (0.35) 0.66 (1.77) 
Obese (BMI≥30) 0.00 (0.00) -0.00 (0.02) 0.00 (0.00) -0.00 (0.02) 0.54 (0.32) 1.49 (1.02) 
Income: 
Poor/Near-Poor  -0.02 (0.01) -0.01 (0.01) -0.01 (0.01) -0.01 (0.01) -1.06 (0.84) -0.95 (0.80) 
Low-Income -0.00 (0.00) -0.01 (0.02) -0.00 (0.00) -0.01 (0.02) -0.28 (0.28) -0.97 (0.82) 
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Table C-7.      (Continued) 
 
Characteristics Linear Probability Model (PDC≥80%) 
Logistic Model 
(PDC≥80%) 
Ordinary Least Squares 
(Continuous PDC) 
 Estimate (Standard Error) 
 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Middle-Income  0.00 (0.00) -0.02 (0.03) 0.00 (0.00) -0.02 (0.03) 0.01 (0.15) -1.59 (1.81) 
Education:  
Less than High 
School 
-0.01 (0.02) -0.01 (0.02) -0.01 (0.02) -0.01 (0.01) -0.41 (1.09) -0.27 (0.82) 
High School 
Diploma 0.00 (0.01) -0.02 (0.04) 0.00 (0.01) -0.02 (0.04) 0.43 (0.60) -1.19 (2.72) 
Drug Coverage 
Plan:  
Part D: PDPs 
0.00 (0.01) 0.00 (0.03) 0.00 (0.01) 0.00 (0.03) 0.60 (0.61) 1.94 (2.11) 
Part D: MA-PD -0.00 (0.01) -0.02 (0.02) -0.00 (0.00) -0.02 (0.02) 0.35 (0.37) 0.60 (1.39) 
Employer/Other 
Private -0.01 (0.01) 0.02 (0.02) -0.01 (0.01) 0.02 (0.02) -1.10 (0.54) 2.78 (1.30) 
Auto Eligible for 
PD Low-Income 
Subsidy 
-0.00 (0.01) 0.00 (0.00) -0.00 (0.01) 0.00 (0.00) -0.68 (0.85) -0.21 (0.22) 
Average Copay for 
CV Drugs ($2010) 0.02 (0.01) -0.03 (0.02) 0.02 (0.01) -0.04 (0.03) 0.47 (0.43) -0.57 (1.47) 
Concurrently taking:      
2-3 CV Drugs 0.00 (0.00) -0.05 (0.03) 0.00 (0.00) -0.05 (0.03) 0.02 (0.15) -2.74 (2.12) 
≥4 CV Drugs -0.01 (0.00) -0.01 (0.01) -0.01 (0.00) -0.01 (0.01) -0.11 (0.19) -0.26 (0.52) 
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Table C-7.      (Continued) 
 
Characteristics Linear Probability Model (PDC≥80%) 
Logistic Model 
(PDC≥80%) 
Ordinary Least Squares 
(Continuous PDC) 
 Estimate (Standard Error) 
 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Difference in 
Characteristics 
Difference in 
Returns to 
Characteristics 
Ambulatory Visits Quantiles      
Q 3 (5-7) -0.00 (0.00) -0.01 (0.02) -0.00 (0.00) -0.01 (0.01) -0.05 (0.14) -0.96 (0.83) 
Q 4 (8-12) 0.00 (0.01) -0.01 (0.02) 0.00 (0.01) -0.01 (0.02) 0.37 (0.46) -1.00 (1.17) 
Q 5 (≥13) -0.00 (0.00) 0.02 (0.02) -0.00 (0.00) 0.02 (0.02) -0.13 (0.32) 0.85 (1.06) 
Had a Usual 
Source of Care 0.00 (0.00) 0.03 (0.15) 0.00 (0.00) 0.02 (0.14) 0.06 (0.16) -2.65 (8.52) 
Any ED Visit- 
Baseline Year 0.00 (0.00) 0.00 (0.01) 0.00 (0.00) 0.00 (0.01) 0.13 (0.14) 0.32 (0.59) 
No. of Pharmacies  0.01 (0.01) -0.03 (0.08) 0.01 (0.01) -0.04 (0.08) 0.63 (0.56) -1.58 (4.90) 
Very Satisfied 
with Healthcare -0.00 (0.00) 0.01 (0.03) -0.00 (0.00) 0.01 (0.03) -0.27 (0.25) 2.39 (2.26) 
Provider 
Explained  0.00 (0.00) -0.02 (0.05) 0.00 (0.00) -0.02 (0.04) -0.03 (0.16) -2.10 (2.64) 
Provider Listened  0.00 (0.00) 0.02 (0.05) 0.00 (0.00) 0.02 (0.05) -0.00 (0.10) 0.59 (2.45) 
Provider 
Respected  -0.00 (0.00) -0.01 (0.06) -0.00 (0.00) -0.01 (0.06) -0.03 (0.14) -1.58 (2.76) 
Constant   -0.23 (0.28)  -0.21 (0.26)  -10.18 (15.41) 
Sample Size 3288 
 
Boldface estimates have P values <0.05. Standard errors were estimated by balanced repeated replications using MEPS-provided 
survey weights and half-sample identifiers. 
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